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AbsTrACT
Background: Cardiovascular disease (CVD) is one of the leading causes of morbidity and 
mortality worldwide. One of the pathophysiology’s that play a pivotal role in the development 
and progression of CVD is a dysfunctional endothelium. An important lifestyle risk factor 
for endothelial dysfunction is the diet and several nutrients have been classified to be either 
beneficial or harmful for the endothelium. Although CVD usually affects middle-aged or older 
adults, the onset of endothelial dysfunction begins in early life, emphasising the need for primary 
prevention. We therefore aimed to identify markers of early perturbations in endothelial health 
by using dietary stressors, e.g. high fat (HF) challenge test. Thereafter we aimed to evaluate if 
the potential early markers are reversible and can be improved after an intervention with a 
dietary anti-stressor.
Methods: First we validated the HF challenge test as a tool to trigger the endothelial response 
capacity. For that purpose, we compared the postprandial response after a HF shake with 
an average breakfast shake in young healthy men by assessing several plasma markers and 
functional measures of endothelial function. To identify new markers for early perturbations 
in endothelial health and to optimized the HF challenge test we applied three HF challenges 
differing in fatty acid type in two populations of middle-aged men, i.e. one at high- and one 
at low risk for developing CVD and characterized the postprandial response by applying 
high-throughput metabolomic and transcriptomic tools next to an extensive phenotyping of 
vascular function and vascular health parameters. Lastly, we evaluated if the, in the studies 
above, identified potential early biomarker profile is reversible and can be improved after an 
intervention with a dietary anti-stressor by means of a high flavanol chocolate intervention.
Results: In young men, we observed that a HF challenge decreased flow mediated dilation 
(FMD), but this decrease was also found after the consumption of an average breakfast shake. 
IL-8 concentrations were more pronouncedly increased after HF shake consumption compared 
to an average breakfast control shake. In middle-aged men, a HF challenge decreased the 
augmentation index (AIX) and elicited an activated state of cellular adherence in the circulation 
as determined by increased plasma soluble adhesion molecules, increased leukocyte cell 
surface integrin and selectin expression and increased number of leukocytes. A challenge 
high in mono-unsaturated fatty acids (MUFAs) elicited the highest postprandial triglyceride 
(TG) concentrations and the most pronounced effects on AIX. By applying high-throughput 
metabolomic tools, we observed that oxylipin profiles were affected by the HF challenge and that 
these changes were depended on dietary fatty acid composition. Application of transcriptome 
profiling revealed that changes in peripheral blood mononuclear cell (PBMC) gene expression 
profiles after a HF challenge test were different between lean and obese subjects, with the 
most deviating effect after MUFA intake. The saturated fatty acid (SFA) shake decreased the 
expression of genes involved in cholesterol uptake and cholesterol biosynthesis and increased 
expression of genes involved in cholesterol efflux. MUFA increased expression of inflammatory 
genes and of peroxisome proliferator-activated receptor α (PPARα) target genes involved in 
β-oxidation. 4-week daily intake of a dietary anti-stressor, e.g. dark chocolate, increased fasting 
FMD and decreased AIX, and elicited a less activated state of cellular adherence, as determined 
by a decrease in plasma soluble adhesion molecules, a decrease in leukocyte cell surface integrin 
and selectin expression and a decrease in the number of leukocytes.
Conclusions: In this thesis we extensively characterized the postprandial response to a HF 
challenge in human subjects with different disease risk profiles and optimized the HF challenge 
test. We identified MUFAs as most potent fatty acids to trigger the vascular and cellular 
response capacity, which makes it the optimal fatty acid type to use in a HF challenge test. We 
demonstrated that besides functional measures of vascular function, also plasma and cellular 
factors involved in leukocyte adhesion to the endothelium are adversely affected by dietary 
stressors and are beneficially affected by a dietary anti-stressor. Therefore, we conclude that 
endothelial health can be more comprehensively measured by means of a biomarker profile 
consisting not only of the vascular function measures FMD and AIX, but also of a subset of 
soluble adhesion molecules in the plasma, leukocyte counts and cell surface integrin and 
selectin expression. To identify potential new leads for biomarkers, we applied whole genome 
gene expression profiling, combined with the HF challenge test which enabled us to detect 
small differences in health status. Furthermore, we identified metabolic and inflammatory 
pathways that are specifically affected by either MUFAs or SFAs. These findings increased our 
understanding on how a SFA or MUFA challenge exert their distinct effects on stress related 
and metabolic compensatory cellular processes and provided us with new potential leads to 
detect early perturbations in endothelial health.
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Cardiovascular disease
Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality 
worldwide. CVD includes coronary heart disease (heart attacks), cerebrovascular disease 
(stroke), hypertension and peripheral artery disease. CVD has a strong genetic component, 
but lifestyle factors such as diet and exercise play also an important role in the onset and 
progression of these diseases. CVD is causally linked to obesity and type 2 diabetes mellitus. 
The incidence of CVD, obesity and type 2 diabetes mellitus is increasing rapidly and accounts 
for a considerable part of health care costs.
CVD is caused by disorders of the heart and blood vessels. The underlying pathological feature 
of most of these disorders is atherosclerosis. Atherosclerosis is a slowly progressing chronic 
disease which is characterised by the formation of atherosclerotic plaques in blood vessels. These 
plaques consists of necrotic cores, calcified regions, accumulated modified lipids, migrated 
smooth muscle cells (SMC), foam cells, endothelial cells, and leukocytes. Atherosclerosis is 
initiated by inflammatory processes in response to accumulated low-density lipoprotein (LDL) 
in the artery wall [1]. One of the pathophysiology’s that play a pivotal role in the development 
and progression of atherosclerosis is a dysfunctional endothelium [2]. Although CVD usually 
affects middle-aged adults, the onset of endothelial dysfunction and subsequently atherosclerosis 
begins in early life, emphasising the need for primary prevention. 
The endothelium 
The endothelium is the thin layer of cells that lines the interior surface of all blood vessels. 
Vascular endothelial cells line the entire circulatory system, from the heart to the smallest 
capillaries and cover a surface area of approximately 1 to 7 m2. The endothelium is involved 
in many aspects of vascular biology. It acts as a physical barrier, plays an important role in 
inflammation and coagulation and it is involved in the dilation and constriction of blood 
vessels, hence controlling vascular tone and heamodynamics [3].
Role of the endothelium in vascular heamodynamics 
The way in which the endothelium regulates vascular tone is by secretion of mediators that 
enables vascular smooth muscle cells to contract or relax, leading to the constriction or dilation 
of blood vessels [3]. Nitric oxide (NO) plays a key role in vasodilatation. NO has a very short 
half-life and is continuously synthesized by the enzyme endothelial nitric oxide synthase 
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(eNOS) from the amino acid L-arginine requiring oxygen and electrons carried by NADPH 
[4]. The principle physiological stimulation for the synthesis and release of NO is the shear 
stress of blood flow [5]. The synthesis and release of NO can also be induced by a variety of 
agonist, including acetylcholine and bradykinin [6]. After being released in the sub-endothelial 
space, NO is able to stimulate soluble guanylyl cyclase in vascular smooth muscle cells to 
produce cyclic guanosine monophosphate (cGMP). This increase in cGMP activates GMP-
dependent kinases, which dephosphorylates myosin light chain kinase, leading to relaxation. 
This relaxation of vascular smooth muscle cells subsequently dilate blood vessels and induce 
an increase in blood flow [7,8]. 
Role of the endothelium in coagulation 
The endothelium plays also an important role in facilitating blood fluidity and blood flow. 
One of the ways endothelial cells maintain blood fluidity and blood flow is by creating an 
anti-thrombotic surface. The endothelium inhibits platelet adhesion and coagulation by 
releasing antithrombotic factors into the lumen, such as tissue factor pathway inhibitors 
(TFPIs), thrombomodulin, NO and prostaglandin I2 (PGI2) [3]. However, upon activation 
by physical forces or by specific molecules such as, thrombin, endotoxins, several cytokines 
and oxidized lipoproteins, endothelial cells can secrete pro-thrombotic factors such as 
fibrinogen, P-selectin and von Willebrand factor (vWF), into the blood stream. The increase 
in pro-thrombotic factors may enhance the formation of fibrin clots and may diminish blood 
fluidity and blood flow [3].
Role of the endothelium in inflammation 
Endothelial cells play also an important role in inflammation. Endothelial cells quiescence 
leukocytes by the release of NO and by suppressing the release of pro-inflammatory cytokines 
[9]. Upon activation, endothelial cells can secrete pro-inflammatory cytokines such as P-selectin, 
E-selectin, IL-6, IL-8 and cell-adhesion molecules (ICAMs), into the lumen. In addition, 
activated endothelial cells up-regulate cell surface expression of adhesion molecules such as 
E-selectin, vascular cell adhesion molecule 1 (VCAM1) and intra cellular adhesion molecule 
1 (ICAM1) by the transcriptional regulation of NF-κB and activator protein 1 (AP1). These 
pro-inflammatory cytokines and adhesion molecules are able to activate and recruit leukocytes 
towards sites of infection or injury. 
Un-activated leukocytes have low affinity to the endothelium, but upon activation, leukocytes 
increase the expression of selectins and integrins on their outer membranes [10-12]. Leukocyte 
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selectins and integrins are able to interact with cell adhesion molecules (CAMs) present on the 
endothelium. During the first steps of leukocyte-endothelial adhesion, low-affinity selectins 
such as L-selectin (CD62L) on leukocytes create weak bonds with P-selectin and E-selectin 
on the endothelium. These weak bonds causing leukocytes to slow their velocity and to 
roll along the endothelial surface under shear forces. During the second step of leukocyte-
endothelial adhesion, leukocytes are more firmly bound to ICAMs and VCAMs on the 
endothelium by high-affinity integrins such as CD11a/CD18 (LFA-1), CD11b/CD18 (MAC-1/
CR3) and CD11c/CD18. This firm adhesion is causing the leukocytes to arrest. During the 
final steps, these firmly bound leukocytes can transmigrate through the endothelium and 
infiltrate inflamed tissues [13]. Besides being important in response to infection or injury, 
the recruitment and trans-endothelial migration of leukocytes are also the initial steps of 
atherosclerosis [13,14].
Reduction in endothelial NO by oxidative stress 
A reduced bioavailability of NO in endothelial cells is considered to be the main cause of 
endothelial dysfunction. A diminished bioavailability of NO causes constriction of arteries 
and facilitates vascular inflammation and coagulation. Several factors can account for the 
reduction in bioactive NO, including a decreased activity of the enzyme eNOS, depletion of 
the eNOS substrate L-arginine or the depletion of NO by reactive oxidant species (ROS). ROS 
are able to inactivate NO by scavenging NO to form peroxynitrite (ONOO-), itself a potent 
oxidant. In addition, ROS can oxidize tetrahydrobiopterin (BH4), a cofactor needed by eNOS 
for the production of NO. Oxidizing BH4 leads to uncoupling of this cofactor from eNOS 
[15]. Uncoupled eNOS produces ROS instead of NO, which will enhance oxidative stress, 
resulting in a vicious cycle. ROS are highly produced by leukocytes and endothelial cells under 
inflammatory conditions [16].
Nutritional impact on endothelial function
The endothelium and leukocytes are continuously exposed to a changing environment. An 
example of a significant change in environment occurs after successive food intake. It is therefore 
not surprizing that the diet plays an essential role in the aetiology of cardiovascular disorders. 
Several nutrients, such as high loads of saturated fat and sugar, have been classified as harmful 
stressors for the endothelium, whereas others have been classified as beneficial. The latter are 
also referred to as anti-stressors.
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Dietary stressors for the endothelium
An example of a nutritional stressor to the endothelium is a high fat (HF) load. The intake 
of HF can temporary decrease vascular function and induce a low-grade pro-inflammatory 
response [17,18]. Elevated postprandial triglyceride levels are considered as a risk factor for 
CVD [19,20]. The ability to respond to a dietary stressor by means of a HF challenge, may 
reflect the flexibility of endothelial cells and leukocytes. A HF meal challenge can therefore be 
a useful tool to detect early perturbations in the endothelium or leukocytes, even before this 
can be measured under fasting conditions [21,22].
The exact impact and underlying mechanism behind this effect remains to be determined. One 
of the current hypothesis is that the elevated plasma triglyceride rich lipoproteins (TRLs) after 
a HF meal activate endothelial cells and leukocytes [20,34,35]. On endothelial cells, TRLs can 
stimulate the expression and secretion of ICAMs and other pro-inflammatory cytokines into 
the blood [11,23]. On leukocytes, TRLs can up-regulate the expression of integrins and selectins 
on their outer membranes and stimulate leukocytes to secrete pro-inflammatory interleukins, 
soluble adhesion molecules and coagulation factors [10-12]. Furthermore, postprandial TRLs 
increase neutrophil counts, with a concomitant production of pro-inflammatory cytokines and 
oxidative stress [24,25]. The combination of activated endothelial cells, increased leukocyte 
adherence and a pro-inflammatory milieu, will reduce the bioavailability of NO, subsequently 
diminishing endothelial function. 
Dietary fatty acids and endothelial function
The impact of a HF challenge on endothelial health may be affected by the type of fat in 
the challenge. One way dietary fatty acids may exert their effect on endothelial health is by 
the modulation of gene transcription. Fatty acids are able to modulate gene transcription 
by regulating the activity of transcription factors, including nuclear receptors such as sterol 
regulatory element-binding proteins (SREBPs), liver X receptor (LXR) and the peroxisome 
proliferator-activated receptors (PPARs) [26]. Changing the activity of these transcription factors 
can alter the expression of genes involved in important processes of cardiovascular health. As an 
example, SREBPs regulates the transcription of genes involved in the biosynthesis of cholesterol 
and fatty acids [27], LXR regulate the transcription of genes involved in cholesterol storage, 
transport and catabolism [28,29] and PPARs are important regulators of lipid metabolism, 
but play also a role in the anti-inflammatory response [30-32]. The affinity of fatty acids for a 
transcription factor can dependent on their molecular structure. For example, mouse studies 
have shown that the best activators for PPARs are long-chained polyunsaturated fatty acids [33].
14
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Dietary fatty acids may also modulate the postprandial inflammatory response by the formation 
of oxylipins. These fatty acid metabolites are involved in both pro- and anti-inflammatory 
processes [34]. Oxylipins are known for their autocrine and paracrine effects, but recent evidence 
suggests that oxylipins may also have systemic endocrine effects [35]. 
Dietary anti-stressors for the endothelium
There is increasing epidemiological evidence that a high intake of fruit and vegetables has a 
beneficial effects on CVD risk [36,37]. Fruit and vegetables may exert parts of their positive 
cardiovascular health effects by their flavonoid content. An important subgroup of the 
flavonoid family are flavanols [38]. Besides being highly present in fruits and vegetables, 
flavanols are also highly present in food products such as red wine and tea, and in particular 
in cacao or cacao derived products such as dark chocolate [38]. Studies are accumulating, that 
despite the fact that dark chocolate also contains high amounts of saturated fat and sugar, it 
still exerts positive cardiovascular health effects [39]. The underlying mechanisms on how 
cacao flavanols affect endothelial cells are not completely understood, but the beneficial 
cardiovascular health effects are most likely due to the increase in bioavailability of NO. 
Cacao flavanols may increase activity and gene expression of eNOS, the enzyme responsible 
for endothelial NO production [40]. Another described beneficial effect of cacao flavanols 
is on decreasing vascular arginase activity, thereby increasing local levels of L-arginine, the 
precursor for the synthesis of NO [41]. In addition, it has been suggested that cacao flavanols 
may improve endothelial function acutely by diminishing the breakdown of NO by free radicals 
through inhibition of NADPH oxidase [42]. Besides the direct effects of cacao flavanols on 
the endothelium, several studies suggest that cacao flavanols may also have anti-inflammatory 
and anti-thrombotic properties, decrease insulin resistance and have a positive effect on blood 
lipids [40,43]. These above described effects of cacao flavanols are mainly based on animal, 
in vitro or human ex vivo studies. Several human intervention studies have demonstrated 
that short term daily intake of flavanol enriched dark chocolate or cacao powder can improve 
endothelium-dependent vasodilatation, as determined by an increase in flow mediated 
dilation (FMD). Recently, the European Food and Safety Authority (EFSA) approved the 
health claim that cocoa flavanols consumption helps to maintain endothelium-dependent 
vasodilation [44].
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Early detection of endothelial dysfunction
Endothelial dysfunction in its early stage is still reversible, which makes early detection 
of endothelial dysfunction of great importance. Identifying early and sensitive markers of 
endothelial function is therefore an important target for disease prevention. 
Functional measures of endothelial dysfunction
The major limitation in studying the endothelium is the limited accessibility of this organ. To 
study endothelial function in vivo in a pre-clinical setting, one is restricted to non-invasive 
methodologies. To date, most research on endothelial function comprises the vascular 
measurement flow mediated dilation (FMD). The assessment of FMD was firstly introduced by 
Celermajer et al. in 1992 [45] and up till now it is still the most accepted and established method 
to study endothelial function. The method assesses the ability of vascular endothelial cells to 
respond to changes in shear stress. A meta-analyses investigating the association between FMD 
on the relative risk of cardiovascular events, found that each 1% increase in FMD is associated 
with a relative risk of cardiovascular events of 0.87 (95%CI: 0.83, 0.91) [46]. In addition, the 
EFSA considers that a sustained increase in FMD under fasting conditions in response to an 
intervention is a beneficial physiological effect [44]. However, the technique is relatively time 
consuming, technically challenging and shows relatively large within-subject variation. The 
question remains if other functional measures of endothelial function are available that are 
easier to use and shows less within-subject variation. 
Comprehensive phenotyping
Comprehensive phenotyping of individuals before and after an intervention of dietary 
stressors, may be a conductive strategy to identify early changes in endothelial function. The 
examination of leukocyte function together with a wide range of plasma markers involved in 
cellular adherence of leukocytes to the endothelium, coagulation and systemic inflammation, 
paralleled by examination of vascular function will provide a more complete picture of the 
impact of an intervention on endothelial health. Furthermore, the application of largely unbiased 
high-throughput techniques, in particular transcriptomics but also metabolomics, may not 
only increase our understanding on how certain nutrients are able to affect inflammatory 
and metabolic processes and hence endothelial health but may also help to identify new 
early biomarker for endothelial dysfunction. As blood leukocytes play an important role in 
inflammation and can interact with the endothelium, peripheral blood mononuclear cells 
16
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(PBMCs) are a potential valuable source of biological material for transcriptomics analyses. 
PBMCs are a mixture of T-cells, B-cells and monocytes and as they are present in blood they 
are exposed to physiological changes including changes in nutrient level and inflammation [47]. 
As endothelial cell are not accessible and PMBCs are easy to collect, they form an important 
biological material to study endothelial heath in vivo. 
Outline thesis
In the current thesis we used HF challenges to identify early markers for reduced endothelial 
function. To identify new early markers for endothelial perturbations we first needed to 
evaluate our stressor model, i.e. the high fat challenge test and evaluated several measures of 
vascular function. Therefore, we compared in chapter 2 the postprandial response after a high 
fat/ high energy shake with an average breakfast shake in young healthy men by determining 
several measures of vascular function and plasma markers of endothelial function. After 
selection of the most promising vascular function techniques we tried to optimize the high fat 
challenge by comparing three different FA, and to identify new early markers for endothelial 
health we applied these three HF challenge tests in two populations of middle-aged men, i.e. 
one at high and one at low risk for developing CVD. To identify early markers for endothelial 
health, the postprandial HF response was comprehensively characterized by measuring a 
combination of vascular function, plasma markers and leukocyte cell surface markers (chapter 
3), and by applying more sensitive techniques, such as plasma metabolomics (chapter 4) and 
transcriptome analysis of PBMCs (chapter 5). To evaluate if the early markers are reversible 
after an intervention with a dietary anti-stressor, we investigated in chapter 6 the effects of acute 
intake and of 4-week daily high flavanol chocolate and normal flavanol chocolate consumption 
on FMD, heamodynamics, arterial stiffness, leukocyte numbers, plasma cytokines and leukocyte 
cell surfaces molecules in healthy overweight middle-aged men. In addition we investigated if 
a high or normal flavanol chocolate background is able to affect the response capacity towards 
a HF challenge. An overall discussion of chapters 2 to 6 will be described in chapter 7.   
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ABSTRACT
Background: High fat meal challenges are known to induce postprandial low-grade 
inflammation and endothelial dysfunction. This assumption is largely based on studies 
performed in older populations or in populations with a progressed disease state and an 
appropriate control meal is often lacking. Young healthy individuals might be more resilient 
to such challenges. We therefore aimed to characterize the vascular and inflammatory 
response after a high fat meal in young healthy individuals. 
Methods: In a double-blind randomized cross-over intervention study, we used a 
comprehensive phenotyping approach to determine the vascular and inflammatory response 
after consumption of a high fat/ high energy (HF/HE) shake and after an average breakfast 
shake in 20 young healthy subjects. Both interventions were performed three times. 
Results: Many features of the vascular postprandial response, such as FMD, arterial 
stiffness and micro-vascular skin blood flow were not different between shakes. HF/HE 
shake consumption was associated with a more pronounced increase in blood pressure, 
heart rate, plasma concentrations of IL-8 and PBMCs gene expression of IL-8 and CD54 
(ICAM-1), whereas plasma concentrations of sVCAM1 were decreased compared to an 
average breakfast. 
Conclusions: Whereas no difference in postprandial response were observed on classical 
markers of endothelial function, we did observe differences between consumption of a HF/
HE and an average breakfast meal on blood pressure and IL-8 in young healthy volunteers. 
IL-8 might play an important role in dealing with high fat challenges and might be an early 
marker for endothelial stress, a stage preceding endothelial dysfunction. 
23
Vascular and inflam
m
atory high fat m
eal responses
Chapter 2
2
INTRODUCTION
A lifestyle factor known to be important in development and progression of cardiovascular 
disease (CVD) is diet. Although several dietary components and patterns have been related 
to vascular function, the postprandial response has gained specific attention since it has 
been associated with an impaired vascular function, low grade inflammation and increased 
cardiovascular risk [1-3]. Postprandial effects on vascular function and inflammation are 
reversible and temporally, but can be of importance since most individuals are in the postprandial 
state the greater part of the day [4-8]. Most studies that investigated the postprandial vascular 
response used flow mediated dilation (FMD) as measure of vascular function. Vascular function 
can also be assessed by other measures, of which some have been applied in postprandial studies 
[9-12]. Postprandial challenges often used in relation to CVD are high fat (HF) meals, as these 
atherogenic meals provide a direct source of stress [13]. However, many previous studies only 
investigated a small part of the postprandial response or were performed in older individuals 
or in populations with a progressed disease state, such as diabetes, metabolic syndrome, 
hypertension or cardiovascular disease. The postprandial impact of high fat/high energy (HF/
HE) meals on both vascular function and inflammation in healthy young subjects has been 
less well studied. In addition, many postprandial studies compared HF/HE meals with water 
consumption, with other macronutrients or only with baseline recordings. In these studies the 
question remains whether observed postprandial changes are due to the high fat content itself, 
to a common meal effect, or to circadian rhythm influences. Hence, it is not completely clear 
whether the HF/HE meal-induced changes in vascular function and inflammation are solely 
caused by the HF content or by the meal itself and whether this temporary impairment is also 
elicited in younger healthy individuals. To address these points, we examined the postprandial 
response after a HF/HE shake in young healthy men on several measures of vascular function 
and blood markers of endothelial function and inflammation, and compared this response 
with an average breakfast milkshake. Since most functional measures of vascular function are 
known to have large variations in reproducibility, the effects of both shakes were studied three 
times within the same individual.
MATeRIAlS AND MeThODS
Ethics statement
All subjects gave written informed consent and the study was approved by the Medical Ethics 
Committee of Wageningen. The study was conducted according to the principles of the 
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Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects 
Act (WMO) and registered at ClinicalTrials.gov (Identifier: NCT00766623).
Subjects
Twenty healthy male volunteers of Western European descent, between 18 and 27 years, were 
recruited. Exclusion criteria were a body mass index (BMI) <18 or >28 kg/m2, urine glucose 
concentrations >0.25 g/l, fasting blood glucose <3 or >5.5 mmol/L or blood Hb values <8.4 
mmol/L and smoking. Furthermore, subjects were excluded if they were diagnosed with any 
long-term medical condition or high blood pressure (systolic BP>140 mmHg and/or diastolic 
BP>90 mmHg). 
Study design
The study was a double-blind randomized cross-over intervention study in which participants 
visited the university six times in total; three times to obtain postprandial responses on a HF/
HE shake and three times to obtain postprandial responses on an average breakfast shake. 
The latter was used to acquire a common postprandial response and shakes were therefore 
not isocaloric. A one-week washout period was the minimum between consecutive study 
days. Shakes were assigned alternately over the study days and order of start was randomly 
assigned. A research assistant generated the random allocation sequence. Shakes were given a 
code and both subjects and researchers were blinded to the intervention. Prior to each study 
day, subjects consumed a standardized low fat evening meal, were refrained from alcohol or 
strenuous exercise and were not allowed to eat or drink anything except water after 08.00 pm. 
For each subject, starting time of every study day was kept constant. 
A study day was executed as follows: upon arrival, a cannula was placed, baseline fasted blood 
samples were collected baseline vascular measurements were done. Subsequently, the subject 
received either a HF/HE or an average breakfast shake. Postprandial vascular measurements 
and blood samples were taken 3 and 6 hours after milkshake consumption. These time points 
were chosen because in previous studies, a maximal FMD response was observed 3 hours 
after high fat meal consumption and the FMD measure was back to baseline values 6 hours 
postprandially [14,15]. Throughout the study day, subjects were not allowed to eat or drink 
anything except water. 
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Shakes 
The HF/HE shake consisted of 53%(w/v) fresh cream, 3%(w/v) sugar and 44%(w/v) water 
and reflected a macronutrient composition of 6g protein, 95g fat (of which 54g saturated), 22g 
carbohydrates and represented a total energy content of 3,992KJ. The average breakfast shake 
was, based on macronutrient composition, comparable to a breakfast as averagely consumed 
by young men in the Netherlands [16]. This average breakfast shake consisted of 43%(w/v) full 
cream milk, 48%(w/v) full cream yoghurt, 4%(w/v) lemonade, 4%(w/v) fantomalt (Nutricia 
B.V., the Netherlands) and 1%(w/v) wheat fiber and reflected a macronutrient composition 
of 17g protein, 14.5g fat, (of which 9g saturated), 49.5g carbohydrates and 2.3g fiber and 
represented a total energy content of 1674KJ (NEVO 2006). Both shakes had a total volume 
of 500ml.  
Metabolic parameters
Plasma triacylglycerol (TG), free fatty acids (FFA), insulin and glucose concentrations were 
assessed at baseline and 1, 2, 3, 4, and 6 hours after milkshake consumption and were measured 
by a hospital laboratory (SHO, Velp, the Netherlands). 
Functional measures of vascular function
Measurements of vascular function included micro-vascular skin blood flow, arterial stiffness 
and FMD. Measures were performed in above mentioned order and whole data was acquired 
at baseline and 3 and 6 hours after shake consumption. All measurements were performed 
in supine position after 10 minutes rest, in a quiet temperature controlled room at moderate 
light intensity.  
Blood pressure
Blood pressure (BP) and heart rate (HR) were assessed automatically (DINAMAP® PRO 100) 
during the functional measurements with a 5 minute interval.
Iontophoresis laser Doppler
Micro-vascular skin blood flow was assessed by laser Doppler iontophoresis [17]. Briefly, two 
ion chambers (MIC-ION6, Moor Instruments, UK) on the volar aspect of the forearm were 
filled with 1% sodium nitroprusside (SNP) (Sigma - 31444-50G) or 1% acetylcholine (Ach) 
(Sigma - A6625-25G) solution and iontophoretically administered (MIC2™, Moor Instruments, 
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UK). Skin blood flow was recorded by laser Doppler (MoorFLPI, Moor Instruments, UK) and 
expressed as incremental area under the curve (AUC) calculated from mean flux outcomes 
plotted against total recorded time period (NCSS software v07.1.4).
Pulse wave analysis of the radial artery
Arterial stiffness was assessed by pulse wave analysis (PWA) of the radial artery by applanation 
tonometry (SphygmoCor®CP System, ATcor Medical). In short, a pressure-sensitive probe was 
placed on the radial artery to generate a pulse pressure wave (Sphygmocor software v8.0). 
In combination with the brachial blood pressure measurements we deduced central aortic 
pressures and the heart rate corrected augmentation index (AIX) [18]. 
Flow-mediated dilation
FMD was performed according to techniques described by the International Brachial Artery 
Reactivity Task Force [19]. In short, after baseline recordings, a pressure cuff on the forearm 
was inflated and kept constant at a pressure of 200mmHg for 5 min. Thereafter, the cuff was 
released and records of the artery were made every 20 seconds for 4 minutes (Picus, ART.LAB 
v2.1, Esaote benelux bv.). FMD was computed as maximum vessel diameter after cuff release 
divided by baseline and expressed in percentage. A nitroglycerin dose was administrated 
sublingually by spray at the end of each day.  
Blood measures 
Plasma markers 
Baseline and postprandial plasma cytokine concentrations were determined once for each 
shake and analyzed on preformatted arrays on a SECTOR Imager 2400 reader (Meso Scale 
Diagnostics, LLC) as described previously [20].
PBMC gene expression 
Peripheral blood mononuclear cells (PBMCs) were isolated by BD Vacutainer Cell Preparation 
Tubes. RNA was isolated (RNeasy Micro kit, Qiagen, Venlo, the Netherlands), quantified 
(Nanodrop ND 1000, Nanodrop technologies, Wilmington, Delaware USA) and quality was 
determined (Agilent 2100 Bioanalyser, Agilent Technologies, South Queensferry, UK). RNA 
with a RIN score >7 was thereafter reverse transcribed (cDNA synthesis kit, Promega, Leiden, 
the Netherlands) and analyzed by qPCR (SensiMix SYBR No-ROX, Bioline, London, UK) on 
a CFX384 Real-Time System (C1000 Thermal Cycler, Biorad, Veenendaal, The Netherlands). 
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Primer sequences were chosen based on the sequences available in Primer3 (v. 0.4.0). Data 
was normalized by the housekeeping gene hUPO.
Statistics
Study outcomes of all three testing days are expressed as pooled mean and SD was calculated by 
the root mean squared error. Statistical comparisons were performed by linear mixed models 
for repeated measures (PASW statistics 17.0.3), using ‘diet’, ‘time point’ and ‘diet x time point’ 
as fixed effects and subject as random effect. Postprandial responses on plasma cytokines were 
determined once for each shake and baseline values were included as covariate in the model if they 
were of significant influence and Studentized residuals >3, obtained from the mixed model, were 
considered outliers and removed from the model. A value of P<0.05 was considered significant. 
ReSUlTS
Subjects characteristics
Twenty volunteers entered the study. Eighteen completed all six study days, one volunteer 
completed four study days and one completed two study days (Figure 2.1). Baseline 
characteristics of the subjects are listed in Table 2.1. 
Assessed for 
eligibility (n=21)
Excluded  (n=1)
Declined to participateEnrolment
Allocation
Analysis
Day 1&2
Analysis
Day 3&4
Analysis
Day 5&6
Allocated to 
treatment order 
(n=20)
Excluded  (n=1)
Declined to participate
Excluded  (n=1)
Declined to participate
Analysed (n=20)
Analysed (n=19)
Analysed (n=18)
Randomized 
(n=20)
Figure 2.1 CONSORT flow diagram.
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Metabolic parameters
Baseline and postprandial changes in TG, FFA, insulin and glucose are listed in Table 2.2. A 
significant difference in response between the HF/HE and the average breakfast shake was 
observed for all parameters. 
Measures of vascular function
Outcomes of all functional vascular measures are listed in Table 2.3. Consumption of both 
shakes resulted in a small but significant postprandial reduction in FMD% at 3 hours that 
returned to baseline after 6 hours. No significant difference in response between shakes was 
observed. Consumption of both shakes resulted in an significant postprandial increase in 
HR and systolic blood pressure (SBP), with a significant higher response after HF/HE shake 
consumption. No significant postprandial changes were observed for diastolic blood pressure 
(DBP). Similar to the effects on SBP, HF/HE consumption also resulted in a higher postprandial 
increase in central aortic pulse pressure. The AIX was decreased for both shakes, with no 
difference in response between shakes. Micro-vascular blood flow was significant reduced after 
consumption of both shakes, with no difference in response between shakes. Similar results 
were observed for both SNP and Ach treatment. 
Plasma cytokines 
Plasma cytokines levels before and after milkshake consumption are listed in Table 2.4. A 
significant increase in IL-8 was observed after HE/HF shake consumption compared to an 
Table 2.1 Baseline characteristics of the participants
Mean ± SD (n=20)
Age (y) 22 ± 2
Length (cm) 185 ± 7
Weight (kg) 78 ± 10
BMI (kg/m²) 22.7 ± 2.4
Glucose (mmol/L) 4.9 ± 0.3
TG (mmol/L) 1.1 ± 0.3
FFA (mmol/L) 0.52 ± 0.18
Insulin (uIU/ml) 6.94 ± 3.22
Systolic BP (mmHg) 111 ± 9
Diastolic BP (mmHg) 59 ± 6
Values are expressed as mean ± SD. TG, triglycerides; FFA, free fatty acids; BP, Blood pressure.
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Table 2.3 Baseline and postprandial values of vascular function measures after high fat/high energy 
(HF/HE) or average breakfast control shake consumption
Time P-value
Shake Baseline 3h 6h Shake Time
Interaction
Shake x Time
Iontophoresis
Total Ach (AUC) HF/HE 2674 ± 982 1328 ± 576 1175 ± 533 NS <0.001 NS
control 2464 ± 1030 1457 ± 861 1134 ± 664
Total SNP (AUC) HF/HE 2964 ± 823 2189 ± 809 2149 ± 787 NS <0.001 NS
control 2731 ± 960 2328 ± 868 1997 ± 1091
Brachial blood pressure
Systolic BP HF/HE 110 ± 5 114 ± 4 116 ± 4 0.001 <0.001 0.003
(mmHg) control 110 ± 4 111 ± 4 113 ± 4
Diastolic BP HF/HE 59 ± 5 58 ± 4 58 ± 4 NS NS NS
(mmHg) control 59 ± 4 58 ± 4 58 ± 4
Heart rate HF/HE 54 ± 5 58 ± 4 57 ± 4 0.001 <0.001 0.001
(BPM) control 55 ± 4 55 ± 4 55 ± 4
Pulse wave analysis
Central systolic BP HF/HE 92 ± 4 93 ± 4 94 ± 3 0.001 NS NS
(mmHg) control 92 ± 4 91 ± 3 92 ± 3
Central pulse HF/HE 33 ± 3 35 ± 2 36 ± 2 <0.001 <0.001 0.028
pressure (mmHg) control 33 ± 3 33 ± 2 34 ± 3
AIX (%) HF/HE -13 ± 10 -15 ± 10 -16 ± 6 0.012 NS NS
control -16 ± 7 -17 ± 7 -18 ± 8
FMD
Baseline vessel HF/HE 4.21 ± 0.15 4.23 ± 0.14 4.22 ± 0.14 NS NS NS
diameter (mm) control 4.21 ± 0.14 4.18 ± 0.13 4.19 ± 0.18
Maximum vessel HF/HE 4.42 ± 0.18 4.42 ± 0.15 4.45 ± 0.19 0.025 0.026 NS
diameter (mm) control 4.41 ± 0.17 4.35 ± 0.13 4.41 ± 0.16
FMD (%) HF/HE 5.05 ± 2.01 4.54 ± 1.88 5.36 ± 2.55 NS 0.004 NS
control 4.87 ± 2.50 4.13 ± 2.02 5.25 ± 2.09
Values are pooled mean ± SD of all three study days (n=20). P-values were calculated using linear mixed models 
for repeated measures. Ach, Acetylcholine; SNP, sodium nitroprusside; AUC, area under the curve; BPM, beats per 
minute; BP, blood pressure; AIX, augmentation index; FMD, flow mediated dilation.
average breakfast. Plasma concentrations of SAA and VCAM-1 were significantly decreased 
after a HE/HF milkshake compared to an average breakfast. Consumption of both shakes 
resulted in a significant postprandial increase in plasma levels of IL-6, whereas E-selectin and 
thrombomodulin were decreased postprandially. 
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PBMC gene expression
We examined expression changes of a selection of genes (Table 2.5), known to be involved 
in inflammation or endothelial function in PBMCs. HF/HE shake consumption resulted in 
a higher postprandial up regulation of IL-8 after 3 and 6 hours, and CD54 (ICAM-1) after 3 
hours, compared to an average breakfast. Several other inflammatory genes, like TNFα, MCP1 
and CD62l, were up-regulated postprandially, with no differences in response between shakes. 
Table 2.4 Baseline and postprandial changes in inflammatory cytokines after high fat/high energy 
(HF/HE) or average breakfast control shake consumption
Time P-value
Shake Baseline 3h 6h Shake Time
Interaction
Shake x Time
CRP HF/HE 464 ± 615 435 ± 573 412 ± 528 NS NS NS
(ng/ml) control 461 ± 746 641 ± 1357 769 ±1841
SAA HF/HE 497 ± 277 422 ± 267 382 ± 206 NS NS 0.022
(ng/ml) control 520 ± 432 532 ± 490 585 ±604
sICAM-1 HF/HE 181 ± 27 179 ± 26 176 ± 30 NS NS NS
(ng/ml) control 177 ± 27 179 ± 31 178 ± 32
sVCAM-1 HF/HE 305 ± 37 296 ± 35 296 ± 35 0.003 NS 0.038
(ng/ml) control 294 ± 45 298 ± 49 304 ± 50
E-selectin HF/HE 6.03 ± 1.91 5.66 ± 1.81 5.79 ± 1.87 NS 0.038 NS
(ng/ml) control 6.40 ± 2.52 5.83 ± 1.83 5.81 ± 1.60
P-selectin HF/HE 51.9 ± 16.1 52.0 ± 15.5 53.0 ± 18.8 NS NS NS
(ng/ml) control 50.5 ± 11.9 51.4 ± 11.0 49.8 ± 13.2
sICAM-3 HF/HE 1.47 ± 0.28 1.48 ± 0.26 1.52 ± 0.27 NS 0.042 NS
(ng/ml) control 1.52 ± 0.33 1.42 ± 0.18 1.50 ± 0.28
TM HF/HE 2.34 ± 0.42 2.23 ± 0.36 2.21 ± 0.37 NS <0.001 NS
(ng/ml) control 2.39 ± 0.40 2.28 ± 0.39 2.24 ± 0.37
IL-1β HF/HE 0.47 ± 0.31 0.47 ± 0.28 0.49 ± 0.32 NS NS NS
(pg/ml) control 0.38 ± 0.17 0.54 ± 0.48 0.57 ± 0.50
IL-6 HF/HE 0.74 ± 0.24 1.18 ± 0.48 1.38 ± 0.73 NS <0.001 NS
(pg/ml) control 1.10 ± 1.01 1.40 ± 0.85 2.31 ± 2.31
IL-8 HF/HE 4.08 ± 0.95 4.36 ± 1.18 4.45 ± 1.00 0.002 NS 0.043
(pg/ml) control 4.15 ± 1.20 3.84 ± 0.74 3.78 ± 0.77
TNFα HF/HE 6.12 ± 1.70 6.07 ± 1.96 6.12 ± 1.91 NS NS NS
(pg/ml) control 5.90 ± 1.57 6.19 ± 1.75 6.19 ± 1.87
Values are mean ± SD from the last study days (n=20). P-values were calculated using linear mixed models for 
repeated measures. TM, thrombomodulin.
32
Vascular and inflammatory high fat meal responsesChapter 2
As illustrated in Figure 2.2, postprandial responses on HR, SBP, FMD and IL-8 gene expression 
were similar for each repeated testing day.
DISCUSSION
In the current study we used a comprehensive approach to study postprandial effects of a HF/
HE meal on vascular function and plasma markers of endothelial function and inflammation 
in young healthy subjects by comparing it to average breakfast milkshake. HF/HE shake 
consumption was associated with a more pronounced increase in HR, SBP, plasma IL-8 and 
PBMC gene expression of IL-8 and CD54 (ICAM-1) compared to average breakfast shake 
consumption. 
Only a limited number of studies on postprandial effects of a HF/HE meal on HR and BP 
have been performed in young healthy individuals. Ayer et al., showed an increase in HR 3 
hours after HF meal consumption in a healthy young population [9]. However no reference 
Table 2.5 Changes in expression of genes involved in inflammation in PBMCs after high fat/high 
energy (HF/HE) or average breakfast control shake consumption
SLR P-value
Shake 3h 6h Shake Time
Interaction
Shake x Time
IL-8 HF/HE 1.23 ± 2.10 1.37 ± 2.56 0.003 <0.001 <0.001
control -0.26 ± 2.00 0.68 ± 2.17
MCP1 HF/HE 0.32 ± 1.20 0.75 ± 1.44 0.049 0.001 NS
control -0.03 ± 1.58 0.28 ± 1.61
TNFα HF/HE 0.40 ± 0.38 0.29 ± 0.70 NS <0.001 NS
control 0.23 ± 0.49 0.22 ± 0.41
CD62l HF/HE 0.03 ± 0.39 0.03 ± 0.61 NS 0.035 NS
control 0.02 ± 0.49 0.19 ±0.49
CD54/ HF/HE 0.25 ± 0.62 -0.03 ± 0.64 NS 0.001 0.006
ICAM-1 control 0.08 ± 0.70 0.12 ± 0.64
IL-1β HF/HE 0.00 ± 0.70 0.00 ± 0.87 NS NS NS
control -0.27 ± 0.90 -0.05 ± 1.09
CD11a HF/HE -0.10 ± 0.50 -0.13 ± 0.66 NS NS NS
control -0.08 ± 0.50 -0.08 ± 0.44
Changes are expressed as signal to log ratio (SLR) compared to baseline values, values are pooled mean ± SD of 
all three study days (n=20). P-values were calculated using linear mixed models for repeated measures.
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Figure 2.2 Postprandial changes after consumption of high fat/high energy (HF/HE) or average 
breakfast shake on heart rate (A), systolic blood pressure (B), FMD (C) and PBMC gene expression of 
IL-8 (D) subdivided for repeated testing days. Values are mean ± SD.
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meal was included and it is therefore unclear if the observed effects are caused by HF or by a 
common postprandial response. With respect to BP, Biston et al. observed that ingestion of a 
mixed meal was associated with a postprandial increase in SBP in young healthy subjects, but 
they did not compared this response with other meal types [21]. Our observed postprandial 
increase in BP and HR after both shakes may point towards sympathetic activation after meal 
intake [22]. Another factor known to affect BP is insulin. By stimulating vasodilatation, insulin 
is able to reduce BP [23]. The lower BP increase after the average breakfast shake may be due to 
the higher postprandial insulin concentrations after this shake. However, the insulin peak was 
increased one hour postprandially, whereas BP was measured three and six hours postprandially.
Although no differences in response between shakes were observed on most vascular 
measurements, several measures were altered after consumption of both shakes and are 
therefore caused by consumption of the meal and/or circadian effects. One example is the small 
but significant postprandial reduction in FMD%. While several previous studies observed a 
postprandial decrease in FMD after HF consumption, many others found no effect or found 
an effect with all intervention meals (reviewed by Jackson et al.) [5]. Interestingly, many of 
the studies with no effect were conducted in healthy individuals [9,24,25]. We hypothesize 
that young healthy individuals are still able to handle a high fat and high energy load in such a 
way that a similar postprandial endothelial response is observed after an averagely consumed 
breakfast meal. 
Besides a postprandial reduction in FMD, consumption of both shakes also altered the AIX and 
micro-vascular blood flow. The postprandial decrease in AIX is in line with previous findings 
[9,10,26]. The mechanism behind this postprandial reduction in AIX has been less well studied, 
but arterial smooth muscle relaxation in the general circulation in response to nutrient delivery 
might be an explanation [26]. AIX values were already negative at baseline and an augmented 
pressure was therefore not present in this study population. The postprandial decrease in AIX 
did therefore not affect postprandial central pulse pressure outcomes. The blunted vasoactive 
compound-induced increase in micro-vascular blood flow after consumption of both shakes 
was observed for both SNP and Ach and is therefore not endothelium dependent. However, 
vasoactive compounds were repeatedly administrated at the same location within a few hours. 
We therefore cannot exclude a reduced sensitivity of the vasculature for these compounds, 
explaining the observed blunted increase in blood flow.
HF/HE shake consumption resulted in an increase in plasma concentrations and PBMC gene 
expression of IL-8 compared to the average breakfast shake. Postprandial studies on IL-8 
measures are limited. Esposito et al. found that serum IL-8 concentrations did not change 
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significantly 4 hours after HF consumption in 30 middle aged diabetic and 30 non-diabetic 
subjects [27]. However, their HF intervention meal was a mixed meal, which contained 
besides 52g of fat also 58g of carbohydrates, which is closely to the 49.5g carbohydrates in 
our average breakfast shake that showed no response on IL-8. Another study that measured 
plasma concentrations of IL-8 in 8 healthy young men found a non-significant increase two 
hours after HF meal consumption [14]. However, they did not measure beyond 2 hours 
postprandially. Although hardly evaluated in postprandial studies, IL-8 is of importance for 
atherosclerosis development as it is involved in neutrophil activation and recruitment [28] 
and triggers monocyte adhesion to the vascular endothelium [29]. IL-8 gene expression and 
production can be regulated by oxidant stress [30,31]. HF/HE consumption may initiate oxidant 
stress and thereby trigger endothelial cells to produce and release IL-8, where it is stored in 
Weibel-Palade bodies [32].
The HF/HE specific decrease in plasma levels of sVCAM-1 is not in line with the general 
prevailing hypothesis that HF meal consumption is associated with an increase in soluble 
adhesion molecules [2]. However, postprandial studies regarding soluble adhesion molecules 
have not shown consistent results. Some studies report elevated sICAM-1 and sVCAM-1 levels 
after HF meal consumption [33,34], whereas many others do not [35-39]. Only one studie found 
a decrease after HF meal consumption [40]. In general, most studies that did not observe a 
postprandial increase were performed in younger and often healthy study populations. 
Besides the prevailing hypothesis that triglycerides rich particles may increase inflammation, 
recent human intervention studies demonstrated that high fat/high energy intake can increase 
circulating endotoxins [41]. These postprandial endotoxins are transported through the gut 
wall during chylomicron uptake and are able to activate inflammation [42]. Harte et al. showed 
that circulating endotoxins levels show more dramatic postprandial changes in groups with 
a higher metabolic risk [41]. This might additional explain why in our young healthy study 
population, several plasma inflammatory cytokines were not altered after HF/HE consumption. 
To draw a parallel with the measures of vascular function, plasma cytokines were measured 
at baseline and 3 and 6 hours after shake consumption. As a consequence changes in plasma 
cytokines that occurred before 3 hours are not detected. It has for example been shown that the 
cytokines CCL5/RANTES and MCP1 are already changed 1 hour after high fat meal intake [43].
The design used in the current study, with three repeated observations of the intervention 
within the same individual, allowed to detect small but significant effect sizes, even for 
measures known for their large variation in reproducibility, such as FMD. In addition, many 
other previous postprandial studies with high fat challenges used water, fasting or other type 
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of macronutrients as a reference meal. These studies cannot rule out that observed effects are 
also elicited by a common meal. To enable distinguishing between a HF/HE and a common 
meal response, we used an averagely consumed breakfast shake as a control. As a consequence, 
both shakes were not isocaloric and observed differences in response between shakes cannot 
solely be described to the high fat content but can also be caused by the high energy content 
or difference in macronutrient composition. Nevertheless, as individuals are daily exposed to 
a breakfast, the usage of an average breakfast meal as a control mirrors the real life situation.
Whereas no difference in postprandial response were observed on classical markers of 
endothelial function, we did observe differences between consumption of a HF/HE and an 
average breakfast meal on blood pressure and IL-8 in young healthy volunteers. The postprandial 
increase in blood pressure and plasma IL-8 concentrations after a high fat meal might create a 
potential harmful environment for the endothelium which in young healthy individuals may 
not directly affect measures of vascular function, but repeated exposure may on the long run 
induce endothelial dysfunction. This may be a likely occurrence, since in the western world 
high fat and high energy meals are regularly consumed. Since IL-8 was one off the only factors 
different in response between the shakes, it might play a role in dealing with high fat challenges 
and one of the first factors that may reflect endothelial stress, a stage preceding endothelial 
dysfunction.
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ABSTRACT
Background: BMI and fatty-acid type affect postprandial metabolic triglyceride (TG) 
responses, but if these factors also affect vascular, inflammatory and leukocyte adherence 
responses remains unclear. We therefore compared those postprandial responses between 
lean and obese men after three high-fat challenges differing in fatty-acid composition. 
Methods: In a cross-over double blind study, 18-lean (BMI 18–25 kg/m2) and 18-obese 
(BMI >29kg/m2) middle-aged men received three isocaloric high-fat milkshakes containing 
95g fat (88 energy-%), either high in saturated fatty acids (SFAs), mono-unsaturated fatty 
acids (MUFAs) or n3 polyunsaturated fatty acids (PUFAs). Hemodynamics, augmentation 
index (AIX), leukocyte cell-surface adhesion markers and plasma cytokines involved in 
vascular adherence, coagulation and inflammation were measured before and after shake 
consumption. 
Results: In both groups and after all shakes, AIX decreased, plasma sICAM1, sICAM3, 
sVCAM1 and IL-8 increased, monocyte CD11a, CD11b and CD621 expression increased, 
neutrophil CD11a, CD11b and CD621 expression increased and lymphocytes CD62l 
expression increased. Lymphocyte CD11a and CD11b expression decreased in lean subjects 
after consumption of all shakes, but did not changed in obese subjects. Obese subjects 
had a less pronounced decrease in heart rate after the consumption of all shakes. MUFA 
consumption induced a more pronounced decrease in blood pressure and AIX compared 
to the other shakes in both lean and obese subjects. 
Conclusions: High-fat consumption initiates an activated state of cellular adherence and 
atherogenic milieu. This response was independent of fatty-acid type consumed or being 
lean or obese, despite the clear differences in postprandial TG responses between the groups 
and different shakes. These findings suggests that besides increased TG, other mechanisms 
are involved in the high-fat consumption induced activated state of cellular adherence. 
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INTRODUCTION
Elevated postprandial TG concentrations are associated with an increased risk of cardiovascular 
diseases (CVD) [1,2]. Although a direct relationship between postprandial triglycerides (TG) 
and elevated CVD risk has been established, the mechanism by which postprandial TG affects 
cardiovascular health remains unknown [3-5]. One of the current hypothesis is that elevated 
triglyceride rich lipoproteins (TRLs) in the postprandial state can deteriorate vascular function 
and inflammation by interacting with endothelial cells and leukocytes [6-8]. First of all, TRLs 
may stimulate endothelial cells to increase the expression of intercellular adhesion molecules 
(ICAMs), paralleled by an increase secretion of pro-inflammatory cytokines into the blood [3]. 
TRLs may also activate leukocytes. Activated leukocytes increase their adherence capacity to 
endothelial cells by up regulation of integrins and selectins on their outer membranes and by 
secretion of pro-inflammatory interleukins, soluble adhesion molecules and coagulation factors 
[9,10]. The combination of activated endothelial cells, increased leukocyte adherence and pro-
inflammatory milieu can diminish the bioavailability of nitric oxide (NO) and subsequently 
diminish vascular function and thereby vascular tone [3,11]. 
The magnitude of the postprandial TG response is largely dependent on the quantity of fat. 
High fat meal challenges are therefore often used to determine vascular and inflammatory 
responses. Postprandial TG responses can be affected by the type of fat and several studies 
indicate that saturated fatty acids may induce a lower postprandial rise of TG if compared to 
unsaturated fatty acids [12-14]. However, studies are still inconclusive [15,16] and the exact 
impact of fatty acid composition on the magnitude of the postprandial TG response remains 
to be determined. Another important determinant of the magnitude of the postprandial TG 
response is BMI. Obese subjects can have a perturbed metabolic postprandial response, which 
is reflected by elevated postprandial plasma TG concentrations if compared to lean individuals 
[17-19]. Despite the clear effect of type of fat and BMI on the postprandial TG response, it 
remains unclear if and how these factors affect leukocyte adherence capacity, inflammatory 
and vascular responses. Based upon findings by our group that polyunsaturated fatty acid 
(PUFA) consumption induced a postprandial pro-inflammatory gene expression response in 
blood leukocytes compared to saturated fatty acid (SFA) consumption [20], and the potential 
increased TG responses after unsaturated fatty acid consumption, we hypothesize that challenges 
high in unsaturated fatty acids will elicit a more pronounced postprandial inflammatory and 
vascular responses if compared to challenges high in SFAs. In addition we hypothesize that 
obese individuals will have perturbed and more pronounced postprandial inflammatory 
and vascular responses if compared to lean subjects. We therefore compared postprandial 
responses after HF challenges with different fatty acid composition in lean and obese men on 
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hemodynamics and arterial stiffness, leukocyte activation and plasma cytokines involved in 
vascular adherence, coagulation and inflammation.
MATeRIAlS AND MeThODS
Subjects
The study population consisted of 18 lean (predefined BMI 18–25 kg/m2) and 18 obese (BMI 
>29 kg/m2) men between 50–70 years old. All subjects were non-smoking, normoglycemic 
(WHO criteria) and not diagnosed with any long-term medical condition or high blood 
pressure (systolic BP> 160 mmHg and/or diastolic BP>100 mmHg). Subjects were excluded 
if they were vegetarian, regular tobacco smoker, allergic to dairy products or fish oil, current 
or recent user of fish oil supplements or consumed fish more than four times/wk. A more 
detailed description of the study population is previously reported [21]. In that study, three 
groups were included; 18 lean subjects, 18 obese subjects and six obese type 2 diabetic subjects. 
We excluded the obese diabetic group from the manuscript because of the low number. All 
subjects gave written informed consent. 
Study design
The study was a double blind randomized cross-over intervention study in which participants 
visited the university three times. On each study day, subjects consumed a milkshake with 
95g of fat (88 energy-%), which was either high in SFAs (54 energy-% of total fat), mono-
unsaturated fatty acids (MUFAs) (83 energy-% of total fat) or n3 PUFAs (40 energy-% of total 
fat). Hemodynamics, augmentation index, a measure of arterial stiffness and wave reflection, and 
plasma cytokines involved in cellular adherence of leukocytes to the endothelium, coagulation 
and inflammation were assessed during fasting condition at baseline and postprandially 2 and 
4h after milkshake consumption. Expression of leukocyte cell surface molecules and relative 
proportion of neutrophils, monocytes and lymphocytes were measured at baseline and 4h after 
milkshake consumption. Subjects were randomly assigned to a treatment order and a one-week 
washout period was the minimum between consecutive study days. On the day prior to each 
study day, subjects consumed a standardized low fat evening meal, were refrained from alcohol 
or strenuous exercise and were not allowed to eat or drink anything except water after 08.00h. 
This study was conducted according to the principles of the Declaration of Helsinki and in 
accordance with the Medical Research Involving Human Subjects Act (WMO). The Medical 
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Ethical Committee of Wageningen University (the Netherlands) approved the study and the 
study was registered at clinicaltrials.gov as NCT00977262.
Intervention shakes
All three shakes were isocaloric and macronutrient composition differed only in fatty acid 
composition (Table 3.1). The shakes contained low-fat yogurt, low-fat milk, strawberry 
flavour, 7.5g of sugar and 95g of the test fat. The SFA shake contained 95g palm oil (Research 
Diet Services BV, Wijk bij Duurstede, The Netherlands) and the MUFA shake contained 95g 
high-oleic acid sunflower oil (Aldoc BV, Schiedam, The Netherlands). The n3 PUFA shake 
contained 40g palm oil and 55g Marinol D-40 (Lipid Nutrition, Wormerveer, The Netherlands), 
of which 40% was docosahexanoic acid (DHA). Vitamin E (165mg Tocoblend L50, Vitablend, 
Wolvega, The Netherlands) was added to the SFA and MUFA shake to match vitamin E present 
in Marinol D-40. All three shakes had a volume of 500mL. Nutritional values of the shakes 
were calculated using the Dutch Nutrient Databank (NEVO 2006) [22]. 
Hemodynamics and pulse wave analysis
Brachial systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were 
assessed automatically (DINAMAP® PRO 100) for 10 minutes with a 3 min interval. Central/
aortic systolic blood pressure and the heart rate corrected aortic augmentation index (AIX), 
Table 3.1 Nutritional values of the three intervention high fat shakes
Nutritional value SFA MUFA n3 PUFA
Energy (kcal) 990 990 990
Protein (g) 10 10 10
Carbohydrates (g) 19 19 19
Fat (g) 95 95 95
Saturated fatty acids (g) 51 8 32
Monounsaturated fatty acids (g) 37 79 25
Polyunsaturated fatty acids (g) 6 8 38
ALA (g) 0 0 0
EPA (g) 0 0 3
DHA (g) 0 0 23
Vitamin E (mg) 165 165 165
Calculated using the Dutch Food Composition table (NEVO 2006). ALA, alpha-linolenic acid (18:3).
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a measure of wave reflection and arterial stiffness, were assessed by pulse wave analysis of the 
radial artery by applanation tonometry (SphygmoCor®CP System, ATcor Medical) [23]. Seven 
obese subjects were excluded from blood pressure and pulse wave analysis. Five because of 
the use of blood pressure lowering medication and two because we were not able to deduce a 
pulse pressure wave due to an irregular heartbeat.
Plasma markers of inflammation   
Plasma cytokine concentrations were analysed on preformatted arrays (Meso Scale Diagnostics, 
LLC) on a SECTOR Imager 2400 reader (Meso Scale Diagnostics, LLC), as described previously 
[24]. Intra- and interassay CV were: IL-6, 6.6 and 15.1%; IL-8, 3.4 and 4.1%; E-selectin, 2.8 
and 7.1%; P-selectin, 3.9 and 5.3%; sICAM3, 3.9 and 8.2%; thrombomodulin, 2.0 and 5.2%; 
CRP, 4.3 and 3.4%; SAA. 3.0 and 10.9%; sICAM1, 3.2 and 3.9%; and sVCAM1, 2.4 and 3.3%, 
respectively. Plasma concentrations of von Willebrand factor (vWF) were measured by a custom 
ELISA, where Dakopatt® capture and conjugated rabbit anti-human vWF polyclonal antibodies 
were used (Dakopatt®, Denmark). Levels were expressed as a percentage of vWf detected in 
pooled citrated plasma of healthy volunteers [24]. Intra- and interassay CV for vWf were 2.8 
and 3.3%, respectively.
Leukocyte relative cell count and cell surface activation markers
Expression of leukocyte cell surface activation markers were determined at baseline and 4h 
after shake consumption by flow cytometry (FACSCanto™II, Becton-Dickinson). Whole blood 
(BD Vacutainer LH) was stained with fluorescent labelled monoclonal antibodies (MAbs) 
(Becton-Dickinson, The Netherlands) FITC conjugated CD11a, Pacific Blue™ conjugated 
CD11b, APC conjugated CD62l and PE-Cy™7 conjugated CD45. After staining, FACS lysis 
solution (Becton-Dickinson, The Netherlands) was added to the samples, washed twice in 
PBS (Lonza) and dissolved in PBS. Immuno-fluorescence was evaluated for 10,000 events. 
Neutrophils, monocytes and lymphocytes were identified by their distinct forward and side 
scattering properties in combination with CD45 cell surface expression (FACSDiva™ Software 
v6.1.2). Non-specific binding of each label was ruled out by using isotype matched MAbs. 
Relative neutrophils, monocytes and lymphocytes count, in proportion to the other two 
populations, are expressed as percentage. Expression of cell surface markers are expressed as 
Mean Florescence Intensity (MFI) in arbitrary units.  
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Metabolic markers and TG fatty acid composition 
Plasma TG, glucose, insulin and free fatty acids (FFA) were assessed during fasting condition 
and postprandially 2 and 4h after milkshake consumption. The TG fatty acid composition 
was determined in pooled serum samples per group (lean n=18 and obese n=18), for each 
shake at baseline and 4 h postprandially by gas-liquid chromatography as previously described 
[25]. Metabolic markers and TG fatty acid composition outcomes are included as compliance 
measures and have been published [21]. 
Statistical analysis
Statistical analysis was performed by linear mixed models for repeated measures (PASW statistics 
18.0.3). Repeated measures were taken into account in the baseline comparisons between groups. 
Comparisons of postprandial responses were performed by using group, shake, time and their 
interactions as fixed effects. Since baseline differences can be expected between subjects and 
baselines values may influence the magnitude of response [26], baseline values were included 
as covariate in the model. The scope of this manuscript was to compare postprandial responses. 
The interaction group x shake does not contain a response and was therefore not determined. 
Studentized residuals >2.5, obtained from the mixed model, were considered outliers. A least 
significant difference (LSD) posthoc analysis was performed if significant differences were 
detected by linear mixed model. A value of P<0.05 was considered significant. All correlations were 
performed by Pearson’s correlations (PASW statistics 18.0.3). Postprandial TG values of one person 
were identified as outlier for the correlation analysis and excluded from the correlation analysis.
ReSUlTS
A total of 18 lean and 18 obese individuals entered and completed the study. BMI, fasting plasma 
TG and insulin concentrations were greater in obese compared to lean subjects (Table 3.2). 
Hemodynamics and pulse wave analysis
HF shake consumption was associated with a decrease in heart rate in lean subjects, whereas 
this postprandial decrease was not observed in obese subjects (P<0.05) (Table 3.3). Compared 
to the SFA and n3 PUFA shakes, the MUFA shake resulted in a less pronounced postprandial 
decrease in HR and a more pronounced postprandial decrease in BP (P<0.05). It also caused 
a more pronounced decrease in AIX compared to the n3 PUFA shake (P<0.05) (Table 3.3).
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Plasma cytokines
Obese subjects had significantly higher fasting plasma concentrations of CRP, SAA and 
vWF compared to lean subjects (P<0.05) (Table 3.4). No differences in postprandial plasma 
cytokine response were observed between lean and obese. For both obese and lean subjects, 
shake consumption resulted in increased plasma IL8, sICAM1, sICAM3 and sVCAM1 
concentrations and decreased plasma IL6, thrombomodulin and SAA concentrations with 
no differences in response between shakes (Table 3.4). SFA consumption was associated with 
higher plasma P-selectin concentrations 2 hours postprandially, compared to MUFA and n3 
PUFA consumption (P<0.05) (Table 3.4).  
Leukocyte relative cell count and cell surface expression 
At baseline obese subjects had fewer monocytes relative to lymphocytes and neutrophils 
compared to lean subjects (P<0.05) (Table 3.5). Consumption of all shakes was associated with 
an increase in relative number of neutrophils at the expense of monocytes and lymphocytes. 
This relative increase in neutrophils was more pronounced in lean compared to obese subjects 
and less pronounced after SFA shake consumption compared to both other shakes (P<0.05) 
(Table 3.5). 
Table 3.2 Baseline characteristics of the lean and obese subjects
Lean Obese 
Age (y) 61.8 ± 5.9 62.6 ± 3.2
BMI (kg/m2) 23.8 ± 0.8 32.4 ± 3.0*
Body fat (%) 21.9 ± 5.7 38.2 ± 5.2*
VAT (cm2) 102 ± 40 231 ± 75*
SAT (cm2) 163 ± 52 350 ± 99*
VAT/SAT ratio 0.64 ± 0.20 0.68 ± 0.24
Waist circumference (cm) 89.3 ± 5.9 115.9 ± 10.0*
Plasma TG (mmol/L) 1.5 ± 0.5 2.1 ± 0.9*
Plasma FFA (mmol/L) 0.51 ± 0.21 0.51 ± 0.13
Plasma Insulin (mU/L) 6.1 ± 2.8 13.4 ± 6.6*
Plasma Glucose (mmol/L) 5.2 ± 0.4 5.5 ± 0.4
HOMA-IR 1.3 ± 0.7 3.4 ± 1.6*
Values are means ± SD, lean n=18 and obese n=18, * Different from lean subjects, P<0.05. TG, triglycerides; FFA, 
free fatty acids; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue. For VAT, SAT and VAT/SAT ratio; 
lean n=17 and obese n=18.
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No significant differences in baseline CD11a, CD11b and CD62l cell surface expression were 
observed between lean and obese subjects. Lymphocyte CD11a and CD11b expression decreased 
significantly after shake consumption in lean subjects, but did not change in obese (P<0.05). 
Expressions of all other markers were postprandially increased with no difference in response 
between lean and obese or between shakes (Table 3.5). 
Plasma metabolic markers and serum fatty acid composition
MUFA consumption was associated with a more pronounced increase in TG if compared 
with the SFA and n3PUFA consumption (P<0.05) (Table 3.6). The increase in plasma TG 
concentration was greater in the obese than in the lean men (P<0.05). The percentage of palmitic 
acid was 10% higher after the SFA challenge, the percentage of oleic acid was 60% higher 
after the MUFA challenge and the percentage of DHA was 950% higher after the n3 PUFA 
challenge, reflecting the composition of the shakes (Supplemental Table S3.1). Outcomes are 
based on single pools for each group at each given time point for each shake. Statistical tests 
were therefore not possible. 
Correlations with postprandial TG 
High fat shake consumption affected the augmentation index and increased plasma markers 
involved in cellular adherence and leukocyte cell surface activation markers. To determine 
if elevated TRLs in the postprandial state may be the cause of these effects, we tested the 
associations between changes in plasma TG concentrations, between 4 hours postprandially 
and baseline, with changes in these markers. Changes in TG correlated positively with changes 
in sICAM3 (r=0.45, P<0.01) after SFA consumption and with changes in sICAM1 (r=0.39, 
P=0.02), sVCAM1 (r=0.46, P<0.01) and IL-8 (r=0.48, P<0.01) after n3PUFA consumption. For 
leukocyte cell surface activation markers, changes in TG correlated negatively with changes 
in neutrophil CD11a expression (r=-0.37, P=0.03) after SFA consumption and positively with 
changes in monocyte CD11a expression (r=0.36, P=0.03) after MUFA consumption.
DISCUSSION
We compared the postprandial impact of high-fat shakes differing in fatty acid composition 
between lean and obese subjects by comprehensive characterization of the vascular, leukocyte 
activation and inflammatory cytokine response. In both groups and after all shakes, aortic 
augmentation index (AIX) decreased, plasma sICAM1, sICAM3, sVCAM1 and IL-8 increased, 
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monocytes and neutrophils CD11a, CD11b and CD621 expression increased and lymphocytes 
CD62l expression increased. For several measures, obese subjects had blunted postprandial 
responses to a HF challenge when compared to lean subjects, including lymphocyte CD11a and 
CD11b expression and heart rate. In addition, differences in postprandial responses between 
different fatty acid shakes were observed, such as a more pronounced decrease in AIX and 
blood pressure after MUFA consumption.
All postprandial changes point towards an activated state of cellular adherence and hence 
a atherogenic milieu. Firstly, the increase in plasma soluble adhesion molecules sICAM1, 
sICAM3 and sVCAM1 can mediate cellular adherence of leukocytes to the endothelium [27]. 
Secondly, the increase in plasma IL-8 can trigger neutrophil activation and recruitment [28] 
and monocyte adhesion to the vascular endothelium [29]. Thirdly, the increase expression of 
CD11a and CD11b as part of LFA-1 and MAC-1 integrins respectively and CD62l ( l-selectin), 
can increase leukocyte recruitment and binding to the ICAMs expressed on the endothelium 
[27]. Altogether, this demonstrates that consumption of a HF challenge initiates an activated 
state of cellular adherence in the circulation, which is the initial phase in the development of 
atherosclerosis [27]. Something which previous studies had only partly demonstrated and in 
separate observations [9-11,30,31]. The current study additional shows that this HF-shake 
induced affect, is largely independent of type of fat consumed or being lean or obese, despite 
the clear differences in postprandial TG response between these factors.
Therefore, the question remains whether elevated TRLs in the postprandial state might be 
responsible for this activated state of cellular adherence [6-8]. Positive correlations between 
changes in TG and some soluble adhesion molecules were almost only observed after n3 PUFA 
consumption, indicating that the change in TG is not solely responsible for the postprandial 
changes in soluble adhesion molecules. Furthermore, the observed correlations between 
changes in TG and changes in neutrophil and monocyte CD11a expression had an opposite 
direction and were not very strong. A previous study did report positive correlations between 
changes in TG levels and changes in monocytes CD11b expression [10]. However, this 
correlation was observed in 10 subjects after 6 hours, whereas our findings were based upon 
35 subjects and after 4 hours. Based on the correlation analysis in the current study, we cannot 
substantiate a role of postprandial TG on the pro-inflammatory postprandial response alone. 
Perhaps other mechanisms, such as increased postprandial plasma endotoxins after high fat 
intake also contribute to this postprandial inflammatory response [32]. These endotoxins 
are transported through the gut wall during chylomicron uptake and are known to activate 
inflammation [33].
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With respect to the differences between fatty acid type in the HF shake, MUFA consumption was 
associated with a less pronounced postprandial decrease in heart rate and a more pronounced 
postprandial decrease in BP and AIX compared to the other shakes. A decrease in AIX a few 
hours after meal intake is well described in literature and probably due to changes in arterial 
stiffness and wave reflections caused by neutrally or hormone mediated peripheral vasodilation 
[34]. To our knowledge we are the first to describe significant differences in postprandial AIX 
between intake of different fatty acids types. Berry et al. compared postprandial effects of 50g 
fat derived from shea butter blend (SFA) or high oleic sunflower oil (MUFA) on AIX in younger 
subjects (18–40y), but did not observe differences between meals [35]. The differences in 
findings with our study might be explained by our older population or by the meal composition, 
as the mixed meal provided by Berry et al. was higher in carbohydrates and lower in fat. 
Interestingly, MUFA consumption was besides associated with a more pronounced decrease 
in AIX, also associated with a more pronounced increase in TG concentrations. However, 
no correlations were observed between changes in postprandial TG concentrations and AIX 
after MUFA consumption. This more pronounced decrease in AIX after MUFA consumption 
may have been caused by the higher insulin and or glucose concentrations after MUFA intake 
compared to SFA or n3 PUFA intake [36,37]. Insulin can induce sympathetic nervous system 
stimulation, which subsequently causes a decrease in vascular resistance hence, a decrease 
in AIX may be expected after an increase in insulin concentrations [36]. Unfortunately, the 
design of the current study was not suitable to verify this hypothesis, as postprandial peaks of 
both glucose and insulin can be expected before 2 hours postprandially. The questions remains 
what the impact would be of a lower postprandial response on the long term. Whereas a lower 
AIX in the fasting state is known to be associated with lower risk of CVD [38], the impact of 
postprandial AIX changes on long term outcome measures such as CVD are unknown.
SFA shake consumption resulted in increased postprandial plasma P-selectin concentrations 
if compared to the other shakes. P-selectin is expressed both by platelets and endothelial cells 
and modulates adhesion of leukocytes and platelets to the endothelium [39]. The observed 
postprandial SFA-induced increase in P-selectin might therefore enhance P-selectin modulated 
leukocyte adherence to the endothelium in the postprandial state. 
Differences between lean and obese in postprandial HF response were characterized by a blunted 
responses in obese on HR, leukocyte count and lymphocyte CD11a and CD11b expression. 
CD11a and CD11b are important for early adhesion of leukocytes to ICAMs located on the 
endothelium [40,41]. The decreased postprandial lymphocyte CD11a and CD11b expression in 
lean subjects might point towards less lymphocyte adherence and subsequently less activation 
of the endothelium in the postprandial state, whereas this was not observed in obese subjects. 
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Interestingly, this decrease was restricted to lymphocyte CD11a and CD11b expression, as all 
other leukocyte adhesion markers were postprandially increased. 
The current study allowed us to compare high fat meal responses of different fatty acids in lean 
and obese men. We investigated the postprandial vascular and inflammatory response before 
and 2 and 4h after milkshake consumption. As a consequence, we may have missed changes 
that occurred at earlier or later time points. Compared to lean individuals, obese individuals 
had higher insulin and TG levels at baseline and after shake consumption, indicating a reduced 
metabolic capacity. Nonetheless, obese subjects were not diabetic and not diagnosed with 
long-term medical conditions. A strong point of the study design is the match for milkshake 
volume, caloric content and macronutrients which enables us to draw conclusions about the 
effects of different fatty acid types. The amount of fat (95g; 88% of energy) used in this study 
is relatively high and does not reflect a common meal. However, the aim of the current study 
was to determine response capacity towards a high lipid load only differing in fatty acid type, 
which can be more easily achieved by these high amounts of fat. The fatty acids used in our study 
are commonly consumed and therefore expected to be well tolerated. As we did not include 
a shake with a normal fat content, we cannot rule out if the postprandial changes observed 
after all shakes are due to the high fat content per see or whether they also can be elicited by 
a common meal or by changes of circadian rhythm. A difference in habitual diet and or other 
lifestyle factors between lean and obese individuals may have influenced the postprandial 
response [42]. In order to minimize the effect of consumption of the meal from the previous 
day, subjects consumed a standardized low fat evening meal prior to each study day. In addition, 
all volunteers were not vegetarian and did not consume fish more than four times/wk and did 
not used fish oil supplements. A factor that may have contributed to the differences in TG 
response between the fatty acids may be the structure of the fat, which is able to modulate the 
intestinal absorption. The liquid structured high oleic acid sunflower oil may have been easier 
and better emulsified compared to the solid structured palm oil, leading to a more rapid lipid 
uptake after MUFA consumption [43]. This does however not explain the extended elevation 
in TG at 4 hours. Another explanation for the difference in TG response may be that the 
MUFA shake contained almost exclusively oleic acid (83% of total fat) while the other shakes 
contained a mixture of fatty acids. The consumption of high amounts of a single fatty acid 
might affect clearance capacity, resulting in higher circulating levels of TG for a longer period 
of time, which might have affected the observed differences in blood pressure, heart rate and 
augmentation index. Yet, no correlations between postprandial changes in TG concentrations 
and AIX were observed after MUFA consumption. Based on the more pronounced increase 
in TG and more pronounced decrease in AIX after MUFA intake, one might speculate that a 
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high fat MUFA shake is metabolic more challenging for the body compared to a shake high 
in SFA or n3 PUFA.
In summary, this study demonstrates that HF shake consumption initiate an activated state 
of cellular adherence and an atherogenic postprandial milieu as reflected by the increase in 
several plasma soluble adhesion markers and the increase in several leukocyte cell surface 
adhesion markers. Repeated exposure to such an atherogenic postprandial milieu may on the 
long run increase CVD risk. We additionally demonstrate that this high-fat induced response 
is largely independent of type of fatty acids consumed or being lean or obese, despite the clear 
differences in postprandial TG responses between groups and the different fatty acids shakes. 
Combined with a lack of clear correlations between changes in postprandial plasma and 
leukocyte adherence markers and changes in TG levels, these findings suggests that besides 
increased TG other mechanisms are involved in the high-fat consumption-induced activated 
state of cellular adherence. Fatty acid type did affected postprandial hemodynamics and arterial 
stiffness with a more pronounced decrease after MUFA consumption. Indicating that this fatty 
acid is the most potent fatty acid to provoke a physiological vascular response.
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Supplemental Table S3.1 Baseline and postprandial changes in metabolic parameters after high 
fat SFA, MUFA and n3 PUFA shake consumption in lean and obese men
Shake
SFA MUFA n3 PUFA
Baseline Δ4h Baseline Δ4h Baseline Δ4h
% of total % of total % of total
Palmitic acid
Lean 27. 5 2.9 25.8 -11.5 27.1 -0.6
Obese 28.1 2.5 27.9 -11.2 29.1 0.3
Oleic acid
Lean 35.8 2.5 38.1 22.8 37.4 -2.5
Obese 36.1 1.1 36.0 20.7 35.7 -0.6
DHA
Lean 0.68 -0.09 0.44 -0.12 0.32 4.56
Obese 0.66 -0.09 0.63 -0.16 0.55 2.86
Pooled samples for lean (n=18) and obese (n=18) men at baseline and 4 hours after shake consumption measured 
in serum. Only values for palmitic acid, oleic acid and DHA are displayed.
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ABSTRACT
Background: : Circulating oxylipins could have an effect on peripheral tissues and seem 
to play an important role in endothelial function. These circulating plasma oxylipins are 
esterified in triglyceride-rich lipoproteins (TRLs). The magnitude of the postprandial TRLs 
response after a high fat meal can be affected by BMI and fatty acid type. We therefore aimed 
to characterize the impact of a high fat meal challenge differing in fatty acid composition, 
on the postprandial oxylipin response in lean and obese men. 
Methods: In a double-blind randomized cross-over challenge study we characterized the 
postprandial oxylipin response after different high-fat challenges, either high in saturated 
(SFA), mono-unsaturated (MUFA) or n3 poly-unsaturated fatty acids (PUFA), in lean and 
obese men. 
Results: Plasma oxylipin profiles were significantly altered at 2 and 4 h after shake con-
sumption when compared to baseline. Eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA)-derived oxylipins increased after n3 PUFA shake consumption. MUFA shake 
consumption increased levels of cytochrome P450 (CYP450)-mediated oxylipins. SFA shake 
consumption led to an increase in linoleic acid (LA)-derived HODEs. No differences were 
observed between lean and obese subjects at baseline or after shake consumption. 
Conclusions: We are the first demonstrating that circulating oxylipins profiles are acutely 
affected after a high fat meal challenge and these changes are strongly influenced by different 
dietary fatty acids. These circulating oxylipins may affect endothelial function. However, 
future research is needed to elucidate how these circulating oxylipins in the postprandial 
phase may affect the endothelium. 
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INTRODUCTION
Oxylipins including eicosanoids are a spectrum of bioactive and signaling compounds made 
by oxidation of essential fatty acids and are involved in pro- or anti-inflammatory processes 
[1]. Three families of enzymes, namely cyclooxygenase (COX), lipoxygenase (LOX) and 
cytochrome P450 (CYP450), allow the biosynthesis of a wide range of oxylipins: prostanoids and 
thromboxanes synthesized by COX, leukotrienes and monohydroxyalcohols [HETEs, HODEs, 
HEPEs] produced by LOX and epoxides synthezised by CYP450 which are transferred to their 
diol form by soluble epoxide hydrolase (sEH) in a fast turnover rate [2-4]. Oxylipins are known for 
their local autocrine and paracrine inflammatory effects, but there is a growing body of evidence 
that oxylipins may also act as endocrine molecules [5]. These circulating oxylipins could have 
an effect on peripheral tissues and seem to play an important role in endothelial function [5]. 
The majority of these circulating plasma oxylipins are esterified in triglyceride-rich lipoproteins 
(TRLs) and can be released by lipoprotein lipase (LPL) anchored on endothelial cells [6,7]. A 
high fat meal causes an increase in plasma TRL and is known to affect endothelial function [8]. 
The magnitude of the postprandial TRLs response after a high fat meal has been shown to be 
affected by BMI and fatty acid type [9]. The question remains whether plasma oxylipins are 
also changed after high fat meals differing in fatty acid composition. It is also unclear, whether 
the acute oxylipin responses are affected by BMI. We therefore aimed to characterize the acute 
effect of different high fat meal challenges on circulating oxylipins in lean and obese men.
MATeRIAlS AND MeThODS
In this manuscript, we included a subpopulation of a previously reported study [9], namely 18 
lean subjects and 18 obese subjects. The six obese type 2 diabetic subjects were excluded from 
this study because of the lower number. 
Subjects 
In total, 18 lean (predefined BMI 18–25 kg/m2) and 18 obese (BMI >29 kg/m2) male subjects 
between 50–70 years old were recruited. All subjects were non-smoking, normoglycemic (WHO 
criteria) and not diagnosed with any long-term medical condition. A more detailed description 
of the study population has been published previously [9]. All subjects gave written informed 
consent and the study was approved by Medical Ethics Committee of Wageningen University. 
The study was conducted according to the principles of the Declaration of Helsinki and in 
accordance with the Medical Research Involving Human Subjects Act (WMO).
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Study design
The study was a double blind randomized cross-over intervention study in which each 
participant visited the research facility three times. On each study day, subjects consumed 
a milkshake with 95g of fat, which was either high in saturated fatty acids (SFA), mono-
unsaturated fatty acids (MUFA) or n3 poly-unsaturated fatty acids (PUFA). Blood was collected 
at baseline (t=0) and 2 and 4 h after milkshake consumption. Subjects were randomly assigned 
to a treatment order and a one-week washout period was the minimum between consecutive 
study days. On the day prior to each study day, subjects consumed a standardized low fat 
evening meal, were refrained from alcohol or strenuous exercise, and were not allowed to eat 
or drink anything after 08.00 pm, except water. 
Shake composition
All three shakes were isocaloric and macronutrient composition differed only in fatty acid 
composition (Supplemental Table S4.1). The shakes contained low-fat yoghurt, low-fat milk, 
strawberry flavour, 7.5g of sugar and 95g of the test fat. The SFA shake contained 95g palm 
oil (Research Diet Services BV, Wijk bij Duurstede, The Netherlands) and the MUFA shake 
contained 95g high-oleic acid sunflower oil (Aldoc BV, Schiedam, The Netherlands). The n3 
PUFA shake contained 40g palm oil and 55g Marinol D-40 (Lipid Nutrition, Wormerveer, The 
Netherlands), of which 40% was docosahexanoic acid (DHA). Vitamin E (165mg Tocoblend 
L50, Vitablend, Wolvega, The Netherlands) was added to the SFA and MUFA shakes to match 
vitamin E present in Marinol D-40. All three shakes had a volume of 500mL. Nutritional values 
of the shakes were calculated using the Dutch Nutrient Databank (NEVO 2006).
Oxylipin profiling analysis
The oxylipin profiling platform is a target analysis and addresses over 100 target metabolites. 
Plasma oxylipin profiles were obtained by a method previously described by Strassburg et 
al. [10]. In short, compound extraction was performed with solid phase extraction using a 
hydrophilic-lipophilic balance (HLB) (Oasis, Waters) and samples were analyzed by liquid 
chromatography (Agilent 1260, San Jose, CA, USA) coupled to electrospray ionization on a 
triple quadrupole mass spectrometer (Agilent 6460, San Jose, CA, USA), while chromatographic 
separation was achieved on an Ascentis Express C18 (2.1x150 mm, 2.7 µm particles) (Supelco). 
Peak determination and peak area integration was performed with Mass Hunter Quan (Agilent, 
San Jose, CA, USA, Version B.04.00). Peak areas of target metabolites were corrected by 
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appropriate internal standards (ISTD) and calculated response ratios were used throughout the 
analysis. Oxylipins which are usually addressed by this analytical platform, but were below the 
detection limits, were not used for further analysis. Batch to batch correction was performed 
based on a method previously described by van der Kloet et al. [11]. 
Statistical analysis
Statistical analysis was performed by linear mixed models for repeated measures (PASW 
statistics 18.0.3). Baseline comparisons between groups were performed using baseline values in 
the mixed model procedure with group as main effect and shake as repeated factor. Comparisons 
of postprandial responses were performed by using group, shake, time and their interactions as 
fixed effects. Since baseline differences can be expected between groups, baseline values were 
included as covariate in the model. Benjamini and Hochberg false discovery rate correction 
(q=5%) was applied to correct for false positives. A least significant difference (LSD) posthoc 
analysis was performed, if significant differences were detected by linear mixed model. A value 
of P<0.05 was considered significant. All correlations were performed by Pearson’s correlations 
(PASW statistics 18.0.3). One subject was identified as an outlier and therefore removed from 
the analysis.
ReSUlTS
A total of 18 lean and 18 obese individuals completed the study. Baseline subject characteristics 
are displayed in Table 4.1. 
Table 4.1 Baseline characteristics of the subjects 
Lean (n=18) Obese (n=18)
Age (yrs) 61.8 ± 5.9 62.6 ± 3.2
BMI (kg/m2) 23.8 ± 0.8 32.4 ± 3.0 *
TG (mmol/L) 1.5 ± 0.5 2.1 ± 0.9 *
FFA (mmol/L) 0.51 ± 0.21 0.51 ± 0.13
Insulin (mmol/L) 6.1 ± 2.8 13.4 ± 6.6 *
Glucose (mmol/L) (mmol/L) 5.2 ± 0.4 5.5 ± 0.4
Data are presented as mean ± SD. TG, triglycerides; FFA, free fatty acids.* Significantly different from lean 
subjects (P<0.05).
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Plasma metabolic markers and TG fatty acid composition
Baseline and postprandial concentrations of glucose, triglycerides (TG), free fatty acids 
(FFA) and insulin are shown in Supplemental Table S4.2. In addition, changes in fatty acid 
composition of the TG fraction in pooled serum samples 4 h after the high-fat challenges are 
shown in Supplemental Table S4.3. At baseline, obese subjects had significantly higher TG 
and insulin levels when compared to lean subjects. All three high-fat challenges increased 
TG and FFA concentrations at 2 and 4 h. The increase in TG was higher after the MUFA 
challenge (P<0.001) in both lean and obese subjects when compared with SFA and n3 PUFA 
shake consumption. Obese subjects showed a significantly higher increase in TG (P=0.046) 
after the MUFA shake when compared to lean subjects. Furthermore, increases in specific FFA 
in de TG fraction were observed that reflected the composition of the shakes (Supplemental 
Table S4.3). The percentage of palmitic acid was 1.1-fold higher after the SFA challenge, the 
percentage of oleic acid was 1.6-fold higher after the MUFA challenge and the percentage of 
DHA was 9.5-fold higher after the n3 PUFA challenge. 
Oxylipin profiling
A total of 36 oxylipins were detected, which were derived from 6 different precursor FA 
(Supplemental Table S4.4). These included oxylipins produced by either n6 PUFAs, e.g. AA and 
LA, or n3 PUFAs, e.g. EPA and DHA. The detected oxylipins including the statistical outcomes 
of the linear mixed model are shown in Table 4.2. No significant differences in oxylipin levels 
between lean and obese subjects were observed at baseline or after high fat shake consumption. 
We therefore do not discriminate between the two groups for the rest of the results section.
Postprandial oxylipin responses 
The majority of the detected oxylipin compounds were affected by shake consumption, with the 
exception of the LA-derived epoxides 12(13)-EpOME and 9(10)-EpOME and the AA-derived 
compounds PGF2α, TXB2, 11-HETE, 12-HHTrE, 12-HETE and 15-HETE (Table 4.2). Fold 
changes of the postprandially changed oxylipins are visualized in a metabolic pathway scheme 
of enzymatic oxylipin formation (Figure 4.1). The COX products PGE2 and PGD2, the LOX 
product, 5-HETE and the CYP450 products 12,13-DiHOME decreased 2 h and 4 h after shake 
consumption. The LA-derived oxylipins 13-HODE, 9-HODE and 9,12,13-TriHOME from the 
LOX pathway increased after shake consumption. In addition, the AA-derived DiHETrEs, EPA-
derived DiHETEs and DHA-derived 19,20-DiHDPA from the CYP450 enzymatic pathway 
were generally increased 4 h after shake consumption
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Table 4.2 Detected oxylipins and the statistical outcomes of the linear mixed model
P-values
Precursor
FA
Enzymatic
pathway
Main effects Interaction
Oxylipin Baseline G S T G x T S x T
LA CYP450 12(13)-EpOME  -  -  -  -  -  -
LA CYP450 12,13-DiHOME  -  -  - <0.001  - <0.05
LA CYP450 9(10)-EpOME  -  -  -  -  -  -
LA CYP450 9,10-DiHOME  -  - <0.001 <0.001  - <0.001
LA CYP450 9,12,13-TriHOME  -  - <0.001 <0.001  - <0.05
LA LOX 13-HODE  -  - <0.001 <0.001  - <0.001
LA LOX 13-HpODE  -  -  - <0.001  -  -
LA LOX 13-KODE  -  -  - <0.001  -  -
LA LOX 9-HODE  -  - <0.001 <0.001  - <0.01
LA LOX 9-HpODE  -  -  -  -  -  -
LA LOX 9-KODE  -  -  -  -  -  -
DGLA COX PGF1a  -  -  -  -  -  -
AA COX PGD2  -  -  - <0.001  -  -
AA COX PGE2  -  -  - <0.001  -  -
AA COX PGF2a  -  - <0.05  -  -  -
AA COX TXB2  -  -  -  -  -  -
AA COX 11-HETE  -  -  -  -  -  -
AA COX 12-HHTrE  -  -  -  -  -  -
AA CYP450 14,15-DiHETrE  -  - <0.01 <0.001  - <0.01
AA CYP450 11,12-DiHETrE  -  - <0.001 <0.001  - <0.001
AA CYP450 8,9-DiHETrE  -  - <0.05 <0.001  -  -
AA CYP450 5,6-DiHETrE  -  -  - <0.001  - <0.01
AA LOX 12-HETE  -  -  -  -  -  -
AA LOX 15-HETE  -  -  -  -  -  -
AA LOX 15-KETE  -  -  - <0.05  -  -
AA LOX 5-HETE  -  - <0.05 <0.001  -  -
ALA LOX 9-HOTrE  -  - <0.001 <0.01  - <0.001
EPA COX TXB3  -  - <0.001 <0.001  - <0.001
EPA CYP450 17,18-DiHETE  -  - <0.001 <0.001  - <0.001
EPA CYP450 14,15-DiHETE  -  - <0.001 <0.001  - <0.001
EPA LOX 12-HEPE  -  - <0.001 <0.001  - <0.01
EPA LOX 15-HEPE  -  - <0.001 <0.01  - <0.01
EPA LOX 5-HEPE  -  - <0.001 <0.001  - <0.001
DHA CYP450 19(20)-EpDPE  -  - <0.001 <0.001  - <0.001
DHA CYP450 19,20-DiHDPA  -  - <0.001 <0.001  - <0.001
DHA LOX 17-HDoHE  -  - <0.001 <0.001  - <0.001
AA, arachidonic acid; DHA, docosahexaenoic acid; DGLA, dihomo-gamma-linolenic acid; EPA, eicosapentaenoic 
aicd; LA, linoleic acid. P-values were calculated using linear mixed models for repeated measures with a false 
discovery rate (FDR) correction for multiple testing. Baseline, baseline comparison between groups; G, group effect; 
S, shake effect; T, time effect; G x T, group x time interaction; S x T, shake x time interaction; -, not significant (P=0.05).
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Differences between shakes
Differences in oxylipin responses between the three different shakes are also visualized in 
the metabolic pathway scheme (Figure 4.1). After SFA shake consumption the increase in 
the LA-derived alcohols 13-HODE, 9-HODE and the triol 9,12,13-TriHOME was more 
pronounced when compared to the other shakes. LA-derived diol 9,10-DiHOME increased 
after MUFA shake consumption, but decreased after SFA and PUFA shake consumption. 
MUFA consumption also caused more decreased levels of the LA-derived diol 12,13-DiHOME 
and the AA-derived alcohol 5-HETE when compared to the other shakes. After the n3 PUFA 
challenge the concentrations of all detected EPA- and DHA-derived metabolites involved in 
the CYP450 pathway were more increased when compared to the other shakes. In addition, 
the EPA-derived HEPEs produced by LOX enzymes and the AA-derived TBX3 produced by 
COX enzymes were only increased after n3 PUFA consumption. High fat n3 PUFA consump-
tion also led to stronger increases in AA-derived DiHETrEs from the CYP450 enzymatic 
pathway.
Correlations of selected oxylipins 
To determine associations between postprandial changes in individual oxylipins, we correlated 
delta values of each oxylipin per shake (Figure 4.2). For this correlation analyzes we used delta 
values of 4 h versus baseline and selected only the oxylipins that were significantly changed 
between the shakes. Changes in LA-derived 13-HODE, 9-HODE and 9,12,13-TriHOME 
strongly correlated with each other, especially after SFA and n3 PUFA consumption. Changes 
in EPA- and DHA-derived metabolites and AA-derived DiHETrEs correlated with each other 
after n3 PUFA consumption. These results demonstrate that these oxylipins all change mostly 
in dependence on their precursor oxylipins. Changes in plasma TG correlated positively with 
the changes in 13-HODE, 9-HODE and 9,12,13-TriHOME after SFA consumption.
DISCUSSION
Oxylipins are involved in a vast number of inflammatory processes and evidence of the 
importance of circulating oxylipins in endothelial function is growing. We are the first 
demonstrating that a high fat meal acutely alters circulating oxylipin profiles and that 
these changes are highly affected by the dietary fatty acid composition. A high fat n3 PUFA 
enriched shake increased EPA- and DHA-derived oxylipins. High fat SFA shake consumption 
predominantly increased LA-derived oxylipins from the LOX pathway. A MUFA enriched 
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shake increased LA-derived oxylipins from the CYP450 pathway. No differences in oxylipin 
response were observed between lean and obese subjects. 
We previously found that high-fat consumption initiates an activated state of cellular adherence 
and an atherogenic milieu [12]. Oxylipins are important modulators of the inflammatory 
response and changes in circulating oxylipins after a high fat challenge test, may contribute to 
this pro-atherogenic response [5]. Overall, high fat meal consumption increased LA-derived 
oxylipins from the LOX pathway and EPA, DHA and AA-derived oxylipins from the CYP450 
pathway. High fat meal consumption did not increase COX-related oxylipins, which are typical 
pro-inflammatory lipid mediators [3]. Many postprandially changed oxylipin tended to decrease 
2 h postprandially, followed by an increase 4 h postprandially. The initial decrease in oxylipin 
after 2 hours might be due to a reduced lipolysis caused by the acute postprandial increase in 
insulin. The increase in insulin may reduce the release of fatty acids from the adipose tissue 
and TRLs and hence may reduce oxylipin formation [13,14]. After a decline in insulin, lipolysis 
is restored and fatty acids are again released from the tissues and TRLs into plasma, hence 
explaining the increase in oxylipins 4 h postprandially [13-15]. 
Fatty acid type highly affected the postprandial circulating oxylipin response. Correlations 
showed that these fatty acid specific-affected oxylipins all changed in a similar direction and 
magnitude. Although, this can be expected, these associations have never been shown in humans 
in a postprandial state. High SFA consumption postprandially increased LOX-mediated and 
LA-derived 9-HODE and 13-HODE. HODEs have been shown to increase inflammatory 
mediators, such as TNFα, ICAM and reactive oxygen species in vitro [5,7]. These changes after 
SFA consumption may point towards a pro-atherogenic environment for the endothelium. 
MUFA consumption increased 9,10-DiHOME and decreased 12,13-DiHOME. These LA-
derived oxylipins have been studied in vitro, but both adverse and beneficial effects have been 
reported [16]. It is therefore unclear how postprandial changes in these oxylipins after MUFA 
consumption may affect vascular health. Most observed differences in circulating oxylipin 
response between fatty acids were observed after n3 PUFA consumption. High fat n3 PUFA 
consumption led to stronger increases in CYP450-mediated and AA-derived DiHETrEs, which 
are hydrolysis products of epoxyeicosatrienoic acids (EETs). EETs were not detected in the 
current study, possibly due to a fast turnover rate to their corresponding DiHETrEs. EETs have 
anti-inflammatory properties, but these characteristics seem to diminish after hydrolysis to 
their corresponding DiHETrEs [2]. The question therefore remains if, how and in which way 
our observed effects on DiHETrEs can affect the endothelium. High fat n3 PUFA consumption 
also increased oxylipins from EPA and DHA precursors. The biological effects of these EPA/
DHA-derived oxylipins are poorly described in literature. It has been suggested that EPA- and 
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DHA-derived oxylipins have a lower pro-inflammatory potency compared to AA-derived 
oxylipins [17]. Shifting the balance from AA-derived oxylipins towards EPA- and DHA-derived 
oxylipins due to enzymatic competition might be beneficial to lower inflammation on the long 
run [17-19]. More studies are needed to disentangle acute and chronic effects. Nonetheless, 
these bioactive oxidized lipids are liberated from TRLs in close proximity to the endothelium. 
Repeated exposure of these elevated oxylipins in the postprandial phase might therefore affect 
endothelial function on the long run. 
The current prevailing hypothesis is that local oxylipins are not stored, but synthesized de 
novo from membrane bound FA [3]. The source of circulating oxylipins in plasma and how 
they are regulated postprandially is still largely unknown [5]. Interestingly, we observed that 
precursor fatty acids of several changed oxylipins reflected the FA composition of the shakes. 
For example, the n3 PUFA shake contained high amounts of EPA and DHA, hence consumption 
of this shake increased many EPA- and DHA- derived oxylipins. Moreover, the SFA shake 
contained the highest amounts of LA due to the palm oil naturally comprising of around 9% 
of LA, followed by the MUFA shake containing high oleic sunflower oil with approximately 
3.6% less LA [20]. The concentration of LA was lower in the n3 PUFA shake as well, because 
a part of the SFA was substituted by n3 PUFA. As a possible consequence of the different 
LA concentrations present in the shakes, the consumption of the SFA shake increased LA-
derived oxylipins 9-HODE, 9,12,13-TriHOME and 13-HODE, while these increases were less 
pronounced after MUFA and n3 PUFA consumption. These findings suggest that the dietary 
exogenous fatty acids may act directly as precursor molecules for the biosynthesis of these 
circulating oxylipins. However, not all observed changes reflected the fatty acids composition 
of the shake. For example, AA was not present in our intervention shakes, whereas many 
AA-derived were increased postprandially. Dietary fatty acids may also postprandially affect 
circulating oxylipin profiles indirectly. It is known that dietary fatty acids are potent signaling 
molecules [21]. Fatty acids may activate distinct enzymatic or inflammatory pathways, thereby 
affecting the synthesis of oxylipin from membrane bound fatty acids. Future postprandial 
challenge studies with 13C-labeled fatty acids are needed to determine if the consumed fatty 
acids affect the biosynthesis of these circulating oxylipins indirectly by activating distinct 
enzymatic pathways and/or can act directly as precursor molecules. 
In conclusion, we are the first demonstrating that circulating oxylipins profiles are affected 
after consumption of a high fat meal challenge and that these changes are strongly influenced 
by the fatty acid composition of the meal challenge. It is difficult to evaluate how these acute 
postprandial changes affect health, but our findings may suggest that SFA consumption creates 
a more pro-atherogenic environment, whereas n3 PUFA consumption seems to create a less 
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harmful environment for the endothelium. This current study urges future research to elucidate 
the formation of these postprandial circulating oxylipins and their mechanism of action and 
potential role in cardiovascular disease risk. 
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SUPPleMeNT
Supplemental Table S4.1 Nutritional values of the three intervention high fat shakes
Nutritional value SFA MUFA n3 PUFA
Energy (kcal) 990 990 990
Protein (g) 10 10 10
Carbohydrates (g) 19 19 19
Fat (g) 95 95 95
Saturated fatty acids (g) 51 8 32
Monounsaturated fatty acids (g) 37 79 25
Polyunsaturated fatty acids (g) 6 8 38
ALA (g) 0 0 0
EPA (g) 0 0 3
DHA (g) 0 0 23
Vitamin E (mg) 165 165 165
Calculated using the Dutch Food Composition table (NEVO 2006). ALA, alpha-linolenic acid (18:3).
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Supplemental Table S4.3 Baseline and postprandial changes in triglyceride fatty acid composition 
after high fat SFA, MUFA and n3 PUFA shake consumption in lean and obese men
Shake
SFA MUFA n3 PUFA
Baseline Δ4h Baseline Δ4h Baseline Δ4h
% of total % of total % of total
Palmitic acid
Lean 27. 5 2.9 25.8 -11.5 27.1 -0.6
Obese 28.1 2.5 27.9 -11.2 29.1 0.3
Oleic acid
Lean 35.8 2.5 38.1 22.8 37.4 -2.5
Obese 36.1 1.1 36.0 20.7 35.7 -0.6
DHA
Lean 0.68 -0.09 0.44 -0.12 0.32 4.56
Obese 0.66 -0.09 0.63 -0.16 0.55 2.86
Pooled samples for lean (n=18) and obese (n=18) men at baseline and 4 hours after shake consumption measured 
in serum. Only values for palmitic acid, oleic acid and DHA are displayed.
81
Postprandial changes in circulating oxylipins after high fat challenges
Chapter 4
4
Su
pp
le
m
en
ta
l T
ab
le
 S
4.
4 
Ba
se
lin
e 
an
d 
po
st
pr
an
di
al
 ch
an
ge
s i
n 
ox
yl
ip
in
s a
fte
r h
ig
h 
fa
t S
FA
, M
U
FA
 a
nd
 n
3 
PU
FA
 sh
ak
e 
co
ns
um
pt
io
n 
in
 le
an
 a
nd
 o
be
se
 m
en
SF
A
M
U
FA
PU
FA
O
xy
lip
in
 
G
ro
up
Ba
se
lin
e
Δ
2h
 
Δ
4h
Ba
se
lin
e
Δ
2h
 
Δ
4h
Ba
se
lin
e
Δ
2h
 
Δ
4h
12
(1
3)
-E
pO
M
E
Le
an
0.
04
±0
.0
06
-0
.0
13
±0
.0
07
-0
.0
04
±0
.0
06
0.
02
7±
0.
00
2
0±
0.
00
5
-0
.0
03
±0
.0
04
0.
04
±0
.0
07
-0
.0
11
±0
.0
08
-0
.0
13
±0
.0
08
O
be
se
0.
04
±0
.0
07
-0
.0
09
±0
.0
07
-0
.0
04
±0
.0
06
0.
04
4±
0.
00
7
0.
00
1±
0.
01
1
-0
.0
15
±0
.0
07
0.
03
2±
0.
00
3
-0
.0
06
±0
.0
04
0.
00
3±
0.
00
4
12
,1
3-
D
iH
O
M
E
Le
an
0.
52
2±
0.
07
5
-0
.2
24
±0
.0
66
-0
.1
18
±0
.0
8
0.
46
4±
0.
10
8
-0
.2
21
±0
.0
9
-0
.2
69
±0
.1
09
0.
58
4±
0.
08
4
-0
.2
4±
0.
07
4
-0
.2
22
±0
.0
92
O
be
se
0.
41
6±
0.
04
6
-0
.1
04
±0
.0
47
-0
.0
23
±0
.0
5
0.
39
3±
0.
06
3
-0
.0
41
±0
.0
65
-0
.1
26
±0
.0
61
0.
39
6±
0.
03
7
-0
.1
1±
0.
03
5
-0
.0
49
±0
.0
37
9(
10
)-E
pO
M
E
Le
an
0.
08
2±
0.
01
2
0.
00
7±
0.
02
2
0.
03
±0
.0
22
0.
06
6±
0.
01
-0
.0
11
±0
.0
1
0.
00
6±
0.
01
7
0.
07
1±
0.
00
9
-0
.0
18
±0
.0
1
-0
.0
18
±0
.0
1
O
be
se
0.
09
5±
0.
02
4
-0
.0
11
±0
.0
28
0.
00
1±
0.
03
1
0.
11
1±
0.
03
3
0.
01
2±
0.
03
2
-0
.0
23
±0
.0
28
0.
06
4±
0.
00
7
-0
.0
06
±0
.0
12
0.
00
1±
0.
01
3
9,
10
-D
iH
O
M
E
Le
an
0.
60
8±
0.
08
8
-0
.2
47
±0
.0
64
-0
.0
7±
0.
08
2
0.
68
7±
0.
12
0.
55
4±
0.
13
7
0.
48
4±
0.
08
7
0.
56
9±
0.
07
8
-0
.1
98
±0
.0
61
-0
.1
07
±0
.0
81
O
be
se
0.
48
8±
0.
10
9
-0
.0
63
±0
.0
52
0.
00
2±
0.
08
4
0.
47
7±
0.
08
7
0.
33
7±
0.
11
3
0.
46
±0
.1
43
0.
42
8±
0.
04
7
-0
.0
75
±0
.0
42
0.
03
5±
0.
04
7
9,
12
,1
3-
Tr
iH
O
M
E
Le
an
0.
25
2±
0.
03
2
0.
14
1±
0.
03
2
0.
25
5±
0.
06
7
0.
19
6±
0.
01
2
0.
07
2±
0.
01
9
0.
07
8±
0.
01
9
0.
35
8±
0.
09
5
-0
.0
26
±0
.0
79
0.
03
2±
0.
07
8
O
be
se
0.
33
4±
0.
07
-0
.0
08
±0
.0
64
0.
26
3±
0.
15
8
0.
22
7±
0.
01
9
0.
08
2±
0.
03
1
0.
07
5±
0.
02
2
0.
23
3±
0.
02
4
0.
01
1±
0.
02
9
0.
1±
0.
03
9
13
-H
O
D
E
Le
an
0.
75
7±
0.
07
2
0.
66
7±
0.
08
8
0.
93
2±
0.
12
7
0.
73
2±
0.
09
9
0.
09
7±
0.
10
8
0.
28
6±
0.
12
7
1.
04
±0
.1
24
-0
.0
02
±0
.1
69
0.
21
9±
0.
16
5
O
be
se
0.
81
±0
.1
36
0.
29
±0
.1
54
0.
74
7±
0.
25
3
0.
89
7±
0.
12
2
0.
01
3±
0.
15
2
0.
32
2±
0.
13
5
0.
82
9±
0.
08
7
-0
.1
05
±0
.1
02
0.
29
3±
0.
17
1
13
-H
pO
D
E
Le
an
0.
11
5±
0.
02
5
-0
.0
53
±0
.0
21
-0
.0
23
±0
.0
22
0.
09
4±
0.
01
4
-0
.0
32
±0
.0
14
-0
.0
2±
0.
01
2
0.
10
8±
0.
01
8
-0
.0
34
±0
.0
16
-0
.0
43
±0
.0
19
O
be
se
0.
11
±0
.0
17
-0
.0
29
±0
.0
21
0.
01
6±
0.
02
1
0.
11
8±
0.
02
6
-0
.0
38
±0
.0
25
-0
.0
12
±0
.0
29
0.
10
9±
0.
01
5
-0
.0
24
±0
.0
18
0.
00
3±
0.
01
1
13
-K
O
D
E
Le
an
0.
19
1±
0.
02
4
-0
.0
33
±0
.0
2
0.
01
9±
0.
01
9
0.
19
5±
0.
02
3
-0
.0
26
±0
.0
19
-0
.0
35
±0
.0
27
0.
21
9±
0.
03
-0
.0
47
±0
.0
3
-0
.0
5±
0.
03
4
O
be
se
0.
20
4±
0.
02
7
-0
.0
35
±0
.0
29
0.
03
8±
0.
03
3
0.
21
9±
0.
03
2
-0
.0
55
±0
.0
34
-0
.0
08
±0
.0
36
0.
19
5±
0.
02
1
-0
.0
2±
0.
02
6
0.
04
2±
0.
01
9
9-
H
O
D
E
Le
an
0.
82
5±
0.
08
4
0.
66
5±
0.
16
3
1.
00
6±
0.
17
6
0.
75
3±
0.
12
1
0.
15
±0
.1
32
0.
41
±0
.1
58
1.
15
7±
0.
14
8
-0
.1
05
±0
.2
34
0.
23
3±
0.
21
6
O
be
se
0.
90
8±
0.
15
0.
18
9±
0.
16
5
0.
83
8±
0.
30
8
1.
06
4±
0.
18
3
-0
.0
32
±0
.2
43
0.
39
2±
0.
22
3
0.
93
8±
0.
09
8
-0
.1
9±
0.
11
6
0.
33
9±
0.
2
9-
H
pO
D
E
Le
an
0.
07
4±
0.
01
4
-0
.0
1±
0.
01
3
0.
00
1±
0.
01
2
0.
08
3±
0.
01
3
-0
.0
18
±0
.0
14
-0
.0
17
±0
.0
14
0.
08
7±
0.
01
6
-0
.0
15
±0
.0
08
-0
.0
29
±0
.0
16
O
be
se
0.
08
±0
.0
14
-0
.0
11
±0
.0
14
0.
02
8±
0.
02
2
0.
09
2±
0.
01
3
-0
.0
15
±0
.0
14
0±
0.
01
6
0.
08
±0
.0
1
-0
.0
01
±0
.0
12
0.
01
1±
0.
00
8
9-
KO
D
E
Le
an
0.
03
1±
0.
00
4
0.
01
3±
0.
00
4
0.
01
9±
0.
00
4
0.
03
3±
0.
00
3
0.
00
2±
0.
00
4
0.
00
7±
0.
00
4
0.
04
±0
.0
05
-0
.0
07
±0
.0
06
-0
.0
06
±0
.0
06
 
O
be
se
0.
04
3±
0.
00
9
-0
.0
07
±0
.0
09
-0
.0
01
±0
.0
12
0.
03
5±
0.
00
5
0±
0.
00
6
0.
00
6±
0.
00
5
0.
03
±0
.0
02
0.
00
1±
0.
00
4
0.
00
8±
0.
00
4
Su
pp
le
m
en
ta
l T
ab
le
 S
4.
4 
co
nt
in
ue
s o
n 
ne
xt
 p
ag
e.
82
Postprandial changes in circulating oxylipins after high fat challengesChapter 4
Su
pp
le
m
en
ta
l T
ab
le
 S
4.
4 
Co
nt
in
ue
d
SF
A
M
U
FA
PU
FA
O
xy
lip
in
 
G
ro
up
Ba
se
lin
e
Δ
2h
 
Δ
4h
Ba
se
lin
e
Δ
2h
 
Δ
4h
Ba
se
lin
e
Δ
2h
 
Δ
4h
PG
F1
a
Le
an
0.
02
5±
0.
00
4
-0
.0
05
±0
.0
04
-0
.0
02
±0
.0
05
0.
02
4±
0.
00
2
0.
00
1±
0.
00
2
-0
.0
01
±0
.0
03
0.
02
7±
0.
00
2
-0
.0
03
±0
.0
02
-0
.0
01
±0
.0
04
 
O
be
se
0.
02
3±
0.
00
1
0.
00
1±
0.
00
2
0.
00
1±
0.
00
3
0.
02
5±
0.
00
2
-0
.0
02
±0
.0
02
0.
00
1±
0.
00
2
0.
02
6±
0.
00
2
-0
.0
01
±0
.0
03
0±
0.
00
3
PG
D
2
Le
an
0.
07
±0
.0
07
-0
.0
18
±0
.0
06
-0
.0
03
±0
.0
07
0.
06
±0
.0
07
-0
.0
11
±0
.0
09
-0
.0
08
±0
.0
05
0.
07
5±
0.
00
8
-0
.0
14
±0
.0
09
-0
.0
06
±0
.0
1
O
be
se
0.
06
5±
0.
00
7
-0
.0
12
±0
.0
07
-0
.0
08
±0
.0
06
0.
06
3±
0.
00
5
-0
.0
13
±0
.0
05
-0
.0
07
±0
.0
03
0.
06
3±
0.
00
5
-0
.0
13
±0
.0
04
0.
00
2±
0.
00
7
PG
E2
Le
an
0.
14
7±
0.
01
5
-0
.0
28
±0
.0
09
-0
.0
05
±0
.0
11
0.
11
9±
0.
01
1
-0
.0
08
±0
.0
14
-0
.0
07
±0
.0
1
0.
15
4±
0.
01
6
-0
.0
31
±0
.0
16
-0
.0
19
±0
.0
18
O
be
se
0.
11
2±
0.
01
1
-0
.0
2±
0.
01
3
-0
.0
06
±0
.0
09
0.
11
1±
0.
01
-0
.0
08
±0
.0
09
-0
.0
04
±0
.0
06
0.
11
8±
0.
00
9
-0
.0
24
±0
.0
09
0.
00
2±
0.
01
1
PG
F2
a
Le
an
0.
09
5±
0.
00
7
0.
00
9±
0.
00
8
0.
00
2±
0.
00
9
0.
09
6±
0.
01
1
0.
00
5±
0.
00
9
0.
00
5±
0.
00
7
0.
10
1±
0.
01
2
-0
.0
15
±0
.0
11
-0
.0
15
±0
.0
09
O
be
se
0.
10
8±
0.
00
9
0.
00
2±
0.
00
6
0.
00
4±
0.
01
0.
11
2±
0.
00
9
0.
00
2±
0.
00
8
0.
01
±0
.0
09
0.
10
4±
0.
01
3
0.
00
2±
0.
00
9
-0
.0
04
±0
.0
09
TX
B2
Le
an
0.
91
8±
0.
1
-0
.0
95
±0
.0
76
0.
06
8±
0.
09
8
0.
89
8±
0.
11
2
0±
0.
12
4
0.
00
3±
0.
12
3
1.
07
5±
0.
15
4
0.
02
4±
0.
20
7
0.
03
4±
0.
20
6
O
be
se
0.
74
2±
0.
09
-0
.0
16
±0
.1
13
0.
12
6±
0.
12
6
0.
95
2±
0.
14
5
-0
.1
16
±0
.1
56
-0
.0
13
±0
.1
81
0.
78
3±
0.
10
4
-0
.0
74
±0
.0
79
0.
06
8±
0.
10
6
11
-H
ET
E
Le
an
0.
85
4±
0.
09
8
-0
.1
1±
0.
13
1
0.
00
5±
0.
11
4
0.
71
3±
0.
10
6
0.
06
3±
0.
17
0.
24
±0
.1
57
0.
90
2±
0.
10
8
0.
04
5±
0.
26
2
0.
09
3±
0.
23
5
O
be
se
0.
60
8±
0.
07
6
-0
.0
69
±0
.1
04
0.
10
8±
0.
11
8
0.
99
6±
0.
21
5
-0
.2
76
±0
.2
37
-0
.0
11
±0
.2
73
0.
63
7±
0.
07
4
-0
.0
26
±0
.0
83
0.
1±
0.
11
4
12
-H
H
Tr
E
Le
an
0.
86
±0
.1
03
-0
.0
15
±0
.1
57
0.
05
1±
0.
11
7
0.
78
3±
0.
14
3
0.
11
5±
0.
19
9
0.
19
3±
0.
20
2
1.
00
2±
0.
15
7
0.
10
9±
0.
27
4
0.
05
7±
0.
31
O
be
se
0.
66
9±
0.
07
4
0.
01
9±
0.
11
0.
17
2±
0.
13
5
0.
98
9±
0.
19
6
-0
.1
53
±0
.2
6
0.
00
3±
0.
26
3
0.
69
2±
0.
10
6
0.
00
5±
0.
08
5
0.
02
4±
0.
12
14
,1
5-
D
iH
ET
rE
Le
an
0.
03
6±
0.
00
2
-0
.0
02
±0
.0
02
0.
00
8±
0.
00
3
0.
03
9±
0.
00
3
0.
01
1±
0.
00
4
0.
01
5±
0.
00
5
0.
04
6±
0.
00
4
0±
0.
00
8
0.
02
3±
0.
00
7
O
be
se
0.
04
±0
.0
02
-0
.0
02
±0
.0
02
0.
00
8±
0.
00
3
0.
03
9±
0.
00
3
0.
00
6±
0.
00
4
0.
00
9±
0.
00
4
0.
05
±0
.0
06
-0
.0
11
±0
.0
07
0.
01
6±
0.
01
11
,1
2-
D
iH
ET
rE
Le
an
0.
01
4±
0.
00
1
0±
0.
00
2
0.
00
6±
0.
00
2
0.
01
6±
0.
00
2
0.
00
6±
0.
00
2
0.
00
7±
0.
00
3
0.
01
9±
0.
00
3
0±
0.
00
4
0.
01
8±
0.
00
5
O
be
se
0.
01
5±
0.
00
1
-0
.0
02
±0
.0
01
0.
00
4±
0.
00
2
0.
01
5±
0.
00
2
0.
00
3±
0.
00
2
0.
00
6±
0.
00
3
0.
02
±0
.0
04
-0
.0
07
±0
.0
05
0.
01
2±
0.
00
7
8,
9-
D
iH
ET
rE
Le
an
0.
00
6±
0.
00
1
0.
00
2±
0.
00
1
0.
00
3±
0.
00
1
0.
00
7±
0.
00
1
0.
00
2±
0.
00
1
0.
00
4±
0.
00
2
0.
01
±0
.0
01
0.
00
1±
0.
00
3
0.
00
5±
0.
00
2
O
be
se
0.
00
7±
0.
00
1
0.
00
1±
0.
00
1
0.
00
3±
0.
00
1
0.
00
8±
0.
00
1
0.
00
2±
0.
00
1
0.
00
2±
0.
00
1
0.
01
1±
0.
00
2
-0
.0
03
±0
.0
02
0.
00
4±
0.
00
3
5,
6-
D
iH
ET
rE
Le
an
0.
00
7±
0.
00
1
0±
0.
00
1
0.
00
2±
0.
00
1
0.
00
9±
0.
00
2
0.
00
2±
0.
00
1
0.
00
2±
0.
00
1
0.
01
1±
0.
00
1
-0
.0
01
±0
.0
02
0.
00
4±
0.
00
2
O
be
se
0.
01
±0
.0
01
-0
.0
01
±0
.0
01
0±
0.
00
1
0.
01
±0
.0
01
-0
.0
01
±0
.0
01
0.
00
1±
0.
00
1
0.
01
3±
0.
00
2
-0
.0
03
±0
.0
02
0.
00
3±
0.
00
2
12
-H
ET
E
Le
an
3.
13
5±
0.
54
2
-0
.3
21
±0
.4
61
-0
.0
8±
0.
43
5
2.
79
1±
0.
69
-0
.1
45
±0
.8
39
0.
37
±0
.7
63
3.
42
7±
0.
60
1
0.
24
6±
0.
89
3
-0
.1
53
±0
.9
26
O
be
se
2.
05
1±
0.
28
7
0.
06
±0
.4
3
0.
57
3±
0.
51
8
3.
43
5±
0.
78
3
-0
.4
85
±1
.1
04
0.
41
5±
1.
00
1
2.
18
2±
0.
33
1
-0
.0
67
±0
.3
02
0.
05
1±
0.
35
9
83
Postprandial changes in circulating oxylipins after high fat challenges
Chapter 4
4
15
-H
ET
E
Le
an
0.
13
9±
0.
02
1
-0
.0
1±
0.
01
0.
02
3±
0.
01
8
0.
10
9±
0.
01
3
0.
01
±0
.0
16
0.
00
1±
0.
01
0.
18
8±
0.
02
6
-0
.0
28
±0
.0
19
-0
.0
38
±0
.0
16
O
be
se
0.
11
2±
0.
01
4
-0
.0
05
±0
.0
16
0.
00
2±
0.
01
4
0.
13
8±
0.
02
9
-0
.0
34
±0
.0
3
-0
.0
18
±0
.0
3
0.
12
5±
0.
01
4
-0
.0
14
±0
.0
1
-0
.0
02
±0
.0
13
15
-K
ET
E
Le
an
0.
04
6±
0.
00
5
-0
.0
04
±0
.0
04
0.
00
2±
0.
00
7
0.
04
5±
0.
00
5
-0
.0
05
±0
.0
05
-0
.0
02
±0
.0
06
0.
05
7±
0.
00
6
-0
.0
05
±0
.0
07
-0
.0
05
±0
.0
06
O
be
se
0.
04
3±
0.
00
7
-0
.0
1±
0.
00
8
0.
00
2±
0.
00
7
0.
04
4±
0.
00
6
-0
.0
07
±0
.0
05
-0
.0
02
±0
.0
06
0.
04
8±
0.
00
5
-0
.0
06
±0
.0
04
0.
01
±0
.0
07
5-
H
ET
E
Le
an
0.
03
4±
0.
00
4
-0
.0
13
±0
.0
04
-0
.0
09
±0
.0
05
0.
02
6±
0.
00
2
-0
.0
09
±0
.0
04
-0
.0
06
±0
.0
03
0.
03
2±
0.
00
3
-0
.0
11
±0
.0
04
0±
0.
00
4
 
O
be
se
0.
03
±0
.0
03
-0
.0
09
±0
.0
04
0.
00
4±
0.
00
3
0.
03
8±
0.
00
9
-0
.0
19
±0
.0
11
-0
.0
16
±0
.0
11
0.
03
8±
0.
00
4
-0
.0
09
±0
.0
03
-0
.0
03
±0
.0
05
9-
H
O
Tr
E
Le
an
0.
04
7±
0.
00
8
0.
00
8±
0.
00
5
0.
02
5±
0.
00
7
0.
05
5±
0.
01
8
-0
.0
31
±0
.0
17
-0
.0
36
±0
.0
18
0.
06
7±
0.
00
9
-0
.0
24
±0
.0
09
-0
.0
15
±0
.0
1
 
O
be
se
0.
04
7±
0.
00
7
-0
.0
02
±0
.0
07
0.
02
5±
0.
01
3
0.
04
±0
.0
06
-0
.0
04
±0
.0
07
-0
.0
07
±0
.0
06
0.
04
8±
0.
00
6
-0
.0
14
±0
.0
06
0.
00
2±
0.
00
7
TX
B3
Le
an
0.
06
9±
0.
00
9
-0
.0
25
±0
.0
07
-0
.0
1±
0.
00
7
0.
06
1±
0.
01
-0
.0
15
±0
.0
08
-0
.0
16
±0
.0
09
0.
08
7±
0.
01
7
0±
0.
02
0.
09
9±
0.
03
O
be
se
0.
05
4±
0.
00
8
-0
.0
1±
0.
00
6
-0
.0
04
±0
.0
08
0.
05
1±
0.
00
8
-0
.0
04
±0
.0
06
0.
00
1±
0.
00
5
0.
06
7±
0.
01
-0
.0
15
±0
.0
1
0.
05
1±
0.
02
3
17
,1
8-
D
iH
ET
E
Le
an
0.
01
8±
0.
00
2
0±
0.
00
2
0.
00
6±
0.
00
2
0.
01
8±
0.
00
2
0.
00
9±
0.
00
2
0.
00
8±
0.
00
2
0.
03
1±
0.
00
6
0.
03
4±
0.
01
7
0.
11
7±
0.
02
5
O
be
se
0.
02
±0
.0
02
-0
.0
04
±0
.0
02
-0
.0
02
±0
.0
03
0.
02
±0
.0
03
0.
00
2±
0.
00
3
0.
00
6±
0.
00
3
0.
04
6±
0.
01
4
-0
.0
12
±0
.0
18
0.
05
6±
0.
02
9
14
,1
5-
D
iH
ET
E
Le
an
0.
00
6±
0.
00
1
0.
00
2±
0.
00
1
0.
00
4±
0.
00
2
0.
00
8±
0.
00
1
-0
.0
01
±0
.0
01
0.
00
2±
0.
00
2
0.
00
9±
0.
00
2
0.
00
9±
0.
00
3
0.
02
4±
0.
00
5
O
be
se
0.
00
9±
0.
00
2
-0
.0
02
±0
.0
02
-0
.0
01
±0
.0
02
0.
00
8±
0.
00
1
0±
0.
00
1
-0
.0
01
±0
.0
01
0.
01
4±
0.
00
3
-0
.0
03
±0
.0
04
0.
01
2±
0.
00
7
12
-H
EP
E
Le
an
0.
86
2±
0.
15
8
-0
.2
84
±0
.0
99
-0
.1
7±
0.
11
1
0.
68
8±
0.
11
4
-0
.1
3±
0.
11
4
-0
.0
88
±0
.0
95
1.
18
9±
0.
32
8
-0
.0
25
±0
.2
61
1.
12
3±
0.
48
3
O
be
se
0.
77
1±
0.
18
3
-0
.1
6±
0.
18
1
-0
.1
01
±0
.1
65
0.
79
9±
0.
13
8
-0
.1
91
±0
.1
21
0.
03
5±
0.
11
6
0.
78
2±
0.
11
2
-0
.0
83
±0
.0
81
0.
47
4±
0.
28
15
-H
EP
E
Le
an
0.
01
8±
0.
00
2
-0
.0
03
±0
.0
02
-0
.0
03
±0
.0
04
0.
01
2±
0.
00
2
-0
.0
03
±0
.0
02
-0
.0
02
±0
.0
02
0.
02
3±
0.
00
5
-0
.0
05
±0
.0
05
0.
00
9±
0.
00
5
O
be
se
0.
01
5±
0.
00
2
0±
0.
00
3
0.
00
3±
0.
00
3
0.
01
7±
0.
00
3
-0
.0
03
±0
.0
03
-0
.0
04
±0
.0
02
0.
01
8±
0.
00
2
-0
.0
02
±0
.0
02
0.
00
9±
0.
00
6
5-
H
EP
E
Le
an
0.
02
9±
0.
00
4
-0
.0
14
±0
.0
04
-0
.0
13
±0
.0
04
0.
01
9±
0.
00
3
-0
.0
12
±0
.0
03
-0
.0
09
±0
.0
04
0.
03
±0
.0
06
-0
.0
14
±0
.0
06
0.
00
8±
0.
00
4
 
O
be
se
0.
02
8±
0.
00
4
-0
.0
13
±0
.0
04
-0
.0
03
±0
.0
03
0.
03
±0
.0
05
-0
.0
11
±0
.0
04
-0
.0
11
±0
.0
04
0.
03
3±
0.
00
3
-0
.0
13
±0
.0
04
0.
00
8±
0.
00
5
19
(2
0)
-E
pD
PE
Le
an
0.
05
9±
0.
01
8
-0
.0
04
±0
.0
05
-0
.0
02
±0
.0
08
0.
03
8±
0.
00
9
-0
.0
07
±0
.0
11
-0
.0
05
±0
.0
1
0.
07
5±
0.
02
7
0.
01
2±
0.
00
6
0.
26
4±
0.
06
5
O
be
se
0.
03
5±
0.
00
4
0.
00
6±
0.
00
9
0.
00
3±
0.
01
1
0.
03
3±
0.
00
4
-0
.0
02
±0
.0
04
0.
01
±0
.0
06
0.
13
6±
0.
04
8
-0
.0
47
±0
.0
48
0.
11
4±
0.
07
1
19
,2
0-
D
iH
D
PA
Le
an
0.
08
9±
0.
01
2
0.
01
2±
0.
00
7
0.
03
3±
0.
00
9
0.
08
6±
0.
01
0.
06
±0
.0
11
0.
05
9±
0.
00
8
0.
14
4±
0.
03
1
0.
10
2±
0.
05
9
0.
44
4±
0.
09
5
O
be
se
0.
09
7±
0.
00
9
-0
.0
05
±0
.0
08
0.
02
3±
0.
01
0.
09
3±
0.
01
2
0.
02
4±
0.
01
2
0.
03
6±
0.
01
4
0.
19
9±
0.
05
5
-0
.0
53
±0
.0
68
0.
24
6±
0.
11
9
17
-H
D
oH
E
Le
an
0.
86
4±
0.
18
7
-0
.0
48
±0
.0
9
0.
14
8±
0.
15
4
0.
86
2±
0.
25
1
-0
.1
56
±0
.1
67
-0
.0
57
±0
.1
35
1.
85
1±
0.
71
2
0.
71
6±
0.
48
4
5.
68
2±
1.
59
8
O
be
se
1.
08
±0
.3
14
-0
.2
63
±0
.2
88
-0
.0
48
±0
.2
24
0.
94
7±
0.
28
3
-0
.2
36
±0
.2
27
-0
.0
04
±0
.1
75
0.
88
9±
0.
17
0.
18
2±
0.
10
1
3.
35
5±
1.
03
3
Re
sp
on
se
 ra
tio
s 
w
er
e 
ca
lc
ul
at
ed
 b
y 
pe
ak
 a
re
a 
of
 o
xy
lip
in
 c
om
po
un
d 
di
vi
de
d 
by
 p
ea
k 
ar
ea
 o
f i
nt
er
na
l s
ta
nd
ar
d.
 V
al
ue
s 
ar
e 
m
ea
n 
± 
SE
M
.
84
Postprandial changes in circulating oxylipins after high fat challengesChapter 4
In preparation.
Chapter 5
Distinct changes in peripheral blood 
mononuclear cell gene expression 
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ABSTRACT
Background: Atherosclerosis usually affects middle-aged adults, but the process often 
starts in early life. A promising strategy to detect early disturbances in vascular health is 
to impose subjects to a metabolic challenge, such as a high fat load. The ability to respond 
to such a challenge may reflect the flexibility of cells and organs and can be used to detect 
early perturbations in health status. We aimed to detect small disturbances in health status 
by comparing whole genome expression changes in peripheral blood mononuclear cells 
(PBMCs) between human subjects with different disease risk profiles after a high mono-
unsaturated fatty acids (MUFA) or high saturated fatty acid (SFA) challenge. 
Methods: In a double-blind cross-over study, 17 lean and 15 obese middle-aged men 
received two high-fat milkshakes containing 95g fat, either high in SFAs or MUFAs. PBMC 
gene expression profiles were determined before and 4 hours after shake consumption and 
induced gene expression changes were compared between obese and lean subjects and 
between the different fatty acids. 
Results: Pro-thrombotic genes were up-regulated in obese relative to lean subjects after 
SFA intake. After MUFA intake, genes involved in posttranslational protein modifications 
were up-regulated and various G-protein coupled receptors were down-regulated in obese 
relative to lean subjects. In both lean and obese subjects, the SFA shake decreased the 
expression of genes involved in the biosynthesis and uptake of cholesterol and increased the 
expression of genes involved in cholesterol efflux. The MUFA shake increased the expression 
of inflammatory genes and of peroxisome proliferator-activated receptor α (PPARα) target 
genes involved in the β-oxidation. 
Conclusions: Subject with different metabolic risk phenotypes have distinct changes in 
PBMC gene expression profiles after a high-fat challenge test with the most deviating effect 
for MUFA. The gene expression changes after SFA intake may suggest an intracellular 
situation of excess cholesterol after SFA intake. The up-regulation in expression of 
β-oxidation genes after MUFA intake may suggest an increased flow of fatty acids towards 
the β-oxidation. Both SFA and MUFA-regulated pathways are important in cellular lipid 
homeostasis. Dysregulation of these pathways may lead to increased lipid accumulation, 
an essential process in the formation of lipid-loaded macrophages. 
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INTRODUCTION
Cardiovascular diseases (CVD) are still one of the leading causes of deaths worldwide and 
the underlying pathological condition of many CVD is atherosclerosis. Atherosclerosis is a 
slowly progressing condition characterized by a thickening of the artery wall as a result of 
lipid accumulation and leukocyte infiltration in the sub-endothelial space [1]. Endothelial 
dysfunction is regarded as a pivotal factor in the onset and progression of atherosclerosis [2]. 
Atherosclerosis often affects older or middle-aged adults, but the process often starts early in 
life. A valuable strategy to detect early disturbances in vascular health is to impose subjects to 
a metabolic challenge test. The ability to respond to such a challenge may reflect the metabolic 
flexibility of cells and organs and can therefore be a useful tool to detect early perturbations 
in health status, even before this can be measured under fasting conditions [3]. A typical pro-
atherogenic meal challenge is a high fat load [4-6]. One of the current hypotheses is that the 
elevated concentrations of plasma triglyceride rich lipoproteins (TRLs) after a high fat meal 
activate endothelial cells and leukocytes and thereby affect endothelial function [20,34,35]. 
We recently observed that a challenge high in mono-unsaturated fatty acids (MUFA) elicited 
a more pronounced postprandial increase in triglyceride (TG) concentrations than a challenge 
high in saturated fatty acids (SFA), especially in obese individuals [7]. These findings suggest 
that MUFAs are more potent fatty acids to challenge the metabolic response capacity than SFAs 
and that obese individuals have perturbed postprandial metabolic responses. 
A major limitation for early detection of atherosclerosis is the limited accessibility of endothelial 
cells, especially in a pre-clinical setting. Cells that are available and easy to collect are circulating 
peripheral blood mononuclear cells (PBMCs). PBMCs are a mixture of T-cells, B-cells and 
monocytes, which can interact with the endothelium and play a role in the onset and progression 
of atherosclerosis. For example, monocytes are able to differentiate to macrophages and foam 
cells that are involved in the formation of fatty streaks during atherosclerosis development [22]. 
PBMCs are therefore a valuable source of material to study changes in metabolic and inflammatory 
processes. A powerful way to evaluate whole genome wide adaptive changes in gene transcription 
is by unbiased high-throughput transcriptome analysis. This allows the identification of affected 
stress related and metabolic compensatory pathways in PBMCs that may reflect the resilience 
capacity of these cells. Comparing postprandial changes in PBMC gene expression profiles after 
intake of SFAs and MUFAs may increase our understanding on how these fatty acids may exert 
their acute effects on PBMCs. Furthermore, challenging lean and obese subjects with a high-
fat shake enriched with SFAs or MUFAs may allow us to detect small disturbances in cellular 
response capacity related to health status. We therefore aimed to characterize PBMC whole genome 
expression changes in response to a high MUFA or high SFA challenge in lean and obese subjects.
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MATeRIAlS AND MeThODS
Subjects
We included 18 lean (predefined BMI 18–25 kg/m2) and 18 obese (predefined BMI >30 kg/m2) 
male subjects between 50–70 years old from a subpopulation of a previously reported study 
[7]. Six obese type 2 diabetic subjects from the original study were excluded because of the 
lower number. All lean and obese subjects were non-smoking, normoglycemic (WHO criteria) 
and not diagnosed with any long-term medical condition. All subjects gave written informed 
consent and the study was approved by the local Medical Ethics Committee. The study was 
registered at clinicaltrials.gov as NCT00977262. 
Study design
The study was a double-blind randomized cross-over intervention study in which each 
participant visited the university two times. On each study day, the subjects consumed 
milkshake with 95g of fat, which was high in either SFA or MUFA. Blood samples were 
collected before and 4 hours after a milkshake consumption. Subjects were randomly assigned 
to a treatment order and a one-week washout period was the minimum between consecutive 
study days. On the day prior to each study day, subjects consumed a standardized low fat 
evening meal, were refrained from alcohol or strenuous exercise and were not allowed to 
eat or drink anything except water after 08.00 pm. This study was conducted according to 
the principles of the Declaration of Helsinki and in accordance with the Medical Research 
Involving Human Subjects Act (WMO).
Intervention shakes
Both shakes had a volume of 500ml, were isocaloric and macronutrient composition differed 
only in fatty acid composition (Supplemental Table S5.1). The SFA shake contained 95g palm 
oil and the MUFA shake contained 95g high-oleic acid sunflower oil. Vitamin E (165mg) was 
added to the shakes to match vitamin E present in the n3 polyunsaturated fatty acid (PUFA) 
shake, that was used in the original study design. A more detailed description of the intervention 
shakes is previously reported [7].
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PBMC and RNA isolation
PBMCs were isolated before and 4 hours after milkshake consumption by BD Vacutainer Cell 
Preparation Tubes. RNA was isolated (RNeasy Micro kit, Qiagen, Venlo, the Netherlands), 
quantified (Nanodrop ND 1000, Nanodrop technologies, Wilmington, Delaware USA) and 
integrity was checked by an Agilent 2100 Bioanalyser with RNA 6000 microchips (Agilent 
Technologies, South Queensferry, UK). 
Micro-array processing 
PBMC samples from 17 lean and 15 obese subjects yielded enough RNA of sufficient quality 
at all collection points to perform microarray analysis. Microarray analysis was performed 
for each individual at baseline and 4 hours after SFA and MUFA consumption, resulting in a 
total of 128 microarrays.
Total RNA was labeled using a one-cycle cDNA labeling kit (MessageAmp™ II-Biotin Enhanced 
Kit; Ambion Inc, Nieuwekerk a/d IJssel, Netherlands) and hybridized to GeneChip® Human 
Gene 1.1 ST Array targeting 19,738 unique gene identifiers (Affymetrix Inc. Santa Clara, CA). 
Sample labelling, hybridization to chips and image scanning were performed according to the 
manufacturers’ instructions.
Microarray analysis
Microarrays were analysed by using MADMAX pipeline for statistical analysis of microarray 
data (https://madmax.bioinformatics.nl/). Microarrays were analysed using the reorganized 
oligonucleotide probes, which combines all individual probes for a gene [8]. Expression values 
were calculated using the robust multichip average (RMA) method and normalized by quantile 
normalization [9,10]. Genes with normalized signals >20 on >8 arrays were defined as expressed 
and selected for further analysis. At baseline, the expression of genes between lean and obese was 
defined as different when the P-value was <0.05 in a t-test with Bayesian correction (Limma) 
[11]. Gene expression was defined as postprandially changed between T0 and T4 when the 
P-value was <0.05 in a paired t-test with Bayesian correction (Limma). Differences in gene 
expression changes between groups or shakes were calculated from the individual signal to 
log ratios (SLR). Between lean and obese, changes after shake consumption were defined as 
different when the P-value <0.05 in a t-test with Bayesian correction (Limma). Changes after 
SFA and MUFA shake consumption were defined as different when the P-value <0.05 in a 
paired t-test with Bayesian correction (Limma). In the latter comparison we combined lean 
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and obese subjects to end up with a total of 32 participants to increase power. Data were further 
analysed with gene set enrichment analysis (GSEA) [12]. Gene sets with a false discovery rate 
(FDR) Q-value <0.25 were defined as significantly regulated. As a large number of gene sets 
was changed with FDR Q-value <0.25 we used a FDR Q-value <0.05 in Cytoscape (Cytoscape 
2.8.3) to visualize clusters of postprandially changed gene sets. 
Plasma metabolic markers and TG fatty acid composition
Plasma TG, glucose, insulin and free fatty acids (FFA) were assessed during fasting condition 
and 2 and 4h after milkshake consumption and have been published [7].
ReSUlTS
Subject characteristics and metabolic response
Baseline characteristics of the 17 lean and 15 obese subjects of which microarrays were 
performed are displayed in Table 5.1. Baseline and postprandial concentrations of glucose, TG, 
FFA and insulin are shown in Supplemental Table S5.2. Obese subjects had higher fasting TG 
and insulin concentrations than lean subjects. MUFA consumption was associated with a more 
pronounced increase in TG compared with the SFA consumption as has been published [7]. 
Differences between lean and obese subjects
Figure 5.1 is a flow chart of the number of genes of which the expression was significantly 
different between lean and obese subjects at baseline and of the number of genes that changed 
differently in expression in obese relative to the lean subjects after a high-fat SFA or MUFA 
challenge. At baseline 294 genes were significant differently expressed between lean and obese 
Table 5.1 Baseline characteristics of the subjects 
Lean (n=17) Obese (n=15)
Age (yrs) 62 ± 6 63 ± 4
Height (cm) 177 ± 8 179 ± 6
Weight (kg) 75 ± 7 105 ± 13*
BMI (kg/m2) 23.8 ± 0.9 32.5 ± 3.3*
Data are presented as mean ± SD. * Significantly different from lean subjects (P<0.05).
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5subjects. The SFA challenge changed the expression of 1,320 genes in obese and 1,517 genes in 
lean and the expression of 607 genes changed significant differently between lean and obese 
(delta obese T4-T0 vs. delta lean T4-T0). The MUFA challenge changed the expression of 3,171 
genes in obese and 2292 genes in lean and the expression of 2,516 genes changed significantly 
different between lean and obese (delta obese T4-T0 vs. delta lean T4-T0). A total of 10 
genes was significant differently expressed between lean and obese at baseline and changed 
significantly different in expression in obese relative to the lean subjects after both challenges 
i.e. TLE2, RNF5P1, VAV3, PLEK2, KIAA1522, SORCS3, IKBKE, ZNF740, CSGALNACT2 and 
TRAV12-2. A total of 82 genes changed significantly different in expression in obese relative 
to the lean subjects after both the SFA and MUFA shake.
At baseline, GSEA identified 15 gene sets that were lower expressed in obese compared to lean 
subjects (FDR Q<0.25). All gene sets were located in one cluster that largely included the same 
Figure 5.1 Flow diagram showing the number of genes of which the expression was significantly 
different between lean (n=17) and obese (n=15) subjects at baseline, the number of genes that 
changed in expression after a high-fat SFA or MUFA challenge and of the number of genes that 
changed differently in expression in obese relative to the lean subjects after a high-fat SFA or MUFA 
challenge. A change was significant if P<0.05. * Baseline differences between lean and obese subject 
were calculated from the mean signal intensities of the two baseline recordings. 
Entrez IDs
19,738 genes
Expressed:
8 arrays >20
14,257 genes
SFA challenge MUFA challenge
Baseline diﬀerences*
Lean Vs Obese
Genes: 294
Postprandial response
Lean (T4-T0)
Genes regulated: 1,517
Postprandial response
Obese (T4-T0)
Genes regulated: 1,320
Postprandial response
Lean (T4-T0)
Genes regulated: 2,292
Postprandial response
Obese (T4-T0)
Genes regulated: 3,171
Diﬀerences in response
(ΔLean Vs ΔObese)
Genes: 607
Diﬀerences in response
(ΔLean Vs ΔObese)
Genes: 2,516
Overlap
Genes: 82
Overlap
Genes: 10
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genes. These genes predominantly belonged to the human leukocyte antigen (HLA) class II 
and included HLA-DQA2, HLA-DQB1 and HLA-DRB5. 
The gene sets (FDR Q< 0.05) significant differently changed in response to SFA challenge in 
obese relative to the lean subjects (delta obese T4-T0 vs. delta lean T4-T0) are visualised in 
Supplemental Figure S5.1. Four gene sets that were up-regulated in obese and down-regulated 
in lean subjects after SFA intake belonged to a cluster involved in ‘platelet activation’. Individual 
changes of significantly changed genes from these gene sets are visualized in Figure 5.2 and 
included chemokine’s released from activated platelets (PF4, PPBP), platelet integrins (ITGA2B, 
ITGB3), P-selectin (SELP) and genes involved in platelet aggregation and thrombus formation 
(PDE3A, CD9, GP1BA, GP6 and GP9). 
The gene sets (FDR Q< 0.05) significant differently changed in response to the MUFA challenge 
in obese relative to the lean subjects are visualised in Supplemental Figure S5.2. A cluster 
with genes involved in posttranslational protein modification was up-regulated in obese and 
down-regulated in lean subjects. A cluster of G protein coupled receptors (GPCR) was down-
regulated in obese subjects and up-regulated in lean subjects. Individual expression changes 
of genes significantly changed within these clusters are visualized in a heatmap (Figure 5.3) 
and included genes involved in protein glycolysation (RFT1, PMM2, B4GALT6, ALG8, ALG2 
and ST3GAL4), glycosylphosphatidyl-inositol (GPI) anchor synthesis (PIGN, PIGF, SEC31A, 
SEC24C, SEC24B and PGAP3) and various G protein coupled receptors.
Differences between a SFA and MUFA challenge
To identify difference in gene expression changes between the SFA and the MUFA challenge, we 
combined data of lean and obese subjects (in total n=32). Figure 5.4 lists a flow diagram with 
the number of genes that changed significantly in expression after a SFA or MUFA challenge. 
SFA consumption changed the expression of 2,122 genes and MUFA consumption changed the 
expression of 2,270 genes. Expression of 1,489 genes changed significantly different between 
the MUFA shake and the SFA shake.
Gene sets identified with GSEA with a FDR Q<0.05 are visualised in Supplemental Figure 
S5.3. The most highly ranked significantly down-regulated gene sets after SFA consumption 
relative to MUFA, included ‘cholesterol biosynthesis’ and ‘biosynthesis of unsaturated fatty 
acids’. Many genes from these gene sets are target genes of the transcription factor SREBP2 
and SREBP1a. The gene SREBF2 itself was also more down-regulated after SFA compared to 
MUFA intake (P<0.001). Furthermore, SFA intake increased the expression of genes involved 
in the efflux of cellular cholesterol i.e. ABCA1 and ABCG1 and decreased the expression of the 
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Figure 5.3 Expression heatmap of significantly changed genes in obese relative to lean subjects 
after the MUFA challenge involved in G protein coupled receptors (GPCR) and posttranslational protein 
modification. Expression changes are indicated as individual signal-log-ratios (SLR) of t=4h versus 
t=0h for lean (n=15) and obese (n=18) subjects. Subjects are ranked based on participant number. 
Down-regulation or up-regulation of gene expression is presented on a colour scale ranging from 
green (down-regulated, SLR ≤ -0.25) to red (up-regulated, SLR ≥ 0.25). 
Cluster GCRP
Genes Entrez ID Description Mean SLR P -values Mean SLR P -values P -values
GALR3 8484 galanin receptor 3 0.14 0.09 -0.25 0.00 0.00
GPR25 2848 G protein-coupled receptor 25 0.18 0.00 -0.09 0.17 0.00
GCGR 2642 glucagon receptor 0.10 0.09 -0.14 0.02 0.00
GPR62 118442 G protein-coupled receptor 62 0.05 0.49 -0.25 0.00 0.00
CXCL1 2919 chemokine (C-X-C motif) ligand 1 0.20 0.00 -0.05 0.42 0.00
GNG4 2786 guanine nucleotide binding protein (G protein), gamma 4 0.00 0.94 -0.26 0.00 0.00
GPR3 2827 G protein-coupled receptor 3 0.11 0.23 -0.26 0.01 0.01
AVP 551 arginine vasopressin 0.13 0.11 -0.18 0.03 0.01
ADCY6 112 adenylate cyclase 6 0.07 0.20 -0.14 0.01 0.01
AVPR1A 552 arginine vasopressin receptor 1A 0.18 0.01 -0.05 0.48 0.01
GNG7 2788 guanine nucleotide binding protein (G protein), gamma 7 0.11 0.02 -0.04 0.40 0.01
WNT1 7471 wingless-type MMTV integration site family, member 1 0.10 0.09 -0.11 0.08 0.01
FFAR1 2864 free fatty acid receptor 1 0.19 0.02 -0.12 0.17 0.01
MTNR1B 4544 melatonin receptor 1B 0.07 0.29 -0.19 0.01 0.01
WNT10B 7480 wingless-type MMTV integration site family, member 10B 0.08 0.18 -0.13 0.04 0.01
CCL17 6361 chemokine (C-C motif) ligand 17 0.04 0.44 -0.14 0.01 0.01
WNT16 51384 wingless-type MMTV integration site family, member 16 0.09 0.07 -0.09 0.07 0.01
ADRA1D 146 adrenergic, alpha-1D-, receptor 0.09 0.13 -0.11 0.08 0.01
BDKRB2 624 bradykinin receptor B2 0.13 0.05 -0.12 0.09 0.01
TUBB3 10381 tubulin, beta 3 0.08 0.40 -0.22 0.02 0.01
DRD2 1813 dopamine receptor D2 0.04 0.53 -0.19 0.00 0.01
PTH2 113091 parathyroid hormone 2 0.04 0.60 -0.21 0.00 0.02
S1PR2 9294 sphingosine-1-phosphate receptor 2 0.03 0.67 -0.20 0.01 0.02
OXTR 5021 oxytocin receptor 0.11 0.04 -0.06 0.31 0.02
ADCY5 111 adenylate cyclase 5 0.06 0.31 -0.17 0.01 0.02
TAS1R3 83756 taste receptor, type 1, member 3 0.10 0.13 -0.13 0.06 0.02
ADRB1 153 adrenergic, beta-1-, receptor 0.16 0.05 -0.12 0.16 0.02
EDN3 1908 endothelin 3 0.03 0.58 -0.15 0.01 0.02
WNT10A 80326 wingless-type MMTV integration site family, member 10A 0.07 0.26 -0.14 0.03 0.02
GRM5 2915 glutamate receptor, metabotropic 5 0.04 0.40 -0.13 0.02 0.02
CHRM1 1128 cholinergic receptor, muscarinic 1 0.09 0.20 -0.13 0.07 0.02
FZD10 11211 frizzled family receptor 10 0.05 0.37 -0.14 0.03 0.03
OPN4 94233 opsin 4 0.05 0.45 -0.15 0.02 0.03
NPY 4852 neuropeptide Y 0.11 0.04 -0.06 0.29 0.03
RLN3 117579 relaxin 3 0.01 0.92 -0.26 0.01 0.03
HRH3 11255 histamine receptor H3 0.04 0.59 -0.17 0.03 0.04
NPW 283869 neuropeptide W 0.06 0.41 -0.16 0.05 0.04
FZD1 8321 frizzled family receptor 1 0.17 0.01 -0.01 0.91 0.04
PDE4C 5143 phosphodiesterase 4C, cAMP-specific 0.03 0.67 -0.16 0.02 0.04
UTS2R 2837 urotensin 2 receptor 0.11 0.16 -0.11 0.16 0.04
GAL 51083 galanin prepropeptide 0.03 0.68 -0.18 0.01 0.04
WNT3A 89780 wingless-type MMTV integration site family, member 3A 0.06 0.29 -0.11 0.09 0.04
TBXA2R 6915 thromboxane A2 receptor 0.18 0.03 -0.07 0.44 0.04
GPR37L1 9283 G protein-coupled receptor 37 like 1 0.03 0.70 -0.19 0.02 0.05
KISS1R 84634 KISS1 receptor 0.06 0.34 -0.12 0.09 0.05
CNR2 1269 cannabinoid receptor 2 (macrophage) 0.02 0.73 -0.15 0.02 0.05
HTR5A 3361 5-hydroxytryptamine (serotonin) receptor 5A 0.03 0.65 -0.18 0.02 0.05
GNG8 94235 guanine nucleotide binding protein (G protein), gamma 8 0.07 0.29 -0.11 0.13 0.05
Cluster protein modification
Genes Entrez ID Description Mean SLR P -values Mean SLR P value P -values
SEC24B 10427 SEC24 family, member B (S. cerevisiae) -0.05 0.06 0.07 0.01 0.00
SEC24C 9632 SEC24 family, member C (S. cerevisiae) -0.08 0.01 0.08 0.02 0.00
SEC31A 22872 SEC31 homolog A (S. cerevisiae) -0.04 0.04 0.03 0.24 0.03
UAP1 6675 UDP-N-acteylglucosamine pyrophosphorylase 1 -0.16 0.00 0.04 0.46 0.00
RFT1 91869 RFT1 homolog (S. cerevisiae) -0.08 0.07 0.06 0.16 0.02
B4GALT6 9331 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypept 6 -0.13 0.12 0.27 0.00 0.00
PIGF 5281 phosphatidylinositol glycan anchor biosynthesis, class F -0.13 0.25 0.31 0.01 0.00
B4GALT4 8702 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypept 4 -0.19 0.01 0.11 0.14 0.01
GANAB 23193 glucosidase, alpha/  neutral AB -0.05 0.04 0.05 0.04 0.01
PIGN 23556 phosphatidylinositol glycan anchor biosynthesis, class N -0.09 0.13 0.15 0.03 0.01
ALG13 79868 asparagine-linked glycosylation 13 homolog (S. cerevisiae) -0.07 0.10 0.10 0.02 0.01
MGAT2 4247 mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase -0.06 0.23 0.14 0.01 0.01
ST8SIA6 338596 ST8 alpha-N-acetyl-neuraminide α-2,8-sialyltransferase 6 -0.19 0.03 0.13 0.14 0.01
PMM2 5373 phosphomannomutase 2 -0.06 0.17 0.11 0.03 0.02
EIF5A 1984 eukaryotic translation initiation factor 5A 0.00 0.95 0.22 0.00 0.02
EDEM3 80267 ER degradation enhancer, mannosidase α-like 3 -0.05 0.15 0.06 0.15 0.02
MAN1A2 10905 mannosidase, alpha, class 1A, member 2 -0.06 0.11 0.06 0.09 0.02
ALG8 79053 asparagine-linked glycosylation 8, α-1,3-glucosyltransf hom. -0.09 0.05 0.06 0.22 0.03
ALG2 85365 asparagine-linked glycosylation 2, α-1,3-mannosyltransf hom. -0.07 0.09 0.06 0.19 0.03
GAS6 2621 growth arrest-specific 6 -0.29 0.00 -0.10 0.12 0.03
ST3GAL4 6484 ST3 beta-galactoside α-2,3-sialyltransferase 4 -0.14 0.01 0.02 0.72 0.03
B4GALT1 2683 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransf, polypep1 -0.06 0.05 0.03 0.32 0.03
PGAP3 93210 post-GPI attachment to proteins 3 -0.04 0.32 0.09 0.03 0.02
Lean vs. Obese
Lean subjects Obese subjects Lean vs. Obese
Individual SLR Individual SLR
Individual SLR Individual SLR
Lean subjects Obese subjects
scavenger low-density lipoprotein receptor (LDLR) involved in influx of cholesterol. Figure 5.5 
shows a heatmap of gene expression changes per person of significantly changed genes after 
SFA of the above described pathways. 
One of the most highly ranked gene set up-regulated after the MUFA challenge relative to the 
SFA challenge was the gene set ‘PPAR targets’. Figure 5.6 shows a heatmap of the significantly 
changed peroxisome proliferator-activated receptor (PPAR) target genes from this gene set. We 
included additional PPARα target genes in the heatmap which were shown to be regulated in 
PBMCs after ex vivo stimulation by the PPARα ligand WY14,643 [13] and were significantly 
95
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5changed by the MUFA challenge. Many PPAR target genes up-regulated after MUFA intake were involved in β-oxidation (Figure 5.6). Moreover, several inflammatory gene sets were also 
more pronouncedly up-regulated after MUFA consumption relative to SFA consumption, such 
as toll-like receptor signalling and IL8-CXCR1/2 pathways (Figure 5.6).
DISCUSSION
In the current study we showed that changes in PBMC gene expression profiles after a high 
fat challenge test are different between lean and obese subjects, with the most pronounced 
effect for MUFA. In both lean and obese subjects, the SFA shake decreased expression of genes 
involved in cholesterol biosynthesis and uptake and increased expression of genes involved in 
cholesterol efflux. The MUFA shake increased the expression of inflammatory genes and of 
PPARα target genes involved in β-oxidation. 
Figure 5.4 Flow diagram showing the number of genes of which the expression was changed after 
a high fat SFA or MUFA challenge and of the number of genes that changed in expression significant 
differently between the MUFA shake and the SFA shake in the whole study population (n=32). A 
change was significant if P<0.05. 
Entrez IDs
19,738 genes
Expressed:
8 arrays >20
14,257 genes
Postprandial MUFA response
(T4-T0)
Genes regulated: 2,270
Postprandial SFA response
(T4-T0)
Genes regulated: 2,122 
Diﬀerences in response
(ΔMUFA vs ΔSFA)
Genes: 1,489
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Whereas before the challenge, under fasting conditions, 294 genes were significantly different 
expressed between lean and obese subjects, the challenge increased those differences to 607 
genes after the SFA challenge and 2,516 genes after the MUFA challenge. Based on this increase 
we conclude that the application of a high fat challenge test magnified differences in PBMC gene 
expression profiles between lean and obese subject. In addition, based on the higher number 
of genes differentially changed in obese relative to lean subjects after the MUFA compared to 
the SFA challenge, we hypothesise that a high MUFA challenge is more potent in inducing a 
transcriptional response in PBMCs than a challenge high in SFAs, hence resulting in expression 
regulation of a higher number of genes. 
The observed differences in PBMC gene expression between lean and obese subjects at baseline 
and after the high fat challenges point towards a difference in haemostasis and immune 
function between lean and obese subjects. Firstly, the lower expression of HLA class II genes 
at baseline in obese relative to lean subjects may be relevant in autoimmunity and adaptive 
immune responses [14,15]. Secondly, SFA elicited in obese subjects a pro-thrombotic gene 
expression profile relative to lean subjects. Thirdly, GPI-anchored protein synthesis genes were 
up-regulated and various G-protein coupled receptors were down-regulated in obese relative 
to lean subjects after MUFA intake. GPI-anchored proteins on leukocytes regulate integrin-
mediated cell adhesion [16,17] and many GPCRs are known to mediate both inflammatory and 
anti-inflammatory processes [18]. Changes in gene expression profiles involved in haemostasis 
and immune function in PBMCs after a high fat challenge may be one of the first detectable 
hallmarks for small disturbances in health status. Yet, it must be noted that this study was 
explorative and to what extend these observed changes in gene expression profiles are early 
markers for disease development and whether these are predictive for atherogenic processes 
remains to be elucidated.
SFA intake resulted in the following gene expression changes; a decrease in cholesterol uptake, a 
decrease in cholesterol biosynthesis and an increase in cholesterol efflux. Transcription of genes 
involved in cholesterol biosynthesis and uptake is largely regulated via SREBP2 activation in a 
cholesterol-dependent manner. An excess of intracellular cholesterol causes a down-regulation 
of genes involved in cholesterol biosynthesis and uptake [19]. The observed gene expression 
changes may therefore suggest an intracellular situation of excess cholesterol after SFA intake. In 
monocytes, an subpopulation of the PBMCs, intracellular cholesterol homeostasis is of crucial 
importance for monocyte health. Excess intracellular cholesterol will be stored as cholesteryl 
esters in lipid droplets, ultimately leading to macrophage activation and foam cell formation 
[20]. Foam cells are involved in the formation of fatty streaks during atherosclerosis development 
[20]. The question remains why those pathways are only affected by SFA and not by MUFA. 
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One might expect that the PBMCs are exposed to a higher concentration of cholesterol but 
the SFA in our shake consisted of cholesterol-free palm oil. However, a previous postprandial 
study in humans showed that the postprandial increase in VLDL, three hours after high fat 
meal intake, was more pronounced after SFA than after MUFA consumption [21]. As VLDL 
has a higher cholesterol content than chylomicrons, PBMCs may have been exposed to higher 
concentrations of cholesterol. 
SFA intake also down regulated SREBP1a target genes encoding for desaturase enzymes 
[22]. SREBP1a is activated via a cholesterol-dependent manner similar to SREBP2 [23]. The 
decrease in gene expression of desaturase enzymes may therefore be an additional effect of 
a possible excess of intracellular cholesterol after SFA intake as described above. Delta 5 and 
delta 6 desaturases, e.g. FADS1 and FADS2, are essential for the formation of long-chain 
polyunsaturated fatty acids from dietary linoleic acid (LA) and α-linolenic acid (ALA). It has 
been proposed that a defect in the activity of delta 5 and delta 6 desaturases may decrease the 
formation of poly unsaturated fatty acids from LA and ALA and in turn, decrease the formation 
of anti-inflammatory mediators, such as prostaglandin E1 (PGE1), prostacyclin (PGI2), PGI3, 
lipoxins and resolvins [24]. The lowering in gene expression of desaturase enzymes after repeated 
SFA intake may therefore, decrease the formation of such anti-inflammatory mediators. 
MUFA intake increased the expression of many PPARα target genes. Previous in vitro and animal 
experiments demonstrated that unsaturated long-chain FA are better ligands of PPARs than 
SFA [25,26]. To our knowledge we are the first to describe such a difference between different 
dietary fatty acid types in vivo in PBMCs of human subjects. Our previous work in human 
PBMCs found that only a few PPARα target genes changed in expression after consumption of 
a high fat shake and no differences in gene expression changes were found between shakes high 
in SFA or PUFAs [27]. In that study, we challenged 21 healthy young men with SFA or PUFA 
enriched shakes of 55g of fat. The reason why we did find clear differences between shakes in 
the current study may be due to the larger samples size, e.g. 32 middle-aged males, the higher 
amount of consumed fat and/or the type of fat. The finding that many PPARα target genes that 
changed in expression were involved in β-oxidation is coherent with previous findings in ex 
vivo PBMC experiments from our group, that showed that one of the main targets of PPARα 
activation in human PBMCs is β-oxidation [13]. By up-regulation of the β-oxidation, PBMCs 
may reduce the amount of fatty acids available for intracellular lipid accumulation an essential 
process in the formation of lipid-loaded macrophages [28]. Besides the identified changes in 
expression of PPARα target genes, MUFA intake also up-regulated the expression of many pro-
inflammatory genes. This may be explained by the fact that MUFAs, due to the unsaturated 
double bond, are more susceptible for oxidation, thereby inducing a pro-inflammatory response. 
100
PBMC gene expression changes after high fat challengesChapter 5
Saturated fatty acids are far less sensitive for oxidative stress, hence explaining the much lower 
pro-inflammatory response after acute intake of these FAs. In addition, we previously showed 
that acute consumption of high n3 PUFAs causes an increased stress and inflammatory gene 
expression response in PBMCs compared to SFA [27]. Long term low intake of n3 PUFAs 
however elicited an anti-inflammatory gene expression response in PBMCs [29]. Interestingly, 
in the latter study, it was also observed that long term low intake of the control, high oleic acid 
sunflower oil, down-regulated the expression of several genes involved in inflammation and 
cell adhesion. Therefore, we hypothesise that repeated moderate exposure to stress-inducing 
fatty acids such as MUFAs, will activate the transcriptional response, hence increasing the 
cellular capacity to adapt. This eventually will improve the resilience capacity of cells, leading 
to positive health effects on the long run. 
In the current study we challenged two populations of middle-aged men with a different 
risk phenotype for developing CVD. Besides the higher insulin and TG levels under fasting 
conditions, the obese subjects were non-diabetic and not diagnosed with a long term medical 
condition. But, despite the apparently small differences in health status between our lean and 
obese subjects, changes in PBMC gene expression profiles were explicit after a challenge test, 
especially after the MUFA challenge. Still, individual responses showed quit some between-
subject variation within the lean and obese group. Interestingly, changes in gene expression 
patterns of some obese individuals mimicked a more ‘lean type’ response. One might speculate 
that these obese individuals may have more healthy metabolic risk profile compared to the other 
obese individuals. The use of such ‘gene expression fingerprints’ after the application of a high 
fat challenge test may better reflect the resilience capacity of a person than BMI alone and may 
improve individual obese-related disease risk prediction in the future. By combining lean and 
obese subjects, we were able to examine the difference between high fat SFA in MUFA challenge 
on the PBMC gene expression response in 32 individuals in a cross-over design. We matched 
shake volume, caloric content and macronutrients which enabled us to draw conclusions 
about the effects of different fatty acid types. We did not discuss gene expression changes that 
were affected by MUFA or SFA, but were not differently affected between shakes. This study 
therefore presents an underestimation of the interpretation of the total transcriptional effects 
of SFA and MUFA challenge. However, those gene expression changes might also be induced 
by change in time as circadian effect on gene expression have been described [30]. The amount 
of 95g of fat (88 energy-%) used in this study is relatively high and does not reflect a common 
meal with more balanced macronutrient compositions. Yet, the high fat shake was used as a 
tool to determine response capacity towards a high lipid load only differing in fatty acid type. 
This can be more easily achieved by these high amounts of fat. By applying this challenge test 
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and comparing the induced gene expression changes after SFA and MUFA intake we were able 
to determine short term direct effects of fatty acids on transcriptional regulation. Still, these 
findings are temporarily and specific for the postprandial situation. Future studies are needed to 
elucidate how repeated moderate exposure to these fatty acids will lead to longer-term systemic 
whole body adaptations and improve the resilience capacity of cells and organs on the long run.
In conclusion, this study demonstrates the strengths of combining high-throughput 
transcriptomic tools with a high fat metabolic challenge test, to detect small disturbances in 
health status between subject with small differences in metabolic risk phenotype. Especially a 
high MUFA challenge magnified differences between lean and obese subjects. The observed 
gene expression changes after SFA intake suggest an intracellular situation of excess cholesterol 
after SFA intake, whereas the up-regulation in β-oxidation genes after MUFA intake may point 
towards a reduced amount of fatty acids available for intracellular lipid accumulation. These 
findings increase our understanding on how a SFA or MUFA challenge exert their distinct 
effects on stress-related and metabolic compensatory processes.   
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SUPPleMeNT
Supplemental Figure S5.1 Enrichment map of gene sets (FDR Q<0.05) significant differently 
changed in response to SFA challenge in obese (n=15) relative to the lean (n=17) subjects. Nodes 
represent gene sets, whereas dotted lines indicate overlapping genes between the gene sets (overlap 
cut-off: 0.9). Grey-scales in the nodes indicate if the gene set was up-regulated (black), down-regulated 
(white) or not affected (grey) in lean (inner node) or obese (outer node) subjects. Clusters of related 
gene sets were assigned a label on the basis of gene sets present in the cluster. Abbreviations: KEGG, 
Kyoto Encyclopedia of Genes and Genomes database; BIOC, BioCarta Pathway Diagrams; REACT, 
Reactome knowledgebase; WIP_HS, WikiPathways Homo Sapiens; NCI, Nature Pathway Interaction 
database. 
Legend:
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Supplemental Figure S5.2 Enrichment map of gene sets (FDR Q<0.05) significant differently 
changed in response to MUFA challenge in obese (n=15) relative to the lean (n=17) subjects. Nodes 
represent gene sets, whereas dotted lines indicate overlapping genes between the gene sets (overlap 
cut-off: 0.9). Grey-scales in the nodes indicate if the gene set was up-regulated (black), down-regulated 
(white) or not affected (grey) in lean (inner node) or obese (outer node) subjects. Clusters of related 
gene sets were assigned a label on the basis of gene sets present in the cluster. Abbreviations: 
GPCRs, G-protein coupled receptors; KEGG, Kyoto Encyclopedia of Genes and Genomes database; 
BIOC, BioCarta Pathway Diagrams; REACT, Reactome knowledgebase; WIP_HS, WikiPathways Homo 
Sapiens; NCI, Nature Pathway Interaction database. 
Legend:
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Supplemental Figure S5.3 Enrichment map of gene sets (FDR Q<0.05) that changed significant 
differently between the MUFA shake and the SFA shake in the combined data of lean and obese 
subject (in total n=32). Nodes represent gene sets, whereas dotted lines indicate overlapping genes 
between the gene sets (overlap cut-off: 0.9). Grey-scales in the nodes indicate if the gene set was 
up-regulated (black), down-regulated (white) or not affected (grey) after MUFA (inner node) or SFA 
(outer node) intake. Clusters of related gene sets were assigned a label on the basis of gene sets 
present in the cluster. Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes database; 
BIOC, BioCarta Pathway Diagrams; REACT, Reactome knowledgebase; WIP_HS, WikiPathways Homo 
Sapiens; NCI, Nature Pathway Interaction database. 
Legend:
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Supplemental Table S5.1 Nutritional values of the intervention high fat shakes
Nutritional value SFA MUFA
Energy (kcal) 990 990
Protein (g) 10 10
Carbohydrates (g) 19 19
Fat (g) 95 95
Saturated fatty acids (g) 51 8
Monounsaturated fatty acids (g) 37 79
Polyunsaturated fatty acids (g) 6 8
ALA (g) 0 0
EPA (g) 0 0
DHA (g) 0 0
Vitamin E (mg) 165 165
Calculated using the Dutch Food Composition table (NEVO-table) using VBS KOMEET v.4 software. SFA = Saturated 
Fatty Acid; MUFA = Mono-Unsaturated Fatty Acid; ALA = alpha-linolenic acid (C18:3); EPA = eicosapentaenoic acid 
(C20:5); DHA = docosahexaenoic acid (C22:6).
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ABSTRACT
Background: Recently, the European food and safety authority improved the health claim 
that cocoa flavanols consumption helps to maintain endothelium-dependent vasodilation. 
We aimed to elaborate on this claim by investigating the effect of chocolate consumption 
on flow mediated dilation (FMD) and other markers of vascular health. We additionally 
investigated if high flavanol chocolate (HFC) consumption is preferred above normal dark 
chocolate (NFC) and if a higher flavanol content affects taste and motivation to consume 
chocolate. 
Methods: In a double-blind cross-over study, we investigated the effects of acute intake 
and of 4-week daily HFC and NFC consumption on FMD, augmentation index (AIX), 
leukocyte numbers, plasma cytokines and leukocyte cell surfaces molecules in healthy 
overweight middle-aged men. In addition, the responsiveness to a postprandial high-fat 
challenge test after a 4-week HFC or NFC background was investigated. We additionally 
constructed sensory profiles from the HFC and NFC and collected motivation scores to 
eat these chocolates during the intervention. 
Results: 4-week daily intake of chocolate increased FMD, decreased AIX, decreased 
leukocyte cell count, decreased plasma soluble adhesion molecules concentrations and 
decreased leukocyte adherence marker expression, with no difference between HFC and 
NFC. Additional flavanols did affect taste and did negatively affect motivation to consume 
chocolate. 
Conclusions: Chocolate consumption improved FMD and AIX and initiated a less activated 
state of cellular adherence. Higher flavanol concentrations did not have an additional 
beneficial effect on vascular health, but did affect taste negatively. 
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INTRODUCTION
Several human intervention studies demonstrated that flavanol-enriched chocolate/cocoa intake 
can improve flow mediated dilatation (FMD) [1,2]. The European Food and Safety Authority 
(EFSA) therefore approved a health claim: ‘cocoa flavanols help maintain endothelium-dependent 
vasodilation, which contributes to normal blood flow’ [3]. Despite a clear cause and effect 
relationship has been established between cocoa flavanol consumption and improvement of FMD, 
the underlining mechanisms remain largely unknown. The major bioactive flavanol considered 
responsible for this beneficial effect seem (–)-epicatechins [4]. Several in vitro experiments in 
endothelial cells demonstrated that (–)-epicatechins are able to increase NO bioavailability [5,6]. 
Other factors known to be important in endothelial health, such as inflammation, leukocyte 
adherence and coagulation, might be affected by cocoa flavanols as well, but are less extensively 
studied in vivo [1]. Recent findings also demonstrated that 100 g/d intake of flavanol-rich dark 
chocolate for 3 days, reduced the postprandial impairment of arterial function after a glucose 
tolerance test [7]. This raises the question whether cocoa flavanols consumption makes subjects 
also more resistant to atherogenic nutritional challenges such as a high-fat meal [8-10].
The scientific evidence for the EFSA health claim that cocoa flavanols help maintain 
endothelium-dependent vasodilation is based on intervention studies in which healthy subjects 
consumed chocolate or cocoa powder beverages with an increased flavanol content. Chocolate 
is the predominantly consumed cocoa derived product. From a public heath perspective, 
increasing chocolate flavanol content might therefore be of strategic importance to improve 
vascular health and thereby decrease cardio vascular disease (CVD) risk at the population 
level. However, the question remains to what extend the increased flavanol content of chocolate 
will enhance the beneficial effect on vascular function and if normal dark chocolate also elicit 
these effects. Furthermore, flavanols have been described as astringent and bitter, increasing 
flavanol content of chocolate might therefore affect taste perception, hence affecting the taste 
[11] and motivation to consume such chocolates on a daily basis for a number of weeks [12-14].
In the current study we aimed to investigate how chocolate consumption affects vascular 
health and if additional flavanols are necessary to elicits these effects on vascular function. We 
investigated the effect of acute and prolonged flavanol-enriched dark chocolate or regular dark 
chocolate consumption on FMD and several other markers related to vascular and endothelial 
function such as heamodynamics, augmentation index, leukocyte count, leukocyte cell surfaces 
activation markers and plasma cytokines involved in cellular adherence, coagulation and 
inflammation. We additively investigated if prolonged daily intake of high flavanol chocolate 
will alter vascular resilience capacity to a high fat challenge test. Our additional aim was to 
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investigate if increased flavanol content in chocolate affects the sensory profile of chocolate, 
the appreciation and the motivation to consume these chocolates for a longer period.
METHODS
Subjects
Healthy overweight (predefined BMI 25–32 kg/m2) male subjects between 45–70 years old 
were recruited. All subjects were non-smoking, normoglycemic (WHO criteria) and not 
diagnosed with any long-term medical condition or high blood pressure (systolic>160 mmHg 
and/or diastolic>100 mmHg). Furthermore, subjects were not allowed to use medication or 
to take food supplements known to interfere with glucose homeostasis, blood pressure (BP), 
coagulation or inflammation. All subjects gave written informed consent and the study was 
approved by the Medical Ethics Committee of Wageningen University. 
4 weeks4 weeks 4 weeks
High Fat 
Challenge test
70g/d HFC
Washout
High Fat 
Challenge test
70g/d NFC
70g HFC
70g N
FC
Study Part I (n=29) Study part II  (n=44)
>2 weeks
Visit 1 Visit 2 Before 
4-weeks
After
4-weeks
Before 
4-weeks
After
4-weeks
Fasting
T= 0h a,b,c,d,f,h a,b,c,d,f,h a,b,c,d,e,h a,b,c,d,e,g,h a,b,c,d,e,h a,b,c,d,e,g,h
Postprandial
T = 1,5h b b
T = 2h a,b,c,d,f,h a,b,c,d,f,h
T = 3h a,b,c,d,e a,b,c,d,e
Washout
Figure 6.1 Study design; Part I; cross-over acute intervention study. Samples were collected at 
baseline and 2 hours postprandially after chocolate intake. Part II; cross-over 4-week intervention 
study. Fasting samples were collected before and after the intervention. A high fat postprandial 
challenge test was implemented at the end of both intervention periods. Additional samples were 
collected 1.5 hours and 3 hours postprandially. Determined study outcomes: a = vascular measures; b 
= plasma metabolic markers; c = plasma cytokines; d = differentiated blood cell count; e = leukocyte 
cell surface markers; f = plasma flavanols; g = urinary flavanols, h = plasma ALAT/ASAT.
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Study design
The study consisted of two study parts (Figure 6.1). Part I comprised an acute intervention study in 
which the postprandial effects of either high flavanol chocolate (HFC) or normal flavanol chocolate 
(NFC) consumption on vascular health was investigated. In part II, the effects of daily intake of 
HFC or NFC for 4 weeks on vascular health were investigated. In addition, the responsiveness to 
a postprandial high fat challenge test after a 4 week chocolate background of either HFC or NFC 
was investigated. Randomization was performed for both study parts by an independent research 
assistant using a computer-generated table. For study part II we constructed 25 blocks with a size 
of 2. Researchers as well as participants were blinded to randomization until after data analysis. 
Sample size was calculated with assumption that within-patient standard deviation of the FMD 
measurement was 2.13. Effect size between treatments were estimated 2.1 units FMD% for study 
part I and 1.6 units FMD% for study part II [15,16]. This study was performed at the Wageningen 
University from January until July 2011, according to the principles of the Declaration of Helsinki 
and in accordance with the Medical Research Involving Human Subjects Act (WMO). 
Part I: Acute effects of chocolate consumption
Part I comprised a double blind randomized cross-over acute intervention study, in which 29 
participants visited the university two times. On each study day, subjects consumed 70g HFC 
or NFC. Vascular measurements, blood count, plasma cytokines, plasma (–)-epicatechins, 
plasma metabolic markers and plasma liver function markers were determined at baseline and 
2 hours after chocolate consumption. This timeframe was chosen, because effects of flavanol 
consumption on vascular function are most pronounced two hours after consumption [17]. 
A minimum of one-week washout period was established between the two study days. All 
participants of part I also entered part II. 
Part II: Long term effects of 4 week chocolate consumption
An additional 15 volunteers were recruited to start up with a total of 44 participants for study 
part II. Part II comprised a double blind randomized cross-over 4-week intervention study 
in which participants consumed 70g of chocolate daily in two 4-week periods, randomly 
assigned to either HFC or NFC, with a 4-week washout period between periods. Chocolates 
were dispensed in bars of 35g; one bar was consumed in the afternoon and one in the evening. 
Fasting vascular measurements, blood count, plasma cytokines, leukocyte activation markers, 
plasma metabolic markers and plasma liver function markers were determined before and after 
both intervention periods. Flavanol concentrations in 24h-urine samples were determined at 
the end of each intervention period as a marker of compliance. 
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After fasting measures at the end of each intervention period, participants received a high-fat 
(HF) challenge test containing 95g of fat, high in MUFA. Additional postprandial measures 
of vascular function, blood count, leukocyte activation markers, plasma cytokines and plasma 
metabolic markers were determined three hours after shake consumption. An additional blood 
sample was taken 1.5 hours after shake consumption, in order to characterize the plasma insulin, 
glucose, triglycerides (TG) and free fatty acid (FFA) response in better detail. 
Chocolates were distributed weekly and extra bars were distributed. Participants were asked 
to bring back empty packages and left-over chocolates, and to keep a diary to record at what 
time bars were eaten. A personal dietary consult was planned before the intervention to 
prevent weight gain. During this consult, participants were advised to refrain from certain 
energy dense food products from their normal diet. If weight gain or loss >1kg was recorded 
during their weekly visit, an additional consult was scheduled to correct. Participants were not 
allowed to consume other chocolates or to consume more than two cups of tea, two glasses of 
red wine and to eat one apple per day, which are important sources of dietary flavanols. On 
the day prior to each testing day, subjects consumed a standardized low-fat evening meal, were 
refrained from alcohol or strenuous exercise and were not allowed to eat or drink anything 
except water after 08.00pm.
Chocolate flavanol content 
HFC and NFC were provided by Barry Callebaut® and had both a cocoa mass of 58.0%. 
According to the manufacturer, the HFC (ACTICOA® chocolate) contained 2.2% flavanols of 
which, based on estimation from previous analysis, 10.5% were assumed to be (–)-epicatechins. 
The NFC was commonly produced chocolate with a similar macronutrient composition, 
caloric content, and caffeine and theobromine concentrations. According to the manufacturer, 
NFC contained 0.2% flavanols of which, based on estimation, 14% were (–)-epicatechins. 
A dose of 70g HFC or NFC would therefore represent respectively 1,540mg and 140mg 
flavanols of which 162mg and 27mg were (–)-epicatechin respectively. To ensure that these 
concentrations were valid for our produced chocolates, we asked the manufacturer to reanalyses 
our samples. Flavanol concentrations deviated from the original product sheet as 70g of HFC 
or NFC comprised a flavanol content of respectively 1,610mg and 490mg which is estimated 
to represents 169mg and 96mg of (–)-epicatechin respectively. As these concentrations 
substantially deviated from the original product sheet, we decided to analyse flavanol content 
independently from the manufacturer, based on a method previously described [18,19]. This 
analysis showed that 70g HFC or NFC comprised 1,078mg and 259mg flavanols of which 349mg 
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and 97mg (–)-epicatechin respectively. Intended and self-analysed flavanol concentrations of 
the chocolates are summarized in Table 6.1.
Table 6.1 Chocolate flavanol composition
Expected  values 
from manufacturer
Re-analysed 
values from 
manufacturer
Self-analysed 
values
NFC HFC NFC HFC NFC HFC
Total flavanols (%) 0.2 2.2 0.7 2.3 0.4 1.5
Total flavanols (mg) 140 1,540 490 1,610 259 1,078
Catechin (mg) 9* 54* 32* 56* 22 45
(–)-Epicatechin (mg) 27* 162* 96* 169* 119 394
All values are calculated for a dose of 70g chocolate. NFC, normal flavanol chocolate; HFC, high flavanol choco-
late. * based on estimation by the manufacturer.
High fat challenge test
The high-fat challenge test consisted of a milkshake containing 95g of fat, high in mono-
unsaturated fatty acids (MUFA). Previous work demonstrated that vascular responses after a 
high-fat MUFA challenge were more pronounced if compared to challenges high in saturated 
fatty acids (SFA) or n3 polyunsaturated fatty acids (PUFA) [34]. The shake contained low-fat 
yoghurt, low-fat milk, strawberry flavour, 7.5g of sugar and 95g of high-oleic acid sunflower 
oil (Aldoc BV, Schiedam, The Netherlands). Nutritional values of the shake were calculated 
based on the food composition table (NEVO 2007) and presented in Supplemental Table S6.1.
Measures of vascular function 
All vascular measurements were performed after 10 min of rest. Brachial systolic BP (SBP), 
diastolic BP (DBP) and heart rate (HR) were assessed automatically (DINAMAP® PRO 100) 
for 10 minutes with a 3 min interval. Central systolic blood pressure (CSBP) and the heart 
rate corrected augmentation index (AIX), a measure of wave reflection and arterial stiffness 
[20], were assessed by pulse wave analysis of the radial artery (SphygmoCor®CP System, 
ATcor Medical) as described previously [34]. FMD was assessed (Picus, ART.LAB v2.1, Esaote 
benelux bv.) as previously described [21]. FMD vessel recordings were analysed and judged 
by a blinded technician. One subject in study part one and 4 subjects in part II were removed 
from the analysis due to bad recordings.
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Blood markers of inflammation and vascular heath
Plasma cytokine concentrations were analysed on preformatted arrays (Meso Scale Diagnostics, 
LLC) on a SECTOR Imager 2400 reader (Meso Scale Diagnostics, LLC) and plasma vWF 
concentrations were measured by a custom ELISA as previously described [22]. A differentiated 
leukocyte cell count was performed by a hospital laboratory (ZGV, Ede, the Netherlands). 
Expression of leukocyte cell surface markers was determined by flow cytometry (FACSCanto™II, 
Becton-Dickinson). Markers were selected based on the involvement in activation and 
adherence to the endothelium. In short, whole blood was stained with fluorescent labelled 
monoclonal antibodies (MAbs) (Becton-Dickinson, The Netherlands); FITC conjugated CD66b, 
APC-cy7 conjugated CD11b, APC conjugated CD62l, PE conjugated CD11c and PerCP-cy5.5 
conjugated CD45. Cell populations were identified by scatter properties and CD45 expression 
(FACSDiva™ Software v6.1.2). Non-specific binding was ruled out by using isotype matched 
MAbs. Expression of cell surface markers is expressed as Mean Florescence Intensity (MFI) 
in arbitrary units (AU).  
Markers of compliance, metabolism and liver function 
Plasma (–)-epicatechins and 24-hour urinary flavanol concentrations were determined by 
HPLC as previously described [23]. Plasma triglycerides (TG), glucose, insulin and free fatty 
acids (FFA) concentrations and plasma concentrations of alanine aminotransferase (ALAT) 
and aspartate aminotransferase (ASAT) were analysed by a hospital laboratory (SHO, Velp, 
the Netherlands). 
Taste and motivation to eat chocolate
During the intervention subjects filled out questionnaires about the motivation to consume 
chocolate on days 1, 7, 14,  21, and 27. Questions were asked about sensory boredom; desire to 
eat something sweet, desire to eat something savoury, and desire to eat chocolate, and questions 
on the liking and wanting of the chocolate; i.e. pleasantness and desire finish. Questions on 
sensory boredom were answered before consumption, questions on wanting and liking of 
the chocolate after consumption of one bite. All questions were answered on a 9-point scale.
In a sensory panel test separate from the main study, 31 untrained subjects (aged 25±7y; BMI 
22.1±2.8 kg/m2) evaluated the analytical sensory properties of the HFC and NFC on a 9-point 
scale. Samples were offered in pieces of 5–7g at room temperature (±20°C) in a randomized 
order. Between samples, subjects cleaned their palate and tongue with crackers and water. The 
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20 attributes in the sensory test were generated by means of a panel of 6 independent subjects 
that had experience with sensory testing. Next to the intervention chocolates, two commercially 
available chocolates with a comparable cocoa content Verkade Puur (Koninklijke Verkade, 
Zaandam, The Netherlands) and Delicata Puur (Albert Heijn, Zaandam, The Netherlands), 
were used for attribute generation and descriptive analyses.
Statistical analysis
Statistical analysis was performed by linear mixed models for repeated measures (PASW 
statistics 18.0.3). Study outcomes of study part I were analysed by using ‘treatment’ [CFH of 
CLF], ‘time’ [T0 or T2 hours] and ‘treatment*time’ as fixed effects. Study outcomes of study part 
II were analysed using ‘treatment’ [CFH of CLF], ‘time’ [before or after 4-week intervention] 
and ‘treatment*time’ as fixed effects. Study outcomes of the high fat challenge test were analysed 
by using ‘treatment’ [CFH or CLF background], ‘time’ [T0 or T3 hours] and ‘treatment*time’ 
as fixed effects. Baseline was included in the model as covariate for all study parts.
RESULTS
Subject characteristics intervention study
Three participants dropped out or were excluded during study part II, one due to medical 
reasons not related to the study, one due to disliking of the chocolate and one due to failure to 
adhere to the treatment. Baseline characteristics of the 29 participants that finished part I and 
the 41 participants that finished part II are listed in Supplemental Table S6.2. 
Part I: Acute chocolate ingestion
Table 6.2 lists mean baseline and postprandial changes after HFC and NFC ingestion on plasma 
(–)-epicatechin concentrations, vascular function, leukocyte count, plasma cytokines and 
metabolic parameters. Plasma (–)-epicatechin concentrations increased 2 hours after chocolate 
intake, with a 5 fold more pronounced increase after HFC compared to NFC ingestion. 
Chocolate ingestion decreased AIX, with no difference in postprandial response between HFC 
or NFC. Other measures of vascular function, such as FMD, were not affected 2 hours after 
chocolate ingestion. Haematocrit and number of thrombocytes, lymphocytes, monocytes and 
neutrophils were increased 2 hours after chocolate ingestion. The increase in erythrocytes 
after chocolate ingestion was more pronounced after HFC consumption if compared to NFC 
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Table 6.2 Mean baseline and postprandial changes after HFC and NFC ingestion on markers of 
vascular health (study part I)
Treatment Time P-value
Baseline Δ2h Treat-
ment
Time Interaction
Time*Treatment
Plasma epicatechin NFC 0.00 ± 0.00 0.13 ± 0.04 <0.001 <0.001 <0.001
HFC 0.00 ± 0.00 0.67 ± 0.23
Vascular function
SBP (mmHg) NFC 128 ± 13 2 ± 7 NS NS NS
HFC 130 ± 12 0 ± 7
DBP (mmHg) NFC 80 ± 7 0 ± 3 NS NS NS
HFC 79 ± 6 0 ± 3
HR (BPM) NFC 60 ± 8 0 ± 5 NS NS NS
HFC 58 ± 7 2 ± 5
AIX (%) NFC 21 ± 5 -5 ± 5 NS <0.001 NS 
HFC 21 ± 5 -5 ± 4
FMD (%) NFC 5.5 ± 2.2 0.9 ± 2.35 NS NS NS
HFC 4.6 ± 2.4 -0.40 ± 3.76
Leukocyte count
Haematocrit (l/l) NFC 0.42 ± 0.02 0.01 ± 0.01 NS <0.001 NS
HFC 0.42 ± 0.02 0.01 ± 0.01
Erythrocytes (#/pl) NFC 4.71 ± 0.37 0.11 ± 0.10 NS <0.001 NS
HFC 4.71 ± 0.38 0.13 ± 0.07
Thrombocytes (#/nl) NFC 201 ± 25 6 ± 6 NS <0.001 NS
HFC 201 ± 28 7 ± 7
Leukocytes (#/nl) NFC 5.1 ± 1.1 0.7 ± 0.6 NS <0.001 NS
HFC 5.0 ± 1.2 0.7 ± 0.7
Lymphocytes (#/nl) NFC 1.49 ± 0.34 0.16 ± 0.29 NS <0.001 NS
HFC 1.51 ± 0.42 0.15 ± 0.24
Monocytes (#/nl) NFC 0.50 ± 0.12 -0.02 ± 0.07 NS NS NS
HFC 0.49 ± 0.15 0.01 ± 0.08
Neutrophils (#/nl) NFC 2.9 ± 0.9 0.6 ± 0.5 NS <0.001 NS
HFC 2.8 ± 0.9 0.6 ± 0.8
Plasma cytokines
CRP (μg/ml) NFC 1.61 ± 1.32 0.10 ± 0.36 NS NS NS
HFC 2.01 ± 2.30 0.02 ± 0.11
SAA (μg/ml) NFC 3.14 ± 8.43 -0.23 ± 1.32 NS NS NS
HFC 2.88 ± 6.35 -0.06 ± 0.20
sICAM1 (ng/ml) NFC 213 ± 39 8 ± 11 0.013 0.015 0.007
HFC 220 ± 43 0 ± 13
Table 6.2 continues on next page
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Table 6.2 Continued
Treatment Time P-value
Baseline Δ2h Treat-
ment
Time Interaction
Time*Treatment
sVCAM1 (ng/ml) NFC 329 ± 57 3 ± 27 NS NS NS
HFC 346 ± 67 2 ± 37
E-selectin (ng/ml) NFC 13.7 ± 4.3 -0.2 ± 2 NS NS NS
HFC 13.9 ± 3.8 -0.1 ± 1.4
P-selectin (ng/ml) NFC 124 ± 28 -0.2 ± 16.5 NS NS NS
HFC 126 ± 27 -0.8 ± 19.7
sICAM3 (ng/ml) NFC 2.0 ± 0.5 0 ± 0.1 NS 0.011 NS
HFC 2.0 ± 0.5 0 ± 0.1
Thrombomodulin (ng/ml) NFC 3.5 ± 0.6 0 ± 0.2 NS NS NS
HFC 3.5 ± 0.7 0 ± 0.2
IL-1β (pg/ml) NFC 0.91 ± 0.68 0.06 ± 0.14 NS 0.001 NS
HFC 0.89 ± 0.69 0.07 ± 0.11
IL-6 (pg/ml) NFC 1.5 ± 0.6 -0.1 ± 0.4 NS 0.006 NS
HFC 1.5 ± 0.7 -0.1 ± 0.3
IL-8 (pg/ml) NFC 4.7 ± 1.3 0.1 ± 0.6 NS NS NS
HFC 4.8 ± 1.6 0.2 ± 0.8
TNFα (pg/ml) NFC 10.3 ± 4.0 0 ± 0.8 NS NS NS
HFC 10.4 ± 3.9 0 ± 0.9
vWF (%) NFC 130 ± 40 1.6 ± 8.7 NS 0.010 NS
HFC 134 ± 46 6.8 ± 14.8
Plasma metabolic parameters
Glucose (mmol/l) NFC 5.7 ± 0.5 0.2 ± 0.6 NS 0.001 NS
HFC 5.8 ± 0.5 0.3 ± 0.6
TG (mmol/l) NFC 1.3 ± 0.5 0.2 ± 0.2 NS <0.001 NS
HFC 1.2 ± 0.4 0.2 ± 0.1
FFA (mmol/l) NFC 0.44 ± 0.12 -0.06 ± 0.12 NS <0.001 NS
HFC 0.46 ± 0.10 -0.06 ± 0.12
Insulin (mmol/l) NFC 7.1 ± 3.7 8.3 ± 6.4 0.046 <0.001 0.042
HFC 6.4 ± 2.3 11.8 ± 7.7
Other
ALAT (U/l) NFC 21 ± 7 2 ± 2 NS <0.001 NS
HFC 21 ± 8 1 ± 1
ASAT (U/l) NFC 33 ± 5 2 ± 2 0.375 <0.001 0.351
HFC 34 ± 5 2 ± 3
Values are mean ±SD, n=29. NFC, normal flavanol chocolate; HFC, high flavanol chocolate; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; HR, heart rate; AIX, heart rate corrected augmentation index; FMD, flow 
mediated dilation; NS, not significant; TG, triglycerides; FFA, free fatty acids.
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consumption. Plasma sICAM1 concentrations were increased after HFC ingestion only. Plasma 
sICAM3, IL-1β and vWF concentrations were increased and plasma IL-6 concentration was 
decreased 2 hours after chocolate intake, with no difference between HFC or NFC. Chocolate 
ingestion increased plasma glucose and TG and decreased plasma FFA. Insulin was increased 2 
hours after ingestion of both chocolates, with a more pronounced increase after HFC compared 
to NFC.
Part II: 4-week chocolate intervention
Participants did not gain or lose weight during the intervention period (P=0.565). Compliance 
to the study protocol was good, as reflected by the consumed bars and urinary flavanol 
concentrations. In total 4,930 out of 4,952 bars were consumed during the intervention, 99.3% 
of the HFC bars and 99.7% of the NFC bars. At the end of the intervention, urinary flavanol 
concentration were 1.34 ± 0.99µg/ml after the NFC period and 8.75 ± 7.79µg/ml after the HFC 
period (P<0.001).
Table 6.3 lists the effects of 4-week daily consumption of HFC and NFC on vascular 
measurements, leukocyte count, plasma cytokines, leukocyte activation markers and markers 
of liver function in the fasting state, including the postprandial outcomes after the HF challenge 
test. 4-weeks chocolate consumption increased fasting FMD by 1% point and decreased 
fasting AIX by 1% point on average, with no difference in response between HFC and NFC. 
Both FMD and AIX values returned to baseline after washout period (Figure 6.2). 4-week 
chocolate consumption additionally decreased number of leukocytes and decreased plasma 
sICAM1 and sICAM3 concentrations in the fating state, with no difference between HFC 
and NFC. Plasma TNFα concentrations were decreased after HFC and increased after NFC 
intervention. 4-week chocolate consumption also lowered expression of several cell surface 
molecules on leukocytes; on lymphocytes, CD62L and CD11b expression decreased by 4.8% 
and 5.0% on average. On monocytes, CD62l expression decreased by 17.9% on average. On 
neutrophils, CD66b and CD11c expression decreased by 3.9% and 10.2% on average. No 
significant differences on leukocyte cell surface molecule expression were observed between 
the HFC and NFC intervention. Chocolate consumption did not affect fasting TG, insulin, 
ALAT or ASAT. A minor but significant increase of 0.1mmol/l in fasting plasma glucose and 
0.3mmol/l in plasma FFA was observed after 4-week chocolate intervention, with no difference 
in response between HFC and NFC (Table 6.4). 
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High fat challenge test
Table 6.3 lists the effects of a 4-week HFC or NFC background on the postprandial response 
to a high-fat shake. High-fat shake consumption decreased FMD by 1.8% point, AIX by 4% 
point and diastolic blood pressure by 2mmHg on average, with no difference between a HFC 
or NFC background. High-fat shake consumption increased haematocrit and number of 
thrombocytes, erythrocytes, lymphocytes, monocytes and neutrophils. Plasma concentrations 
of sICAM1, sVCAM1, sICAM3, P-selectin, IL-8 and TNFα concentrations were increased, 
whereas plasma concentrations of IL-6 were decreased three hours after shake consumption. In 
addition, shake consumption increased lymphocyte CD11c and CD11b expression, monocyte 
CD11c and CD11b expression and neutrophil CD62l and CD11b expression, while monocyte 
CD62l expression was decreased. No differences between a HFC or NFC background were 
observed on blood cell count, plasma cytokines or leukocyte activation markers. No differences 
in response in plasma glucose, TG, insulin and FFA between a HFC or NFC background were 
observed (Table 6.4). 
Figure 6.2 The effects of 4-week HFC or NFC consumption on AIX and FMD. Results are split for 
both intervention periods in order to visualize the effect of the washout period. Data are presented 
as mean ± SD.
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Taste and motivation to eat chocolate
The sensory profile of the HFC and NFC are visualized in radar charts (Supplemental Figure 
S6.1). The HFC chocolate was less grainy, less hard, more soft, less creamy, less sweet, more 
astringent, more bitter and had a higher off-flavour compared to the NFC. The aftertaste of the 
HFC was described as more bitter, less sweet, higher after taste and higher dry mouth. These 
differences in taste did affect motivation scores of the participants during the intervention 
(Supplemental Table S6.3). The desire for chocolate score was on average 1.7 point lower if 
subjects received HFC compared to NFC. The chance that they would choose the chocolates 
themselves was on average 2.8 points lower for HFC compared to NFC. The wanting to finish 
the chocolate score was 2.5 point lower for the HFC group compared to the NFC group.
DISCUSSION
We extensively characterised the impact of chocolate consumption on vascular health and 
investigated if high flavanol dark chocolate in this respect is preferred above common dark 
chocolate. 4-week daily consumption of dark chocolate improved FMD and decreased AIX, 
leukocyte cell count, plasma concentrations of soluble adhesion molecules and protein 
expression of adherence marker on leukocytes. Chocolate with an increased flavanol content 
did not have an additional beneficial effect on markers of vascular health if compared to regular 
dark chocolate. However, higher flavanol content affected taste and had a negative effect on 
the motivation to eat chocolate.
The 1% point increase in FMD after 4-week daily consumption of dark chocolate is in line with 
the approved health claim by EFSA that cocoa flavanols have a positive effect on endothelium-
dependent vasodilation [3]. A meta-analysis investigating the association between FMD on 
the relative risk of cardiovascular events, found that each 1% increase in FMD is associated 
with a relative risk of cardiovascular events of 0.87 (95%CI: 0.83, 0.91) [24]. These findings 
illustrate that our observed changes in FMD after chocolate intervention may contribute to 
a cardiovascular disease risk reduction. Next to the improvement in FMD, we are the first 
demonstrating that 4-week daily intake of dark chocolate additionally lowers AIX by 1% point. 
The AIX is a measure of wave reflection and arterial stiffness and a meta-analysis investigating 
the association between fasting AIX on the relative risk of cardiovascular events, found that 
each 10% increase of AIX is associated with a relative risk of cardiovascular events of 1.32 
(95%CI 1.093–1.588) [25]. Based on the observed improvements in FMD and AIX, our results 
support the EFSA health claim that chocolate consumption is able to improve vascular function. 
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Interestingly, we did not observe an additional beneficial effect of the HFC on measures of 
vascular function.
Besides investigating the effect of chocolate consumption on vascular function, we additionally 
aimed to elucidate how chocolate is able to affect endothelial function. The observed changes 
in leukocyte cell count, plasma cytokines and leukocyte adherence markers after chocolate 
consumption, point towards a less activated state of cellular adherence and hence a less 
atherogenic milieu. First, 4-week daily consumption of dark chocolate lowered leukocyte cell 
count in the circulation. Leukocytes can transmigrate through the endothelial layer and therefore 
play a crucial role in the formation of atherosclerosis. In addition, elevated leukocyte cell count 
is a marker for systemic inflammation and is associated with an increased CVD risk [26,27]. 
Secondly, dark chocolate consumption decreased protein expression of lymphocyte CD62L and 
CD11b, monocyte CD62L and neutrophil CD66b and CD11c. These cell surface molecules are 
involved in leukocyte recruitment and adherence to the endothelium during the initial steps of 
atherosclerosis. CD11b is part of MAC-1 integrin and together with CD11c and CD62L they 
can bind to ICAMs and CD34 on endothelial cells, thereby activating the endothelium [28]. 
CD66b is a degranulation marker of neutrophils and up regulated after activation [29]. Thirdly, 
chocolate consumption decreased plasma concentrations of soluble adhesion molecules sICAM1 
and sICAM3. Both sICAMs can be secreted by the endothelium and by leukocytes. Lower levels 
of these soluble adhesion molecules have been postulated to be associated with lower risk of 
cardiovascular events [28]. The combination of lower numbers of leukocytes, decreased leukocyte 
adhesion molecules expression and decreased plasma soluble adhesion molecules after 4-week 
dark chocolate consumption, point towards reduced leukocyte adherence and subsequently 
reduced activation of the endothelium, the initial state of atherosclerosis. Interestingly, this 
decrease in endothelial activation is coherent with our observed improvement in vascular 
function as reflected by the increase in FMD and decrease in AIX. 
Previous reports investigating the impact of chocolate consumption on factors of cellular 
adherence are limited or evaluated only few measures. The impact of chocolate consumption 
on leukocyte cell count has not been reported before. One previous study investigated the effect 
of cocoa powder intake leukocyte adherence markers and observed that 4-week daily intake of 
cocoa did not affect CD11b [30]. The difference with our decrease in CD11b may be because 
they included patients at high risk of CVD and used cocoa powder instead of chocolate. In 
addition to CD11b, we also studied CD66b, CD11c and CD62L. Chocolate/cocoa intervention 
studies investigating soluble adherence molecules in plasma are more abundant but inconclusive. 
Most are performed with cocoa powder [30-32] or in patients at risk of CVD [30-33] whereas 
our observations are in overweight, but apparently healthy men. 
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We additionally investigated in the same study population how chocolate ingestion affects 
vascular health postprandially, and if a background of 4-week NFC or HFC consumption is 
able to improve the capacity to respond to a high fat MUFA challenge test. Acute chocolate 
intake decreased AIX and plasma IL-6 and increased in plasma sICAM1, sICAM3 and leukocyte 
count, two hours after chocolate intake. As we did not observe a difference between HFC 
and NFC ingestion, these changes are likely caused by the high energy, sugar or fat content of 
chocolate. We therefore can neither verify nor rebut that chocolate intake acutely improves 
vascular function [2]. Similar changes as after acute chocolate consumption were observed three 
hours after high-fat shake consumption. Since this high-fat challenge test was implemented at 
the end of both interventions only, we could not determine if 4-week chocolate consumption, 
independent of the type, affected the capacity to respond to a high-fat challenge. Our observed 
postprandial high-fat responses are in line with our previous findings that a high-fat shake 
affects vascular function and leukocyte adherence capacity [34].
No differences were observed between NFC and HFC consumption on measures of vascular 
health. This observation is supported by a meta-analysis, in which the authors found that 
chronic chocolate or cocoa powder intake improved FMD regardless of the dose consumed 
[2]. Our results indicate that flavanol enriched chocolate was not healthier than regular dark 
chocolate with respect to vascular health markers. This cannot be explained by maximal flavanol 
absorption capacity in the gut, considering the 5 fold increase in plasma (–)-epicatechins 2 
hours after intake and the 6.5 fold increase in 24-hour urine flavanol concentrations after 
4-week intake of HFC compared to NFC intake. But the maximal effect on vascular health 
might have been reached by the flavanol dose in the NFC. So, if the vascular health effects are 
due to flavanols, it might still be relevant from a public’s health prospective to increase chocolate 
flavanol content in order to reduce saturated fat and sugar intake per portion. However, this 
strategy would only work if adding flavanols would not negatively affect the high standards 
of chocolate flavour.
The EFSA approved health claim is largely based on studies using cocoa powder beverages. 
We specifically choose chocolate since it is the most commonly consumed cocoa derived 
product. Chocolate is also an energy dense product with high contents of sugar and fat. It 
must be noted that we observed a small, but significant increase in plasma glucose and FFA 
concentrations after 4-week chocolate intake. But despite these unfavourable trades of chocolate, 
we did observe clear improvements in vascular function markers. As no differences between 
both chocolates were observed we cannot rule out an intervention effect. However as vascular 
function outcomes returned to baseline after the washout period, subjects remained weight 
stable and the infringement in habits and life style were minimal, the results evidently points 
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towards an effect of chocolate intake on vascular function. Chocolate contains many potentially 
bioactive constituents in addition to flavanols [35]. These components or the synergy of these 
components may also be responsible for the observed effects. 
An important aspect of this study was the independent analyses of chocolate flavanol content. 
Flavanol concentrations strongly deviated from the original product sheets. Apparently these 
concentrations are not constant and vary between batches. Previous chocolate intervention 
studies barely report self-analysed chocolate flavanol content and rely on the product sheets 
obtained from the manufacturer. Deviating concentrations in previously published studies can 
therefore be expected. We acknowledge that the NFC, which reflected regular dark chocolate, 
was relatively high in flavanols. Nonetheless this chocolate was produced by the company as 
a regular consumed dark chocolate and these concentrations can therefore be expected in 
common dark chocolate. 
This study underlines and elaborate on the approved EFSA health claim by demonstrating that 
dark chocolate not only improves endothelium-dependent vasodilatation but also augmentation 
index. We additionally provide new insights on how chocolate affects the endothelium by 
demonstrating that chocolate consumption lowers the adherence capacity of leukocytes in the 
circulation. Extra flavanols did not result in an additional beneficial effect on these outcome 
measures, which might indicate that the maximal vascular response capacity has been reached, 
and/or that other chocolate components are relevant for vascular health effects. Increasing the 
flavanol content of chocolate may be relevant to reduce portion sizes and to decrease saturated fat 
and sugar consumption. However, additional flavanols do affect flavour and thereby negatively 
affecting motivation to eat chocolate. Therefore, chocolate-producing companies that want to 
increase the amount of flavanols in chocolate will have to deal with the preservation of taste.
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SUPPLEMENT
Supplemental Table S6.1 Nutritional values of the high fat shake 
Energy 990 kcal
Protein 10 g
Carbohydrates 19 g
Fat 95 g
Saturated fatty acids 8 g
Mono unsaturated fatty acids 79 g
Poly unsaturated fatty acids 8 g
ALA 0 g
EPA 0 g
DHA 0 g
ALA = alpha-linolenic acid (C18:3); EPA = eicosapentaenoic acid (C20:5); DHA = docosahexaenoic acid (C22:6).
Supplemental Table S6.2 Baseline characteristics of participants
Study part I (n=29) Study part II (n=41)
Age (years) 64 ± 4 63 ± 5
Weight (kg) 89.7 ± 10.5 87.8 ± 10.5
Height (m) 1.79 ± 0.05 1.78 ± 0.06
BMI (kg/m2) 27.8 ± 2.65 27.6 ± 2.31
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Supplemental Figure S6.1 Radar charts of the sensory profile of both intervention chocolates. 
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Recapturing aim
The ability of a person to respond to a metabolic challenge can reflect the capacity to adapt 
and might give a better indication of health and disease risk than fasting measures [1,2]. In this 
thesis we aimed to identify early markers for reduced endothelial function by using metabolic 
challenges. We applied different high fat (HF) challenges as a tool to trigger endothelial response 
capacity and to magnify differences in health status. To identify markers of early perturbations 
in endothelial health, we applied high-throughput metabolomic and transcriptomic tools 
in addition to an extensive phenotyping of vascular function parameters. Furthermore, we 
evaluated whether these potential early markers are reversible and can be improved after an 
intervention with a dietary anti-stressor. 
Using a high-fat challenge test to trigger endothelial 
response capacity
A HF challenge is able to activate endothelial cells and leukocytes and is an acute source of 
dietary stress for the endothelium. The ability to respond to a HF challenge can be seen as 
measurement of endothelial flexibility. The endothelial response after a HF challenge may 
therefore be useful to detect early perturbations in endothelial health, even before this can be 
revealed during fasting. In all studies described in this thesis, we challenged the endothelium 
by means of a HF challenge and measured several outcome parameters to determine the 
endothelial response. An overview of the outcome parameters affected by a HF challenge is 
depicted in Table 7.1.
In two separate studies we observed that in middle-aged men, a HF challenge elicits a decrease 
in augmentation index (AIX), an increase in plasma concentrations of IL-8, sICAM1, sICAM3 
and sVCAM1 and an increase in leukocyte adherence marker expression (chapters 3 and 6). 
In chapter 6 we additionally measured flow mediated dilation (FMD), and showed that those 
observations were accompanied with a decrease in FMD. We performed a similar study with 
young healthy men (chapter 2) and also observed a postprandial decrease in FMD after HF 
shake consumption. However, this decrease was also found after the consumption of an average 
breakfast shake. Interestingly, the decrease in FMD in young healthy men of 0.5%-point after 
the HF shake (chapter 2) was less pronounced than the decrease in FMD observed in middle-
aged overweight men of 1.8%-point (chapter 6). Beside the smaller postprandial decrease 
in FMD, the AIX values in young healthy men were negative, meaning that no augmented 
central systolic blood pressure was present in this young study population. Furthermore, in 
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Table 7.1 Overview of the main outcomes of endothelial health markers after the high-fat challenges 
described in this thesis
Chapter 2 Chapter 3 Chapter 6
Intervention shake HF High-MUFA
HF/HE Regular 
breakfast
SFA MUFA PUFA NFC HFC
Amount of fat 95g 15g 95g 95g 95g 95g 95g
Subjects Lean young men 
(n=20)
Lean (n=18) + Obese 
(n=18) middle-aged men
Overweight 
middle-aged 
men (n=42)
Time points T= 0, 3 and 6h T= 0, 2 and 4h T= 0 and 3h
Vascular function
FMD ↓ ↓ N/A ↓ ↓
AIX ↓  ↓ ↓ ↓ ↓ ↓ ↓
Plasma markers
SAA ↓ - ↓ ↓ ↓ - -
IL-6 ↑  ↑ ↓ ↓ ↓ ↓ ↓
TNFα - - - - ↑ ↑
TM ↓ ↓ ↓ ↓ ↓ - -
E-selectin ↓ ↓ - - - - -
P-selectin - - ↑ - - ↑ ↑
IL-8 ↑ - ↑ ↑ ↑ ↑ ↑
sICAM1 - - ↑ ↑ ↑ ↑ ↑
sICAM3 - - ↑ ↑ ↑ ↑ ↑
sVCAM1 ↓ - ↑ ↑ ↑ ↑ ↑
Leukocyte surface markers
Neutrophils CD11a N/A ↑ ↑ ↑ N/A
                        CD11b N/A ↑ ↑ ↑ ↑ ↑
                        CD11c N/A N/A - -
                        CD62L N/A ↑ ↑ ↑ ↑ ↑
Monocytes   CD11a N/A ↑ ↑ ↑ N/A
                        CD11b N/A ↑ ↑ ↑ ↑ ↑
                        CD11c N/A N/A ↑ ↑
                        CD62L N/A ↑ ↑ ↑ ↑ ↑
Leukocytes   CD11a N/A ↓ lean ↓ lean ↓ lean N/A
                          CD11b N/A ↓ lean ↓ lean ↓ lean ↑ ↑
                         CD11c N/A N/A ↑ ↑
                         CD62L N/A ↑ ↑ ↑ - -
Leukocyte count N/A Shift to more neutrophils* ↑ ↑
HF, high-fat; HE, high energy; SFA, saturated fatty acids; MUFA, mono-unsaturated fatty acids; PUFA, poly- unsatu-
rated fatty acids; NFC, normal flavanol chocolate background; HFC, high flavanol chocolate background; FMD, flow 
mediated dilation; AIX, augmentation index; TM, thrombomodulin; ↑, increased after HF challenge; ↓, decreased 
after HF challenge; N/A, not measured in the study. * relative count, in proportion to lymphocytes and monocytes.
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young healthy men, HF challenge intake did not elicit an increase in plasma sICAM1, ICAM3 
and VCAM1, whereas it did in middle-aged men (chapter 3 and 6). The modest reduction 
in FMD, together with the absence of a clear increase in soluble adhesion markers after a HF 
challenge, suggests that young healthy men are able to handle a high-fat and high-energy load 
in such a way that it does not adversely affect endothelial function. This can be explained 
by an adequate metabolic and endothelial response capacity in young men, which is likely 
diminished in middle-age men. This finding is supported by many studies that did not observe 
a postprandial impairment in endothelial function after a HF meal in healthy younger aged 
volunteers [3-9]. Studies comparing the FMD response after a HF meal between middle-aged 
and young volunteers in a single study have not been performed yet. Due to adequate endothelial 
responses in young men, the HF challenge test in young men seems less applicable to identify 
early perturbations in endothelial health.
Fatty acid type of the HF challenge
In chapters 3, 4 and 5 we challenged lean and obese middle-aged men with a HF challenge, 
either high in saturated fatty acids (SFA), mono-unsaturated fatty acids (MUFA) or n3 poly-
unsaturated fatty acids (PUFA). We observed that MUFA intake elicited the highest postprandial 
plasma triglyceride (TG) concentrations. The higher postprandial rise of TG after MUFA intake 
compared to SFA intake was in line with previous observations [10-12]. MUFA intake also 
caused a more pronounced decrease in AIX compared to SFA and n3 PUFA intake (chapter 3). 
A more pronounced postprandial decrease in AIX after MUFA intake has not been reported 
before. Although we did not compare the postprandial impact of different fatty acids on FMD, 
one study showed that consumption of high oleic sunflower oil (high MUFA, rich in oleic acid) 
caused a more pronounced postprandial reduction in FMD compared to shea butter (high SFA, 
rich in stearic acid) consumption [13]. Based on the more pronounced postprandial rise of TG 
and more pronounced effects on vascular function after MUFA consumption, we selected the 
MUFA challenge for PBMCs transcriptome analysis. We compared gene expression changes 
after MUFA intake to those induced by a challenge of commonly consumed fatty acids, i.e. the 
SFA challenge (chapter 5). Transcriptome analysis showed that a high MUFA challenge changed 
the expression of more genes than a high SFA challenge did, especially in obese subjects. Taken 
together, we hypothesize that MUFAs are more potent fatty acids to trigger the vascular response 
capacity and to initiate gene expression changes in PBMCs, than SFAs or n3 PUFAs. For this 
reason, we chose the high MUFA challenge to trigger the endothelial response capacity after 
consumption of a dietary anti-stressor (chapter 6).
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The total amount of fat in the HF challenge
All HF intervention shakes described in this thesis contained 95g of fat. Although the fatty 
acids used in our studies are commonly consumed and therefore expected to be well tolerated, 
this amount of fat is relatively high and does not reflect a common meal. Yet, the HF challenges 
described in this thesis were used as a tool to trigger the endothelial response capacity and can 
be compared to an oral glucose tolerance test (OGTT) in which a glucose load of 75g is provided 
to determine how quickly glucose is cleared from the blood [14]. In the OGTT the amount of 
glucose is also relatively high and does not reflect a common meal. The question remains if we 
need these high amounts of fat to elicit an endothelial response. The optimal amount of fat to 
trigger the endothelium is currently unknown and previous postprandial HF meal challenges 
described in the literature vary considerably in the amount of fat or adjust the amount of fat for 
body surface area (reviewed by Hall et al.[15] and Jackson et al.[16]). This makes comparisons 
between postprandial challenge studies difficult. In addition, as also observed in this thesis and 
summarized above, the required amount of fat to challenge endothelial function may depend 
on age, health status of the human volunteer and type of fat. 
Factors affecting vascular function parameters
Measures of vascular function, such as FMD, have large variations in reproducibility [17]. 
Furthermore, small effect sizes can be expected in short term nutritional interventions. A 
reduction in the variation is of pivotal importance to detect small changes in endothelial health 
induced by relatively short-term nutritional intervention studies. Several factors are known 
to induce variation, such as changes in circadian rhythm [18,19]. For example, we observed a 
difference in postprandial FMD response between subjects that started the intervention at 07.30 
a.m. compared to subjects that started at 09.30 a.m. (chapter 2, data not shown). To minimize 
variation induced by circadian rhythm, we recommend that the vascular measurements for each 
subject should be performed at the same time on each intervention day. Another aspect that 
may induce variation is the last meal consumed before the measurements. Although baseline 
measurements should be performed during fasting, the fat from the last meal consumed may 
still be in the intestinal tract and become available upon the second meal [20]. This is however 
based on studies that evaluated the impact of a HF breakfast on the TG response of a following 
meal 5 hours later, i.e. lunch. Nevertheless, to minimize the possible effect of fatty acid spill-over 
from the previous day, we recommend that subjects consume a standardized low-fat evening 
meal prior to each study day. Many other factors are also known to influence endothelial function 
including, age, use of certain medications such as blood pressure or cholesterol lowering drugs, 
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cigarette smoking, habitual dietary intake, gender, ethnicity, disease status and exercise [21]. To 
minimize between-subject variation, the target population should be as homogenous as possible. 
To minimize within-person variation, one might consider to replicate observations within the 
same individual in combination with a cross-over design. The latter strategy will enhance power 
and enabled us to detect the small postprandial changes in FMD in young men (chapter 2).
Potential mechanisms of endothelial triggering by a HF 
challenge
In the introduction we described that one of the current hypothesis is that elevated TRLs in the 
postprandial state can activate leukocytes and endothelial cells and thereby affect endothelial 
function [22]. In chapter 3 we showed that a high-fat MUFA challenge induced the most 
pronounced plasma TG response compared to a high-fat SFA and n3 PUFA challenge, especially in 
obese subjects. However, despite this clear difference in postprandial plasma TG, the HF-induced 
response in plasma markers involved in cellular adherence and leukocyte cell surface activation 
markers was independent of fatty acid type consumed or being lean or obese. In addition, we 
correlated changes in plasma TG concentrations with changes in plasma markers involved in 
cellular adherence and leukocyte cell surface activation markers, but did not observe conclusive 
correlations (chapter 3). Furthermore, in healthy young men (chapter 2), marked differences in 
plasma TG response between the HF/HE shake and the average breakfast shake were observed, 
but no differences in FMD or other markers of endothelial activation, except for IL-8 were seen 
(chapter 2). Our findings suggest that besides the magnitude of the postprandial TG response, 
other factors are involved in triggering the endothelial response capacity. A possible factor that 
may contribute to the postprandial inflammatory and vascular response is endotoxin [23,24]. 
Previous studies demonstrated that HF meal intake causes a postprandial increase in plasma 
endotoxins levels. Endotoxins derive from gram negative gut bacteria and can be transported 
through the gut wall during chylomicron release in the lymph [25]. Once endotoxins are in the 
circulation, they may activate inflammatory processes in endothelial cells and leukocytes [25]. 
A study in mice showed that high fat diet-induced changes in gut microbiota were associated 
with an increase in plasma endotoxin levels [26]. These findings suggest that also gut microbiota 
composition may be of importance in the endotoxin induced inflammatory response. It is 
known that gut microbiota composition is altered in people who are obese [27] and it has been 
demonstrated that the postprandial increase in plasma endotoxins upon HF intake is higher in 
obese subjects with an impaired glucose tolerance and type 2 diabetic subjects if compared to 
normal weight healthy subjects [23]. In chapter 3 we compared the postprandial responses of 13 
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cytokines involved in cellular adhesion, coagulation and systemic inflammation between lean 
and obese subjects, but did not observe a clear difference between the groups. This might be due 
to the fact that the obese subjects were relatively healthy and did not have diabetes. Still, by using 
more sensitive transcriptomic tools, we observed changes in gene expression profiles involved in 
immune function in PBMCs after a HF challenge between lean and obese subjects (chapter 5), but 
whether these changes are due to endotoxin or to HF challenges per se remains to be elucidated. 
The composition of postprandial TRLs may also contribute to the postprandial inflammatory 
and vascular response. Postprandial TRLs differ in apolipoprotein composition, lipid content 
and probably also in oxylipin composition compared to fasting TRLs (chapter 4) [28-30]. These 
changes in TRL composition may create more atherogenic TRLs in the postprandial phase. 
Still, other causes not related to the HF meal may also have contributed to the activation of the 
endothelium and leukocytes in our studies. As we did not compare the postprandial HF response 
in middle-aged men to a response to a common meal, we cannot rule out if postprandial changes 
after these shakes were due to the high energy content, the meal intake per se or by changes of 
circadian rhythm (chapters 3 to 6). Although, the latter effect is hard to control for in postprandial 
challenge studies, due to the strong integration between the circadian rhythm and meal intake [31]. 
Markers of early perturbations in endothelial health
In this thesis we demonstrate that endothelial function, as estimated by FMD, is impaired after 
a dietary stressor, i.e. a HF challenge (chapter 2 and 6) and is improved after consumption of a 
dietary anti-stressor, i.e. dark chocolate (chapter 6). Although FMD is still the most accepted 
and established method to study endothelial function, it has serious drawbacks. FMD is time 
consuming, technically challenging and shows relatively large variations in reproducibility. 
The latter is also proven by the fact that FMD outcomes in similar target populations vary 
considerably between research centres. In addition, early perturbations in endothelial health 
may not always be detected by FMD. Therefore, the question remains whether other measures 
of vascular function are more sensitive and easier to use than FMD and, additionally, also reflect 
endothelial health. In the current thesis we used different techniques to measure endothelial 
health. Besides measures of vascular function, we measured 13 cytokines in plasma involved in 
cellular adhesion, coagulation and systemic inflammation, determined the protein expression 
of leukocyte cell surface activation markers and applied high-through put nutrigenomics 
techniques such as metabolomic and transcriptomic tools. By using such a comprehensive 
characterizing approach we identified potential leads for early biomarkers that may be suitable 
to reflect perturbations in endothelial health.
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Vascular markers of endothelial perturbations
Besides FMD as measurement of vascular function, we measured the augmentation index (AIX) 
in all intervention studies (chapters 2, 3 and 6). The AIX can be relative easily and fast deduced 
from a pulse wave analysis of the radial artery, which makes it an interesting vascular measure 
to implement in complex study designs. The AIX is an estimate of stiffness and wave reflection 
and a lower AIX in the fasting state is associated with a lower risk of cardiovascular disease 
(CVD) [32]. The question remains if the AIX is also a potential early marker for endothelial 
function. The AIX is largely determined by the structural composition of the artery wall [33,34]. 
Short term induced changes in AIX are not caused by structural changes, but are most likely 
caused by changes in vascular tone, which is partly regulated by the endothelium. Yet, vascular 
tone can also be regulated by other factors such as autonomic nerves. The rapid postprandial 
changes in AIX after HF meal intake (chapters 3 and 6) were probably due to fast neuronal 
or hormone mediated peripheral vasodilation in response to nutrient intake [35]. Although 
these postprandial changes in AIX may still be of importance for vascular health, they may not 
always reflect changes in endothelial function. Changes in AIX under fasting conditions are 
more likely to reflect changes in endothelial function, because the acute effects of a meal can 
largely be ruled out [35]. This was also nicely reflected by our chocolate intervention study, 
where under fasting conditions, we observed that the decrease in AIX after 4-week daily intake 
of dark chocolate was accompanied with an improvement in FMD (chapter 6). Taken together, 
in both long term and postprandial studies, we consider the AIX to be a valuable outcome 
measure in addition to, but not instead of other endothelial markers, such as FMD. 
Blood markers of endothelial perturbations
To identify potential early perturbations in endothelial health in the blood, we measured 13 
cytokines in plasma involved in cellular adhesion, coagulation and systemic inflammation. In 
young men, we observed that high-fat/high-energy (HF/HE) shake consumption increased 
plasma IL-8 concentrations, compared to an average breakfast control shake, while no increases 
were observed in the more classical markers of endothelial function such as soluble adhesion 
molecules sICAM1, sICAM3 and sVCAM1. This increase in plasma IL-8 was paralleled by 
an increased gene expression of IL-8 in PBMCs (chapter 2). In middle-aged men as well, we 
observed an increase in plasma IL-8 concentrations after high SFA, MUFA and n3 PUFA 
intake (chapters 3 and 6). Similar to the effects observed in young healthy volunteers (chapter 
2), this increase in plasma IL-8 was accompanied by an increase in PBMC gene expression of 
IL-8 [36]. IL-8 is produced by leukocytes and endothelial cells [37] and activates and recruits 
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neutrophils [38] and triggers monocyte adhesion to the endothelium [39,40]. Taken together, 
these findings suggest that IL-8 may be a potential marker for acute endothelial activation 
upon a dietary stressor such as a HF meal. In addition to the increase in IL-8, we observed 
that a HF challenge increased plasma concentrations of soluble adhesion molecules sICAM1, 
sICAM3 and sVCAM1, but only in middle-aged men (chapters 3 and 6). These soluble adhesion 
molecules are involved in the recruitment and adherence of leukocytes to the endothelium 
[41]. A HF challenge also increased the number of leukocytes in the circulation (chapter 6), 
indicating an activation of the systemic immune response [42]. Furthermore, in two separate 
studies we observed that a HF challenge increased leukocyte cell surface integrin and selectin 
expression (chapter 3 and 6). These integrins and selectins are able to interact with cell adhesion 
molecules (CAMs) present on the endothelium, thereby facilitating the adherence of leukocytes 
to the endothelium [41]. In summary, in two separate studies we observed, that a HF challenge 
increased plasma soluble adhesion molecules, increased leukocyte cell surface integrin and 
selectin expression and increased the number of leukocytes in the circulation in middle-aged 
men. These findings evidently point towards an activated state of cellular adherence in the 
circulation after a HF challenge. This activated state of cellular adherence after a HF challenge 
was accompanied by a decrease in FMD and AIX (chapter 6). Since endothelial health is 
determined by a complex interplay of endothelial cells, leukocytes and factors circulating in the 
plasma, the assessment of endothelial function based on a single outcome measure, such as FMD, 
would provide an oversimplified picture of endothelial health status. Based on the findings in 
this thesis we recommend that endothelial health is better determined by means of a biomarker 
profile consisting of the vascular measures FMD and AIX, a subset of soluble adhesion molecules 
in the plasma, leukocyte counts and cell surface integrin and selectin expression. As prove of 
principle, we investigated whether this biomarker profile could be beneficially changed by a 
dietary anti-stressor (chapter 6). We showed that the increase in fasting FMD after 4-week 
daily intake of dark chocolate was paralleled by a decrease in AIX and a less activated state of 
cellular adherence, reflected by the decrease in plasma concentrations of sICAM1 and sICAM3, 
the decreased leukocyte cell surface integrin and selectin expression and the decrease in 
leukocyte count, all pointing towards an improvement of our identified biomarker profile for 
endothelial health. Still, this biomarker profile is a combination of functional measures and 
blood markers as we are not able to determine the intracellular effects in the vascular wall due 
to the limited accessibility to endothelial cells in a pre-clinical setting. The fact that factors 
involved in leukocyte adherence to the endothelium are affected by dietary stressors and are 
reversibly affected after an intervention with a dietary anti-stressor, point towards a potential 
role of leukocytes in early perturbations of endothelial health. The use of transcriptome analysis 
in a subset of those leukocytes, the PBMCs, allowed the identification of stress related and 
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metabolic compensatory pathways affected by HF challenges differing in fatty acid type. For 
example, the SFA induced changes in expression of genes involved in cholesterol biosynthesis, 
cholesterol influx and efflux, may point towards an intracellular situation of excess cholesterol 
in the PBMCs after SFA intake. Abundant intracellular cholesterol in monocytes is stored in 
lipid droplets and excess storage may eventually lead to foam cell formation [43]. Further 
exploration of the effects of SFA on cholesterol homeostasis in the monocyte fraction of PBMCs, 
especially after repeated exposure, may increase our understanding on the mechanisms behind 
the more atherogenic effect of diets high in SFA compared to diets high in MUFAs. The MUFA 
challenge up-regulated the expression of many peroxisome proliferator-activated receptor α 
(PPARα) target genes, including genes involved in β-oxidation. Up-regulation of the β-oxidation 
may reduce the amount of fatty acids available for other processes such as intracellular lipid 
accumulation, an important process involved in the formation of lipid loaded macrophages 
[44]. In contrary to what can be expected from activation of PPARα, i.e. a down-regulation in 
expression of genes involved in inflammation, MUFA intake up-regulated the expression of 
genes involved in inflammation. This might be explained by the unsaturated double bond in 
MUFAs, which makes them more susceptible to oxidative stress compared to SFAs. A MUFA 
challenge may therefore elicit higher stress and subsequent higher inflammatory response in 
PBMCs compared to a SFA challenge. We hypothesize that repeated moderate exposure to 
such stress-inducing fatty acids, will activate the transcriptional response, hence increasing the 
cellular capacity to adapt. This may improve the resilience capacity of cells, ultimately leading 
to positive health effects and potentially reducing the risk of CVD on the long run. Future 
studies are needed to elucidate how repeated moderate exposure to these fatty acids will lead 
to longer-term adaptations, and what their effect is on endothelial health. 
Besides exploring the use of transcriptomics techniques in PBMCs, we also applied metabolomic 
tools on plasma samples to determine whether a HF challenge is able to affect circulating 
oxylipin profiles (chapter 4). Oxylipins are involved in both pro- and anti-inflammatory 
processes and are well known for their local effects, but recent evidence suggests that these 
molecules may also exert systemic effects. We showed that oxylipin profiles are changed by the 
intake of a HF challenge test. Also, the postprandial changes of many oxylipins were affected by 
dietary fatty acid composition. Considering their involvement in pro- and anti-inflammatory 
processes, these findings suggest that postprandial changes in circulating oxylipins may have an 
effect on endothelial health. This study was explorative and little is known yet on the effect of 
circulating oxylipins on endothelial cells. Future research is needed to elucidate their potential 
role in endothelial function and CVD risk. 
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How to measure health status
In chapters 3, 4 and 5 we comprehensively characterized middle-aged lean and obese men 
before and after a HF challenge. Under fasting conditions, obese individuals had higher 
plasma insulin and TG levels compared to lean individuals. Obese individuals also had higher 
fasting concentrations of plasma C-reactive protein (CRP), serum amyloid A (SAA) and von 
Willebrand factor (vWF) compared to lean individuals (chapter 3). Both CRP and SAA are 
produced predominantly by the liver and can be considered markers of systemic inflammation 
[45,46]. vWF can be produced by endothelial cells and plays a major role in blood coagulation. 
Increased concentrations of CRP, SAA and vWF have been associated with a higher risk of CVD 
and belong to the classical and coarse biomarkers for CVD [47]. In addition to these plasma 
markers, gene expression profile analysis in PBMCs identified 294 genes that were significantly 
differently expressed between lean and obese subjects under fasting conditions (chapter 5). 
Hence, quite some differences were already present between lean and obese subjects under 
fasting conditions. We applied a HF challenge with the ultimate goal to magnify differences 
between lean and obese subjects. With respect to plasma, we observed that obese individuals 
had elevated TG and insulin responses after HF intake. The postprandial responses of 13 
cytokines involved in cellular adhesion, coagulation and systemic inflammation and oxylipins 
profiles in plasma were not different between lean and obese (chapter 3 and 4). When only 
taking the plasma pool into account, differences between lean and obese subjects were only 
observed with regard to metabolic markers and not inflammatory or endothelial markers. 
Of note, most circulating inflammatory factors can be secreted by several different organs. 
Postprandial responses of those markers in plasma may therefore not always reflect the cellular 
response capacity of the endothelium or leukocytes.
With respect to the differences in cellular responses between lean and obese subjects, we 
observed that lymphocyte CD11a and CD11b expression after a HF challenge was decreased in 
lean, but not in obese subjects (chapter 3). This may be due to a reduced capacity of lymphocytes 
in obese subjects to respond adequately to a HF load. Differences in postprandial cellular 
responses between lean and obese subjects became especially explicit by the application of 
transcriptomics in PBMCs (chapter 5). While prior to the challenge, under fasting conditions, 
294 genes were significantly differently expressed between lean and obese subjects, this 
amount was increased to 607 genes after the SFA challenge and to 2,516 genes after the MUFA 
challenge. Several biological pathways that may be perturbed in obese subjects were identified. 
We found that SFA intake elicited a pro-thrombotic gene expression profile in obese but not 
in lean subjects. Furthermore, after MUFA intake, the expression of GPI-anchored protein 
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synthesis genes was up-regulated while expression of various G-protein coupled receptors 
was down-regulated in obese relative to lean subjects. GPI-anchored proteins on leukocytes 
regulate integrin-mediated cell adhesion [48,49] and many GPCRs are known to mediate 
both inflammatory and anti-inflammatory processes [50]. Changes in expression of genes 
involved in haemostasis and immune function in PBMCs after a HF challenge may be one of 
the first detectable hallmarks for small disturbances in health status. Whether these findings 
are consistent and to what extent those changes are linked to endothelial health remains to 
be elucidated. 
Recommendations for future research
Although the scope of this thesis was to evaluate factors involved in vascular function and 
leukocyte adherence, our findings in several chapters suggest that also coagulatory processes 
are affected after a HF challenge. First, in middle-aged men, we observed a decrease in plasma 
thrombomodulin (TM) after the intake of a HF challenge (chapter 3 and 6). TM is secreted 
by the endothelium and inhibits platelet adhesion and coagulation. A decrease in TM causes 
a more pro-thrombotic environment [51]. Secondly, in chapter 3 we observed an increase in 
plasma P-selectin after SFA consumption, which was not observed after MUFA or n3 PUFA 
consumption. P-selectin is expressed both by platelets and endothelial cells and modulates 
adhesion of leukocytes and platelets to the endothelium [52]. The observed postprandial 
SFA induced increase in P-selectin might therefore enhance P-selectin modulated leukocyte 
adherence to the endothelium in the postprandial state. Thirdly, after SFA intake, we observed 
an up-regulation of expression of genes involved in the activation of platelets in obese subjects, 
whereas a down-regulation was seen in lean subjects (chapter 5). All together, these findings 
point towards a HF induced pro-thrombotic environment, especially after SFA consumption. 
Therefore, it is of interest to further explore the effects of a high SFA challenge, on markers 
of platelet activation and coagulation, such as platelet aggregation, ex vivo bleeding time and 
platelet activation marker expression, particular in obese subjects.
In this thesis we propose that changes in endothelial function may best be determined by a 
biomarker profile consisting of the vascular measures FMD and AIX combined with a subset of 
soluble adhesion molecules in the plasma, leukocyte counts and cell surface integrin and selectin 
expression. Still, long-term studies are needed to confirm these findings and to elucidate to what 
extent changes in this biomarker profile are predictive for CVD risk. We also demonstrate that 
a HF challenge triggers the endothelial response capacity and has the potential to detect small 
differences in health status. However, we did not observe a difference response to a HF challenge 
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after an intervention with two different doses of a dietary anti-stressor (chapter 6). As we did 
not incorporate a HF challenge before the intervention, we were unable to determine whether 
the dietary anti-stressor, independent of dose, would have affected the capacity to respond to 
a HF challenge. This stresses the importance of applying a HF challenge test before and after a 
nutritional intervention. The sensitivity will increase even more if these HF challenge tests are 
combined with high-throughput nutrigenomics tools, as we identified these tools to be highly 
suitable to detect small differences in health status after a HF challenge test. Such tools are 
also suitable to identify biological pathways that may have been affected by the intervention. 
Final conclusion
In this thesis we extensively characterized the postprandial response to a HF challenge in 
human subjects with different disease risk profiles and optimized the HF challenge test. We 
identified MUFAs as most potent fatty acids to trigger the vascular and cellular response 
capacity, which makes it the optimal fatty acid type to use in a HF challenge test. We 
demonstrated that besides functional measures of vascular function, also plasma and cellular 
factors involved in leukocyte adhesion to the endothelium are adversely affected by dietary 
stressors and are beneficially affected by a dietary anti-stressor. Therefore, we conclude that 
endothelial health can be more comprehensively measured by means of a biomarker profile 
consisting not only of the vascular function measures FMD and AIX, but also of a subset of 
soluble adhesion molecules in the plasma, leukocyte counts and cell surface integrin and 
selectin expression. To identify potential new leads for biomarkers, we applied whole genome 
gene expression profiling, combined with the HF challenge test which enabled us to detect 
small differences in health status. Furthermore, we identified metabolic and inflammatory 
pathways that are specifically affected by either MUFAs or SFAs. These findings increased our 
understanding on how a SFA or MUFA challenge exert their distinct effects on stress related 
and metabolic compensatory cellular processes and provided us with new potential leads to 
detect early perturbations in endothelial health.
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Hart- en vaatziekten behoren tot de meest voorkomende chronische ziektes wereldwijd. De 
onderliggende pathofysiologie voor het krijgen van hart- en vaatziekten is veelal atherosclerose, 
een sluipend ziekteproces waarbij vet en ontstekingscellen zich ophopen aan de binnenkant van 
de slagaders. Een belangrijke voorbode voor het krijgen van atherosclerose is het hebben van 
niet goed werkende endotheelcellen, ook wel endotheeldysfunctie genoemd. Endotheelcellen 
bekleden de binnenkant van de bloedvaten en spelen een belangrijke rol in de verwijding en de 
vernauwing van bloedvaten, in ontstekingsprocessen en in de bloedstolling. Endotheeldysfunc-
tie wordt gekenmerkt door een vernauwing van de bloedvaten, een milde vorm van ontsteking 
en verhoogde aanwezigheid van stollingsfactoren. Er zijn verschillende voedingstoffen die een 
effect op de endotheelfunctie kunnen hebben. Deze kunnen gekwalificeerd worden als positief 
of negatief voor het endotheel. 
Een voorbeeld van een negatief voedingscomponent voor het endotheel is de inname van 
een grote hoeveelheid vet. De inname van grote hoeveelheden vet kan tijdelijk de vaatfunctie 
verslechteren en zorgen voor een voorbijgaande milde ontstekingsreactie. De mate waarin een 
persoon kan reageren op een maaltijd met veel vet, weerspiegelt de flexibiliteit en daarmee 
ook de gezondheid van onder andere het endotheel. Het meten van de endotheelfunctie na het 
blootstellen van personen aan zo’n hoog-vetmaaltijd kan daarom mogelijk gebruikt worden 
om vroege verstoringen in het endotheel aan te tonen, eerder dan onder nuchtere condities. 
Hoewel hart- en vaatziekten vaak mensen treffen van middelbare of oudere leeftijd, begint 
endotheeldysfunctie vaak al op vroegere leeftijd. Endotheeldysfunctie in een vroeg stadium 
is nog omkeerbaar en het vroeg kunnen opsporen van verstoringen is daarom van cruciaal 
belang. Echter, de toegankelijkheid van het endotheel bemoeilijkt het onderzoek bij mensen. Bij 
onderzoek met mensen is men aangewezen tot het meten van vaatfunctie op een niet invasieve 
manier. Op dit moment is de meest gebruikte en geaccepteerde manier om endotheelfunctie te 
bepalen een ultrasoundmeting genaamd ‘flow mediated dilation’, ofwel FMD. Deze meting is 
erg lastig, duurt lang en heeft veel variatie. De vraag blijft of er ook andere gevoeligere metingen 
zijn, die makkelijker uit zijn te voeren. Een mogelijke andere manier om de gezondheid van 
bloedvaten te bepalen is door het meten van de bloeddrukgolf. Aan de hand van de bloeddruk-
golf kunnen we de augmentatie-index (AIX) berekenen, een maat voor bloeddrukgolfreflecties 
en een mogelijke indicatie van slagaderlijke stijfheid. 
Naast het meten van vaatfunctie kan men ook bloed afnemen. In het bloed kan men aspecten 
bepalen die een rol spelen bij de gezondheid van het endotheel. Zo kan men bijvoorbeeld de 
eiwitexpressie van zogenaamde ‘adhesiemoleculen’ meten aan de buitenkant van witte bloed-
cellen, die een rol spelen bij het aanhechten aan het endotheel. Ook kan men in het plasma 
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eiwitten bepalen die faciliteren bij het hechten van witte bloedcellen aan het endotheel, of een 
rol spelen bij ontsteking en bloedstolling. 
Daarnaast kunnen we ook gebruik maken van relatief nieuwe, gevoelige en uitgebreide 
screeningstechnieken zoals ‘metaboloom’- en ‘transcriptoom’-analyses. Met een metaboloom-
analyse kan men ‘oxilipin’-profielen meten. Oxylipins zijn afbraakproducten van vetzuren 
die een rol spelen bij ontsteking. Met een transcriptoomanalyse kan men de activiteit van al 
onze genen in één meting bepalen. Een verandering in de activiteit van genen kan inzichten 
verschaffen over welke processen er in het lichaam veranderen. Dit geeft ons informatie via 
welke mechanismen voeding een effect kan hebben op ontsteking, metabolisme en zo ook op 
endotheelfunctie. Perifere bloedmononucleaire cellen (PBMC’s), een subpopulatie van witte 
bloedcellen, zijn relatief makkelijk verkrijgbaar, spelen een belangrijke rol bij ontsteking en 
kunnen interactie aangaan met het endotheel. PBMC’s zijn daarom belangrijke cellen om 
transcriptoomonderzoek aan te doen.
Het doel van dit promotieonderzoek was om markers te identificeren die vroege verstoringen 
in endotheelfunctie weerspiegelen. Om potentiële vroege markers te identificeren hebben we 
deelnemers blootgesteld aan een stresstest voor het endotheel, namelijk een hoog-vet maaltijd 
met 95 gram vet. 
In hoofdstuk 2 hebben we de hoog-vet stresstest gevalideerd door bij jonge gezonde vrijwilligers 
de response na een vetrijke milkshake te vergelijken met die van een normaal ontbijt. Voor en 
na de inname van deze milkshakes hebben we verschillende vaatmetingen uitgevoerd en heb-
ben we ontstekingsfactoren in het plasma gemeten. In deze jonge gezonde vrijwilligers zagen 
we dat de hoog-vet stresstest de endotheelfunctie tijdelijk verslechterde, gezien de daling in 
FMD. Deze effecten werden echter ook gevonden na het consumeren van een normaal ontbijt. 
Jonge gezonde vrijwilligers zijn daarom kennelijk nog in staat om op een adequate manier te 
reageren op een vetrijke maaltijd. De concentratie van interleukine-8, een eiwit betrokken bij 
het plakken van witte bloedcellen aan de vaatwand, was toegenomen na de consumptie van 
hoog-vet ten opzichte van de consumptie van een normaal ontbijt.
Om nieuwe markers voor vroege verstoringen in endotheelfunctie te identificeren hebben 
we hoog-vet stresstesten toegepast op twee type deelnemers van middelbare leeftijd met een 
verschillend risicoprofiel voor het krijgen van hart- en vaatziekten, namelijk slanke mensen en 
mensen met obesitas. Ook hebben we in deze studie de hoog-vet stresstesten geoptimaliseerd 
door 3 verschillende soorten hoog-vet testen toe te passen, namelijk met verzadigde vetten, 
enkelvoudig onverzadigde vetten of omega-3 meervoudig onverzadigde vetten (hoofdstukken 
3 tot en met 5).
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Na het toepassen van de hoog-vet testen bij mannen van middelbare leeftijd, zagen we in 
hoofdstuk 3 dat de consumptie van een hoog-vet stresstest een daling induceerde van de AIX, 
een toename induceerde van de adhesiemoleculen aan de buitenkant van witte bloedcellen en 
een toename induceerde van eiwitten in het plasma die faciliteren bij de aanhechting van witte 
bloedcellen aan de vaatwand. De daling van de AIX en de toename van vetten in het bloed 
waren het sterkst na de inname van hoog-vet met enkelvoudig-onverzadigde vetten. 
Ook hebben we in deze studie uitgebreide screeningstechnieken toegepast. Hoofdstuk 4 be-
schrijft dat ‘oxilipin’-profielen veranderden na het consumeren van een hoog-vet stresstest en 
dat de mate waarin deze profielen veranderden voor een groot deel afhankelijk was van het type 
vet dat geconsumeerd was. De toepassing van transcriptome analyse in PBMC’s (hoofdstuk 
5), onthulde dat de veranderingen in genexpressieprofielen na een hoog-vet stresstest anders 
zijn in slanke mensen dan in mensen met obesitas. Deze verschillen werden nog duidelijker 
na een hoog-vet stresstest met enkelvoudig-onverzadigde vetten. Ook zagen we dat verzadigd 
vet leidde tot een verlaging van activiteit van genen betrokken bij cholesterolopname en cho-
lesterolaanmaak en een verhoging van de activiteit van genen betrokken bij cholesterolflux uit 
de cellen. De consumptie van enkelvoudig-onverzadigde vetten leidde tot een verhoging van 
de activiteit van genen die betrokken zijn bij de vetverbranding en bij ontsteking.
In hoofdstuk 6 hebben we gekeken of de aspecten die veranderen na een hoog-vet test, ge-
identificeerd in hoofdstuk 3, ook verbeterd kunnen worden na een interventie met een positief 
voedingsmiddel voor het endotheel, namelijk pure chocolade. Een 4-weekse interventie met 
pure chocolade zorgde voor een verbetering van de FMD, een verlaging van de AIX, een afname 
van adhesiemoleculen aan de buitenkant van witte bloedcellen en een afname van eiwitten in 
het plasma die faciliteren bij de aanhechting van witte bloedcellen aan de vaatwand. Er werd 
geen verschil gevonden tussen twee type chocolades met verschillende concentraties flavanolen.
Tot slot bediscussiëren we in hoofdstuk 7 de belangrijkste bevindingen van dit proefschrift. In 
dit proefschrift hebben we de effecten van een hoog-vet stresstest uitgebreid in kaart gebracht 
bij deelnemers met een verschillend risicoprofiel om hart- en vaatziekten te ontwikkelen. 
Daarnaast hebben we enkelvoudig-onverzadigde vetten gekwalificeerd als meest geschikte 
soort vet om de vasculaire functie te testen. We achten deze vetten dus het meest geschikt om 
te gebruiken in een hoog-vet stresstest. 
Ook hebben we aangetoond dat de inname van negatief voedingsproduct voor het endotheel, 
namelijk hoog vet, factoren in het bloed verhoogt die een rol spelen bij de binding van witte 
bloedcellen aan de vaatwand. Deze factoren zijn verlaagd na de interventie met pure chocolade, 
een voedingsproduct welke een positieve werking heeft op endotheelcellen. Wij concluderen 
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daarom dat de gezondheid van het endotheel het best kan worden bepaald door vaatmetingen 
te combineren met het meten van factoren die een rol spelen bij het binden van witte bloedcel-
len aan de vaatwand. 
Ook tonen we in dit proefschrift aan dat het gebruik van een hoog-vet stresstest in combina-
tie met het gebruik van gevoelige transcriptoomanalyse, verschillen in gezondheidstatus kan 
uitvergroten. Daarnaast hebben we met deze transcriptoomanalyse metabole en ontstekings-
processen in kaart gebracht die specifiek veranderen na het consumeren van verzadigde of 
enkelvoudig-onverzadigde vetten. Deze uitkomsten vergroten onze kennis op het gebied van 
de werking van verschillende vetzuren in het lichaam met als uiteindelijk doel te begrijpen hoe 
de consumptie van vet onze gezondheid beïnvloedt.  
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Zo… en dan nu eindelijk het dankwoord. Laten we beginnen met de mensen waarmee ik 
direct te maken kreeg toen ik dit avontuur begon en die er gedurende het hele project nauw 
bij betrokken zijn geweest.
Lydia, ik vond mijn sollicitatie bij jou al direct prettig. Voor mij is de (werk)sfeer enorm be-
langrijk en die is altijd fantastisch gebleken. Ik heb veel van je geleerd op een leuke manier en 
met veel lachen. Je deur staat altijd open, je wilt altijd een stap verder, bent erg betrokken en 
lekker direct. Ik ben daarom ook erg blij dat wij nog een tijdje kunnen samenwerken. 
Michael, mijn promotor, bedankt voor je begeleiding, kritische blik en discussies. Wanneer 
er problemen waren of belangrijke beslissingen genomen moesten worden binnen het project 
was jouw inbreng en hulp van onmisbare waarde.           
Een bijzondere plek in dit dankwoord is gereserveerd voor Els. Els, wat heb jij een enorme 
bijdrage geleverd aan dit proefschrift. Ik denk dat we samen een enorm goed team vormden en 
ik kijk met veel plezier terug op onze samenwerking. Tijdens de studies hebben we enorm veel 
lol gehad en ook erg hard gewerkt. Jou bedanken en typeren in een paar zinnen is praktisch 
onmogelijk, je kunt er namelijk een krant mee vullen ;). 
Naast de mensen van het eerste uur zijn er een hoop mensen die in de loop van mijn promo-
tietraject een belangrijke rol zijn gaan spelen.
Allereerst bedank ik alle (oud-)collega’s van de NMG-groep voor de fantastische werksfeer, 
feedback, hulp, lol en potjes voetbal. Daarnaast wil ik alle collega-AIO’s van Lydia bedanken. 
Ook al waren de onderwerpen vaak verschillend, onze methodes hadden vaak raakvlakken. 
De inmiddels gepromoveerde Mark, Susan en Dieuwertje, bedankt voor al jullie hulp. Susan 
ook bedankt voor de samenwerking tijdens de PIFA-studie. We hebben enorm veel uit deze 
studie kunnen halen! Vera, ik heb altijd leuk met je kunnen sparren over van alles en nog wat 
en ik word altijd vrolijk van je! Juri en Inge, succes met jullie onderzoek de komende jaren! 
Ook wil ik graag in het bijzonder iedereen in kamer 0051 bedanken voor alle geluidjes (met 
name Rinke), hulp, geduld/ incasseringsvermogen (met name Milene en Daniëlle), discussies 
en grappen. Het is ook leuk om te zien dat zelfs de dames steeds vaker de ‘slechte mannengrap-
pen’ op waarde weten te schatten! Sophie… sterkte straks! 
Collega’s en partners van TIFN A-1004, bedankt voor de samenwerking, input en leerzame 
bijeenkomsten. Lisette en Jolanda bedankt voor al jullie betrokkenheid, interesse, hulp en bemid-
deling. Jos op ’t Roodt bedankt voor je hulp en bergen ultrasoundbeelden die je geanalyseerd 
hebt in de avonduren. Ik heb onze samenwerking altijd prettig gevonden. 
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Alle hoofdstukken in dit proefschrift komen voort uit drie interventiestudies. Ik bedank alle 
deelnemers die mee hebben gedaan aan deze studies. Deze deelnemers hebben vrijwillig, 
zonder (al te veel) te zeuren, op nuchtere maag 95 gram vet gedronken, of weken lang choco-
lade moeten eten (die ze vaak niet eens lekker vonden). Zonder deze deelnemers is dit soort 
onderzoek onmogelijk. Ook is er een heel team van personeel voor en achter de schermen 
bezig geweest om alles goed te laten verlopen tijdens dit soort studies. Er is hard gewerkt, veel 
gelachen en de sfeer was altijd erg goed. Hiervoor wil ik alle medewerkers bedanken. Jantien en 
Jan bedankt voor alle hulp tijdens de EMPEF. Shoreh en Mechteld (a.k.a. Buuv), super dat jullie 
altijd konden invallen als iemand ziek was of als iemand op het laatste moment besloot niet 
meer te komen ;). Els, Karin en de rest van het diëtistenteam, bedankt voor de kilo’s macaroni 
(smullen!), de hulp bij de shakes (ook smullen), de ontbijtjes en blindering. Daarnaast heeft een 
kopje koffie bij jullie op de kamer er zelfs voor gezorgd dat er een onderdeel sensoriek in dit 
proefschrift is te vinden. Monica, dankzij jou kunnen we nu echt zeggen dat die ene chocolade 
toch echt minder lekker is. Anita, Marco en alle prikmedewerkers heel erg bedankt voor de 
hulp bij het biopteren, prikken en indelen. Verder hebben studenten tijdens de studies veel 
inspanningen en nuttig werk geleverd; Sonja bij de EMPEF, Martine bij de PIFA en Tessa, Iris, 
Jeske, Edith en Anneke bij de CHOC-studie. Dank jullie wel! Jenny en Buuv bedankt voor al 
het micro-array-werk!
Nadat alle verzamelde beelden en materialen van de studies omgezet waren in een gigantische 
berg met getallen, kon het puzzelen starten. Hierbij heb ik veel geleerd en hulp gekregen van een 
aantal knappe koppen. Ohid, thank you for all your statistical help and your knowledge about 
linear mixed models. Michiel, heel veel dank voor je hulp bij het oxylipinhoofdstuk. Philip en 
Mark bedankt voor alle array-hulp. Guido ‘handymen hairball helpdesk’ Hooiveld, bedankt 
voor al je vreemde computerprogramma’s, hulp met figuren en hersenspinsels. 
Daarnaast zijn er een heleboel mensen die misschien niet direct een rol hebben gespeeld bij 
de totstandkoming van dit proefschrift, maar achter de schermen hebben zij wel degelijk een 
belangrijke rol vervuld. Ik heb het voorrecht om veel bijzondere vrienden te hebben en deze wil 
ik bedanken voor de (geweldige) weekenden, vakanties, duiken, m’n nichtje, etentjes, vrolijk-
heid als parttime huisgenoot, squashpartijen, culturele uitstapjes München, racefietsrondjes, 
lache gyre smullen, New Kingen, interesse in m’n werk (nooit teveel), bakkies, jasavondjes, 
bijzondere ervaringen, hulp, risken, thialf, etc., etc., etc.… te veel om op te noemen. Ik zet 
graag af en toe de knop om en dat is door jullie mogelijk gemaakt. Zonder jullie was alles 
misschien wel sneller af geweest, maar dat is eigenlijk een heel groot compliment naar jullie 
toe. Toch kan ik het niet laten om een enkeling apart te noemen, omdat ze niet alleen achter, 
maar toch ook voor de schermen een rol hebben gespeeld. Else, fijn, handig en ook grappig 
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om een topvriendin te hebben die ook nog eens dezelfde carrièrekeuzes maakt in haar leven. 
Dat heeft me geholpen deze jaren en ik weet zeker dat we in de toekomst elkaar weer vinden! 
Pa en ma, super dat bij jullie alles kan en mag. Jullie tonen altijd interesse, betrokkenheid en 
ondersteunen iedere zoon (en kleindochter inmiddels) waar nodig. En mam… zelfs drammen 
is af en toe wel eens goed voor mij (@ Dorien: dit meen ik niet ;). Ook bedank ik graag mijn 
broers (+ koude kant ;) die geen idee hebben waar ik aan gewerkt heb en die nog steeds denken 
dat ik onderzoek in ontlasting doe.
Ook in de laatste fase van mijn promotie zijn er een aantal personen die cruciaal zijn geweest 
voor succesvolle afronding. 
Roos, enorm bedankt voor de fantastische cover. We hadden meteen hetzelfde idee en de uit-
werking is in mijn ogen subliem. Ik blijf er in de toekomst met veel plezier en trots naar kijken! 
Edith Feskens, Anne Marie Minihane, Peter Heeringa en Ben van Ommen thank you for your 
willingness to join my thesis committee. I sincerely hope you all read this thesis with great 
interest. 
Daarnaast zitten er tijdens de verdediging ook twee ‘ceremonial slaves’ naast me, ofwel para-
nimfen. Deze mensen heb ik gekozen vanwege de klik die ik met ze heb gehad tijdens mijn 
promotietraject. Ik ben daarom ook erg trots dat Noortje en Mike deze taak op zich hebben 
willen nemen. Noortje, bedankt voor je rol als katalysator in kamer 0051. Mike, ik ben blij dat 
ik bij voeding in Wageningen een ‘partner in crime’ heb kunnen vinden!
En toen kwam ik ook nog eens aan het eind van mijn promotietraject Dorien (weer;) tegen… 
elk weekend was vanaf dat moment genieten (jaja, ik weet het: Dr.cheesy… maar ik meen het 
wel). Kunnen we nu dan eindelijk eens op vakantie? ;)
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